General practice activity in Australia 2015–16 by Britt, Helena et al.

General practice activity 
in Australia 2015–16 
Bettering the Evaluation and Care of Health 
Helena Britt, Graeme C Miller, Joan Henderson, Clare Bayram,  
Christopher Harrison, Lisa Valenti, Ying Pan, Janice Charles, Allan J Pollack, 
Carmen Wong, Julie Gordon 
Family Medicine Research Centre 
Sydney School of Public Health 
The University of Sydney
GENERAL PRACTICE SERIES NUMBER 40 
September 2016 
 ii 
Published 2016 by Sydney University Press 
SYDNEY UNIVERSITY PRESS 
The University of Sydney Library 
sydney.edu.au/sup 
 
© Sydney University Press 2016 
 
Reproduction and communication for other purposes  
Except as permitted under the Act, no part of this edition may be reproduced, stored in a 
retrieval system, or communicated in any form or by any means without prior written 
permission. All requests for reproduction or communication should be made to Sydney 
University Press at the address below: 
 
Sydney University Press 
Fisher Library F03 
University of Sydney NSW 2006 AUSTRALIA 
Email: sup.info@sydney.edu.au 
 
Any enquiries about or comments on this publication should be directed to: 
 
Christopher Harrison, Menzies Centre for Health Policy  
Sydney School of Public Health, University of Sydney 
Email: christopher.harrison@sydney.edu.au or helena.britt@sydney.edu.au 
Phone: 0411 197 938 
 
This publication is part of the General practice series based on results from the BEACH 
program conducted by the Family Medicine Research Centre (FMRC). A complete list of the 
Centre’s publications is available from the FMRC’s website <sydney.edu.au/medicine/fmrc/>. 
 
ISSN  1442-3022 
ISBN  9781743325131 (print) 
ISBN  9781743325148 (online) 
 
 
Suggested citation  
Britt H, Miller GC, Henderson J, Bayram C, Harrison C, Valenti L, Pan Y, Charles J, 
Pollack AJ, Wong C, Gordon J. General practice activity in Australia 2015–16. General 
practice series no. 40. Sydney: Sydney University Press, 2016. 
Available at <purl.library.usyd.edu.au/sup/9781743325131> 
 
Keywords 
Australia, delivery of health care/statistics and numerical data, family practice/statistics and 
numerical data, general practice, health services utilization, healthcare surveys/methods. 
 
Companion publication  
Britt H, Miller GC, Bayram C, Henderson J, Valenti L, Harrison C, Pan Y, Charles J, 
Pollack AJ, Chambers T, Gordon J, Wong C. A decade of Australian general practice activity 
2006–07 to 2015–16. General practice series no. 41. Sydney: Sydney University Press, 2016 
Available at <purl.library.usyd.edu.au/sup/9781743325155> 
 
Cover design by Miguel Yamin 
 
Printed in Australia 
 iii 
 Preface 
This report and its companion volume A decade of Australian general practice activity 2006–07 to 
2015–16 are the last annual reports from the Bettering the Evaluation and Care of Health (BEACH) 
program. 
The BEACH program was born in the late 1990s out of the growing perceived need for the 
development and collection of standardised data on primary medical care encounters in Australia. 
While sections of the Commonwealth Department of Health (DoH) clearly recognised the need for 
ongoing up-to-date information about the clinical activities of GPs, the DoH was not willing or able to 
fund a continuous program in full. However, it did agree to consider a contribution to its costs.  
After about 20 years of methods development, largely funded by NHMRC grants, in 1997 the Family 
Medicine Research Unit (FMRU) in the Department of General Practice at the University of Sydney 
was ready to launch a continuing data collection program, and approached the Australian Institute of 
Health and Welfare (AIHW) as a collaborator. This led to the establishment of the General Practice 
Statistics and Classification Unit (GPSCU), a collaborating unit of the AIHW located within the FMRU 
at the University of Sydney.  
We sought funding from the pharmaceutical industry, and approached a range of other Government 
Departments and instrumentalities. Sufficient research contracts were established for the GPSCU to 
start the BEACH program on 1st April 1998 and data collection continued uninterrupted until 30 March 
2016. The FMRU became a recognised Centre (FMRC) of the University in 1999. 
The BEACH program built on the lessons learned in the Australian Morbidity and Treatment Survey 
and Country Metropolitan Study conducted by the FMRU in 1990 and on further methods using that 
data as the basis for modelling the required sample size to represent Australia, developing more 
specific coding systems for pharmaceutical and clinical treatments, and new analytical tools to deal 
with the complex relationships between patients, GPs, patient’s reasons for encounter, problems 
managed, and management actions provided by GPs in management of each individual problem.  
In BEACH we also added a new concept of patient based sub-studies (called Supplementary Analysis 
of Nominated Data (SAND) studies) conducted in conjunction with the collection of GP–patient 
encounter data. BEACH was designed as a continuous ongoing program rather than the ‘snapshot’ 
approach used in previous Australian studies and virtually all overseas GP data collection programs.  
Over 18 years BEACH has provided an invaluable source of timely data to describe general practice 
activity and inform improvements in primary health care service provision. BEACH and the associated 
SAND studies have also provided a rich source of data for analysis by the BEACH research team, 
frequently in collaboration with other stakeholders and academics across Australia. 
The FMRC research outputs include:  
• 41 BEACH books, 7 other books and contributions to a further 10 books 
• about 178 refereed articles in recognised journals (with 3 in press, 5 under review and more about 
to be submitted),  
• 140 unrefereed articles in recognised journals  
• 71 papers in other journals and publications (e.g. ‘Bytes from BEACH’ FMRC web site, articles in 
The Conversation, etc.) 
• 16 theses and treatises (incl. 5 PhDs) 
• 223 SAND sub-studies on a wide range of topics (all published as Abstracts) 
• hundreds of conference presentations 
• over 1000 bespoke reports for stakeholders, researchers, governments and industry. 
 iv 
Funding for BEACH has never been certain throughout the 18 years of the program and the team 
have lived with annual renewable appointment (dependent on funding availability) throughout. BEACH 
and the FMRC have now closed due to lack of direct support from the Australian Government and 
dwindling support from a health industry plagued by a lack of research resources.  
The BEACH resource is unique in its ability to inform research, policy and practice and it is of deep 
concern that there is currently nothing to replace it. Its demise will leave a large gap in our 
understanding of the care provided by GPs to the community.  
The FMRC was not the only casualty of the withdrawal of government support – the Australian Primary 
Health Care Research Institute and its associated research centres have closed and the Primary 
Health Care Research and Information Service is on borrowed time. This brings to an end 25 years of 
high quality general practice research, funding for which was initiated by the recommendations of the 
Senate Select Committee on vocational registration in 1989 and long supported by the 
Commonwealth Government. 
In this new era, download of data collected by GPs in patient’s electronic health records (EHRs) is the 
flavour of the month. Basic methodological processes developed by the BEACH team – such as 
standardised coding and classification, and mandatory recorded relationships between problem 
management and the management actions taken – are being ignored. 
‘Big data’ is seen as the solution – people seem to believe that sheer size overrides the need for data 
quality. Based on our experience, big data will not be better than ‘small data’ until standards are 
applied to the core information in the EHRs, including standardised data elements and data 
definitions, specified data element relationships (e.g. management actions linked to a problem 
managed), minimum data sets for ‘patient’ and ‘encounter’, standardised classifications and 
terminologies and a standard definition of what constitutes ‘chronic’.1 Currently, NPS MedicineWise, 
almost all the Primary Health Networks, multiple university departments, state governments and 
commercial consulting organisations all collect and analyse data in their own way, and so none of the 
results can be comparable with the other. This work is being done at massive cost, and yet we have 
yet to see published reports of findings. We can only conclude that in the foreseeable future, without 
BEACH there will be very little reliable, independent national information publicly available about GP 
clinical activity. 
The care of accumulated BEACH databases has been transferred within the University of Sydney, to 
the Menzies Centre for Health Policy, and will continue to be a rich resource of data for research into 
general practice. Researchers, government, and industry are encouraged to visit the FMRC website 
for further contact details to request reports from the BEACH data. The website will remain a source of 
information about a wide range of topics related to general practice in Australia. 
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 Summary 
This report describes clinical activity at, or associated with, general practitioner (GP) encounters from 
April 2015 to March 2016 inclusive. It summarises results from the 18th year of the Bettering the 
Evaluation and Care of Health (BEACH) program, using a nationally representative sample of 96,500 
patient encounters with 965 randomly selected GPs, each of whom recorded details of 100 patient 
encounters. After post-stratification weighting, 97,398 encounters were analysed in this report (see 
Chapter 2, Methods). 
The companion report highlighting major changes over the most recent 10 years of BEACH,  
A decade of Australian general practice activity 2006–07 to 2015–16,1 is available at 
<purl.library.usyd.edu.au/sup/9781743325155>. 
The general practitioners (Chapters 3 and 4) 
Of the 965 participating GPs: 
• 55% were male, 45% were aged 55 years and over, 61% had graduated in Australia 
• 63% were Fellows of the Royal Australian College of General Practitioners (RACGP), and 7% 
Fellows of the Australian College of Rural and Remote Medicine (ACRRM) 
• 69% practised in major cities 
• the average hours per week in direct patient care was 37 
• the vast majority (84%) worked in a practice employing practice nurses, and 81% in practices 
with co-located pathology collection services 
• less than half (38%) worked in practices that supplied their own or cooperative after-hours care. 
The mean number of Medicare Benefits Schedule (MBS) GP service items claimed by participants 
over the previous year did not differ from the average for all GPs in the sample frame. The BEACH 
GP sample had slight over-representation of GPs aged 55 years or over. Statistical weighting was 
applied to correct this. After weighting, the age–sex distribution of patients at BEACH encounters had 
an excellent fit (precision ratios 0.87–1.08), with that of patients at all GP services claimed through the 
MBS. 
The encounters (Chapter 5) 
The patient was seen by the GP (direct encounters) at 99% of all encounters at which a payment 
source was recorded: 97% of these were claimable through the MBS or the Department of Veterans’ 
Affairs (DVA), of which 77% were designated standard surgery consultations (Item 23). In a 
subsample of 32,191 MBS/DVA-claimable encounters at which start and finish times were recorded, 
the mean length of consultation was 14.9 minutes, and the median was 13.0 minutes. 
Clinical content of the GP–patient encounters (Chapters 5 and 8) 
Chapter 5 shows that at an average 100 encounters, patients gave 153 reasons for encounter 
(RFEs), and GPs managed 154 problems, including 53 chronic and 60 new problems. 
They prescribed 82 medications, supplied a further 9 and advised purchase of 11 over-the-counter 
medications. They provided 39 clinical treatments, undertook 18 procedures, made 10 referrals to 
medical specialists and 6 to allied health services, placed 48 pathology test orders and 11 imaging 
test orders. 
Chapter 8 shows that on average for every 100 problems they managed, GPs provided 53 
prescriptions and 25 clinical treatments, undertook 11 procedures, made 6 referrals to medical 
specialists and 4 to allied health services, and placed 31 pathology test orders and 7 imaging test 
orders. 
 xiii 
At least one management action occurred at 92% of encounters, for 86% of problems managed. 
When extrapolated to all MBS-claimed GP consultations: 
• at least one medication was prescribed, advised for over-the-counter purchase, or supplied at 
about 90 million GP–patient encounters in 2015–16 
• at least one procedure was undertaken at 23 million encounters 
• at least one referral to a specialist, allied health professional, hospital or emergency department 
was provided by GPs at 21 million encounters nationally 
• one or more pathology, imaging or other test was ordered at 37 million encounters. 
Who were the patients and why did they see the GP? (Chapter 6)  
Female patients accounted for 57% of encounters, and the greater proportion of encounters in all 
adult age groups. Patients aged less than 25 years accounted for 19% of encounters; those aged 
25–44 years for 23%; 45–64 years for 27%; and those aged 65 years and over for 31% of encounters. 
• The patient was new to the practice at 7% of encounters. 
• Nearly half the encounters were with patients who held a Commonwealth concession card (46%) 
and/or a Repatriation Health Card (2%). 
• One in ten encounters was with a patient from a non-English-speaking background. 
• At 2% of encounters the patient identified themselves as an Aboriginal and/or Torres Strait 
Islander person. 
At an average 100 encounters, patients presented 153 RFEs including 64 symptoms/complaints, 
28 diagnosed diseases, 24 procedural needs and 16 requests for treatment. At 59% of encounters 
only one RFE was recorded, at 30% two and at 12% three. The most common RFEs were requests 
for prescriptions, test results and check-ups. 
What problems do GPs manage at patient encounters? (Chapter 7) 
There were 150,279 problems managed, an average 154 problems per 100 encounters: one problem 
was managed at 61% of encounters, two at 26%, three at 9%, and four at 3%. The number of 
problems increased steadily with patient age from young adulthood. 
Two-thirds (65%) of problems were described as diagnoses or diseases, but 19% remained 
undiagnosed symptoms or complaints, and 10% were labelled procedures (for example, check-ups). 
• The most commonly managed were those of a general and unspecified nature (20 per 100 
encounters), respiratory (20), musculoskeletal (18), skin (17), and circulatory (15) problems. 
• Individual problems most often managed were hypertension (8 per 100 encounters), check-ups 
(6), upper respiratory tract infection (6), immunisation/vaccination (5) and depression (4). 
• At least one chronic problem was managed at 40% of encounters. More than half of all chronic 
problems managed were accounted for by: non-gestational hypertension (14% of chronic 
conditions), depressive disorder (8%), non-gestational diabetes (8%), chronic arthritis (7%), lipid 
disorder (6%), oesophageal disease (5%), and asthma (4%). 
Extrapolation of these results suggests that nationally in 2015–16, 11 million encounters involved 
management of non-gestational hypertension, 6 million involved depression and 6 million involved 
non-gestational diabetes. 
Medications (Chapter 9) 
One or more medications were prescribed at 52% of encounters, for 42% of the problems managed. 
There were 79,871 prescriptions recorded, at rates of 82 per 100 encounters or 53 per 100 problems 
managed. Extrapolated results suggest GPs prescribed at least one medication at 74 million 
encounters nationally. 
 xiv 
GPs recorded 76% of prescribed medications by brand (proprietary) name and 24% by their generic 
(non-proprietary) name. For 37% of prescriptions, no repeats were prescribed, and for 36% five 
repeats were ordered. Ordering one repeat was also quite common (14%). 
Medications most often prescribed were those acting on the nervous system (accounting for 24% of 
all prescribed medications), particularly opioids and antidepressants; anti-infectives for systemic use 
(18%), including antibiotics and antivirals and medications for the cardiovascular system (18%), 
particularly anti-hypertensives and lipid lowering agents. However, the 10 individual drugs most 
frequently prescribed (accounting for 20% of all), included three antibiotics, paracetamol and 
paracetamol/codeine, oxycodone and three lipid-lowering agents. 
GPs supplied 9 medications direct to the patients per 100 encounters, or 6 per 100 problems 
managed. The most frequently supplied were largely vaccines. 
Over-the-counter medication was advised at 9% of encounters, (paracetamol accounting for 28% of 
these medications), equivalent to an estimated 13 million encounters nationally in 2015–16. 
Other treatments (Chapter 10) 
The GP provided other treatments at 42% of encounters, for 36% of all problems managed. 
Clinical treatments accounted for two-thirds of all other treatments, and were provided at a rate of 
39 per 100 encounters, or 25 per 100 problems managed. General advice and education (16% of 
clinical treatments) and counselling about the problem being managed (13%) were the most common 
treatments recorded. Preventive counselling/advice about nutrition and weight, exercise, smoking, 
lifestyle, prevention, and/or alcohol, were together given at a rate of 8 per 100 encounters. 
One in five problems was managed with a clinical treatment. Upper respiratory tract infection, 
depression, diabetes and hypertension represented the largest proportion of problems managed with 
a clinical treatment. 
Procedural treatments were recorded at a rate of 18 per 100 encounters, or 11 per 100 problems 
managed. Excision (17% of procedural treatments), local injection (14%) and dressing (14%) 
accounted for almost half of these. One in ten problems were managed with a procedure. 
Laceration/cut (5%), female genital check-up/Pap smear (5%) and solar keratosis/sunburn (4%) 
accounted for the largest proportion of problems managed with a procedure. 
Referrals and admissions (Chapter 11) 
GPs made 16 referrals per 100 encounters, or 10 per 100 problems managed. The most frequent 
were to medical specialists (10 per 100 encounters, 6 per 100 problems managed), and to allied 
health services (6 per 100 encounters, 4 per 100 problems managed). Very few patients were 
referred to hospitals or emergency departments (0.6 per 100 encounters). 
Referrals to specialists were most often to orthopaedic surgeons (9% of specialist referrals), 
dermatologists (8%), surgeons (8%) and cardiologists (8%). Malignant skin neoplasms, osteoarthritis, 
sleep disturbance and diabetes were the problems most often referred to medical specialists. The five 
problems most frequently referred to each of 10 medical specialties are described in Chapter 11. 
Referrals to allied health services were most often to physiotherapists (29% of allied health referrals), 
psychologists (22%), podiatrists/chiropodists (12%) and dietitians/nutritionists (9%). Problems most 
likely to be referred to allied health services were depression, diabetes and back complaint. 
Tests and investigations (Chapter 12) 
Pathology tests ordered: GPs recorded 48 orders for pathology tests (or batteries of tests) per 
100 encounters (31 per 100 problems managed). At least one pathology test was recorded at 18% of 
encounters, or 14% of problems managed. 
• Chemistry tests accounted for 59% of pathology test orders. Lipid tests, electrolytes, urea and 
creatinine tests, thyroid function tests, and multi-biochemical analysis were the most common 
(each ordered at a rate of 2 per 100 problems managed). 
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• Haematology tests accounted for 17% of pathology tests ordered and included full blood count, 
the most frequently ordered individual test (14% of all pathology). 
• Microbiology accounted for 14% of pathology orders; urine microscopy, culture and sensitivity 
was the most commonly ordered. 
• Almost 40% of all pathology tests ordered were generated in the management of 10 problems. 
The problems generating the highest volumes of testing were diabetes, hypertension, general 
check-ups, and weakness/tiredness. 
Imaging ordered: 11 imaging tests were ordered per 100 encounters, and 7 per 100 problems 
managed. At least one was ordered at 9% of encounters (for 6% of problems managed). Ultrasound 
accounted for 44% and diagnostic radiology for 39% of all imaging orders. 
Patient risk factors (Chapter 13) 
Overweight and obesity in adults (18 years and over): Of 31,662 adults, 63% (70% of males and 
59% of females) were overweight (35%) or obese (29%). Estimated prevalence in adults who 
attended general practice at least once in 2015–16 was 34% overweight and 28% obese. 
Overweight and obesity in children (2–17 years): Of 3,077 children, 28% were overweight (18%) or 
obese (10%). Prevalence pattern by age did not differ between the sexes. 
Smoking status (adults 18 years and over): Of 32,664 adults, 13% (16% of males and 12% of 
females) were daily smokers. For the population attending one or more times, an estimated 16% were 
daily smokers, 3% occasional, 25% previous smokers and 56% had never smoked. 
Alcohol consumption in adults (18 years and over): Of 31,720 adult patients, 23% (27% of males, 
20% of females) reported at-risk alcohol consumption. Adjusted data suggested 25% of the attending 
population are consuming at-risk levels of alcohol. 
Adult risk profile (18 years and over): Of the 30,672 patients providing all risk factor data: 25% had 
none, 54% one and 21% two or three risk factors. Adjusted to the attending population, 24% had no 
risk factors, 52% had one, 20% two and 4% had all three risk factors. 
Care of middle-aged people in general practice (Chapter 14) 
This feature chapter explores the care of people aged 45–64 years in general practice between 
April 2000 and March 2016 using data from the BEACH study and several of its substudies. We 
examine GP services provided, the content of the encounters, and the prevalence of chronic 
problems and multimorbidity. We also examine lifestyle risk factors (smoking, alcohol consumption 
and overweight) for patients in this age group. 
By examining this group of patients we may identify areas where interventions delivered now could 
prevent some of the complex morbidity found in older patients, and potentially improve and enhance 
their long term health. 
Supplementary Analysis of Nominated Data (SAND) substudies (Chapter 15) 
Abstracts are provided for each of 13 recent SAND substudies which investigated aspects of the 
health of subsamples of patients at the encounter that are not captured in the encounter data. 
Changes in general practice activity over the decade, 2006–07 to 2015–16  
The companion publication A decade of Australian general practice 2006–07 to 2015–16 reports the 
results of each of the most recent 10 years of BEACH data and identifies changes in practice over the 
decade based on almost one million GP–patient encounter records, from 9,721 participating GPs. 
Estimates of the national effect of changes in activity are made through extrapolation to total Medicare 
GP consultation items claimed in the first and last year of the decade. 
Over the decade, Australia’s population rose by 17% and the proportion aged 65 years and over  
rose by one-third. About 83% of the population claimed one or more GP services from Medicare in 
2006–07 and compared with 87% in 2015–16. However, the number of Medicare-claimed GP 
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consultations grew by 38%, from 103 million to 143 million. The average GP visits per capita rose 
from 5.0 to 6.0, and for those who saw a GP at least once, from 6.0 to 6.9 visits. 
The general practice profession became more feminised, were older, were less likely to be Australian 
graduates, and worked fewer hours per week. The average length of MBS-claimed consultations 
increased from 14.1 to 14.9 minutes and the median length from 12 to 13 minutes. Patients aged 
65 years or more accounted for an increasing proportion of GPs’ workload. 
In 2015–16, GPs managed 154 problems per 100 encounters, significantly more than a decade 
earlier (149). This increase and the increased visit rate has had a huge national effect on the 
complexity of GP services. When the growth in problems managed is combined with increase in 
actions per 100 problems managed, even larger national growth occurs. The management rate of 
chronic conditions did not change over the decade, but there were increases in depressive disorder, 
hypothyroidism/myxoedema, chronic back pain and unspecified chronic pain. Extrapolation of results 
to all MBS-claimed GP consultations suggests that nationally, GPs managed 67 million more 
problems, including 21 million more chronic problems, in 2015–16 than a decade earlier. 
The major changes that occurred from 2006–07 to 2015–16 are summarised below.  
• Prescribed medications decreased from 56 to 53 per 100 problems. However, due to the increase 
in problems managed and the higher attendance rate, we estimate 31 million more prescriptions 
were given in 2015–16 than in 2006–07. 
• The rate of GP-supplied medications did not change significantly but supplied childhood vaccines 
increased. 
• Clinical treatments increased (from 20 and 25 per 100 problems managed). Combined with the 
increase in problems managed and higher attendance rates, this equated to 25 million more 
clinical treatments given nationally. 
• Procedural treatments increased significantly, from 10 to 11 per 100 problems managed, with a 
national extrapolated effect of about 10 million more procedures in 2015–16. 
• The rate of referrals to both medical specialists and allied health services increased. These 
results suggest 5 million more referrals were made to medical specialists and 5 million more to 
allied health.  
• Orders for pathology tests/test batteries increased by 8%, from 29 to 31 per 100 problems, with a 
national extrapolated effect of about 24 million more tests/batteries ordered by GPs in 2015–16. 
• Orders for imaging tests increased significantly from 6 to 7 per 100 problems managed, 
suggesting 6 million more tests were ordered nationally in 2015–16 than in 2006–07. 
Patient risk factor data are presented in the companion report for each year from 2007–08 to  
2015–16. Prevalence of obesity, smoking and alcohol consumption among the adult patient 
population who attended general practice at least once in each year showed: 
• obesity increased from 23% to 28% 
• daily smoking decreased from 19% to 16% 
• at-risk alcoholic consumption decreased from 29% to 25%. 
 
 
  
 1 Introduction 
This is the 18th annual report and the 40th book in the General practice series from the BEACH 
(Bettering the Evaluation and Care of Health) program, a continuous national study of general practice 
activity in Australia. It provides the annual results for the period April 2015 to March 2016 inclusive, 
using details of 965,000 encounters between general practitioners (GPs) and patients from a random 
sample of 965 practising GPs across the country. 
Released in parallel with this report is a summary of results from the most recent 10 years of the 
BEACH program, A decade of Australian general practice activity 2006–07 to 2015–16,1 available at 
<purl.library.usyd.edu.au/sup/9781743325155>. The major changes that occurred over the decade 
are summarised at the end of each chapter of this annual report. 
BEACH began in April 1998 and closed in June 2016 after 18 years of continuous data collection. 
BEACH was supported financially by government and private industry (see Acknowledgments). 
BEACH was a continuous national study in which ever-changing random samples of about 1,000 
individual general practitioners (GPs) participated each year. Each participating GP recorded details of 
100 consecutive GP–patient encounters with consenting patients. 
BEACH was the only study of its kind in the world, and the only national program that provides direct 
linkage of management actions (such as prescriptions, referrals, investigations) to the problem under 
management. The BEACH database now includes information for almost 1.8 million encounters from 
17,707 participating GPs representing 10,789 individual GPs. Researchers and the public can 
continue to access reports from the BEACH data set (see Section 1.4). A discussion of principles for 
consideration in future general practice data collection is included in the Preface of this report. 
1.1 Background 
General practitioners (GPs) are usually the first port of call in the Australian healthcare system, 
generally receiving payment on a fee-for-service basis. There are no formal patient lists or registration. 
People are free to see multiple practitioners and visit multiple practices of their choice. A universal 
medical insurance scheme (managed by Medicare Australia) covers all, or part of a person’s costs for 
a GP visit. 
From June 2006 to June 2015, the population of Australia rose by 17%, from 20.6 million to 
24.1 million.2 At least one GP consultation was claimed from Medicare by 82.7% of the population in 
2006–073 and this increased to 86.9% in 2015–16 (personal communication, Australian Government 
Department of Health [DoH], May 2016). The number of Medicare-claimed GP consultation items 
(total non-referred attendances excluding practice nurse items) grew by 38% from 103.4 million to 
143.0 million.3,4 This equates to about 760,000 more Medicare-claimable GP consultations provided 
nationally per week than a decade earlier. 
In 2006–07, the average number of GP visits per capita was 5.0, and those who visited at least once 
claimed an average 6.0 visits.3 For the 2015–16 BEACH year, the average number of GP visits per 
capita was 6.0 or 6.9 visits per person who visited at least once (personal communication, Australian 
Government DoH, May 2016). 
Australia’s health expenditure in 2013–14 was $154.6 billion, $6,639 per capita, and accounted for 
9.8% of gross domestic product (GDP). Governments funded 60.8% of the total, with the remainder 
(39.2%) paid by the non-government sector and by individuals.5 In the 2015–16 financial year, 
government expenditure on general practice services (total non-referred attendances including 
GP/vocationally recognised GP, Enhanced Primary Care, other, and practice nurse items) was almost 
$6.8 billion.3 
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According to reports from the Australian Institute of Health and Welfare (AIHW), in Australia in 2014 
there were 26,885 medical practitioners self-identifying as GPs, making up 110.6 full-time equivalents 
(FTE, based on a 40-hour week) per 100,000 population.6 In contrast, general practice workforce 
statistics from DoH indicate that in 2013–14 there were 32,401 GPs (defined as GPs or Other Medical 
Practitioners who provided at least one Medicare-claimed GP service during that year), making up 
19,365 FTE.7 
While Medicare statistics provide information about frequency and cost of visits claimed from Medicare 
for GP service items, they cannot tell us about the content of these visits. The BEACH program has 
filled this gap by providing an understanding of this content. 
1.2 The BEACH program 
In summary, the BEACH program was a continuous national study of general practice activity in 
Australia. Each year, an ever-changing random sample of about 1,000 practising GPs participated, 
each recording details of 100 patient encounters on structured paper-based recording sheets 
(Appendix 1). This provided details of about 100,000 GP–patient encounters per year. The GPs also 
provided information about themselves and their major practice (Appendix 2). The BEACH methods 
are described in Chapter 2 of this report. 
Aims 
The three main aims of the BEACH program were to: 
• provide a reliable and valid data collection process for general practice that is responsive to the 
ever-changing needs of information users, and provides insight into the evolving character of GP–
patient encounters in Australia 
• provide an ongoing database of GP–patient encounter information 
• assess patient risk factors and health states, and the relationship these factors have with health 
service activity. 
Current status of BEACH 
BEACH began in April 1998 and closed in 2016 at the end of its 18th year. The BEACH database now 
includes records for almost 1.8 million GP–patient encounters from 17,707 participating GPs. 
Each year we have published an annual report of BEACH results collected in the previous 12 months. 
This year’s publication reports results from April 2015 to March 2016. The companion publication A 
decade of Australian general practice activity 2006–07 to 2015–161 provides summaries of the 
changes observed in general practice over the most recent decade. 
The strengths of the BEACH program 
• BEACH was the only national study of general practice activity in the world that was continuous, 
relying on a random ever-changing sample of GPs. The ever-changing nature of the sample 
(where each GP can participate only once per triennium) ensured reliable representation of what 
was happening in general practice across the country. 
• The sheer size of the GP sample (1,000 per year) and the relatively small cluster of encounters 
around each GP, provided more reliable estimates than a smaller number of GPs with large 
clusters of patients and/or encounters.8 Our access to a regular random sample of recognised 
GPs in active practice, through DoH, ensured that the GP sample was drawn from a very reliable 
sample frame of currently active GPs. 
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• The sampling methods ensured that new entrants to the profession were available for selection 
because the sample frame was based on the most recent Medicare data. Where data collection 
programs use a fixed set of GPs over a long period, measuring what that group is doing at any 
one time or how that group has changed over time, there may well be a ‘training effect’ inherent in 
longer-term participation. Such measures cannot be generalised to the whole of general practice. 
Further, where GPs in the group have a particular characteristic in common (for example, all 
belong to a professional organisation to which not all GPs belong; all use a selected software 
system which is not used by all GPs), the group is biased and cannot represent all GPs. 
• We have sufficient details about the characteristics of all GPs in the sample frame to test the 
representativeness of the final BEACH GP sample, and to apply post-stratification weighting to 
correct for any under-representation or over-representation in the sample when compared with 
the sample frame. 
• Each GP recorded for a set number of encounters (100), but there is wide variance among them 
in the number of patient consultations they conduct in any one year. DoH therefore provided an 
individual count of activity level (that is, number of Medicare GP service items claimed in the 
previous period) for all randomly sampled GPs, allowing us to give a weighting to each GP’s set of 
encounters commensurate with his or her contribution to total general practice encounters. This 
ensured that the final encounters represent encounters with all GPs. 
• BEACH included all patient encounters and management activities provided at these encounters, 
not just those encounters and activities funded by Medicare. 
• The structured paper encounter form leads the GP through each step in the encounter, 
encouraging entry of data for each element (see Appendix 1), with instructions and an example of 
a completed form. The structure itself forces linkage of actions to the problem being managed. In 
contrast, systems such as electronic health records rely on the GP to complete fields of interest 
without guidance. 
• BEACH was the only continuous national study in the world in which management actions at 
encounter are directly linked by the GP to the problems under management. This provided a 
measure of the ‘quality’ of care rather than just a count of the number of times an action occurred 
(for example, how often a specific drug was prescribed). 
• The medication data include all prescriptions, rather than being limited to only those prescribed 
medications covered by the Pharmaceutical Benefits Scheme (PBS). BEACH is the only source of 
information on medications supplied directly to the patient by the GP, about the medications GPs 
advised for over-the-counter (OTC) purchase, the patients to whom they provide such advice and 
the problems managed in this way. 
• The inclusion of other (non-pharmacological) treatments such as clinical counselling and 
procedural treatments, provides provide a broader view of the interventions used by GPs in the 
care of their patients than other data sources. 
• The use of an internationally standard well-structured classification system (ICPC-2)9 designed 
specifically for general practice, together with the use of a clinical interface terminology, facilitates 
reliable classification of the data by trained secondary coders, and removes the guesswork often 
applied in word searches of available records (in free text format) and in classification of a 
concept. 
• The use of the World Health Organization’s (WHO) Anatomical Therapeutic Chemical (ATC) 
classification for pharmaceuticals at the generic level ensures reporting of medications data are in 
accordance with the international standard. 
• The analytical techniques applied to the BEACH data ensure that the clustering inherent in the 
sampling methods is dealt with. Results are reported with 95% confidence intervals. Users are 
therefore aware of the level of reliability of any estimate. 
• Reliability of the methods has been demonstrated by the consistency of results over time where 
change is not expected, and by the measurement of change when it might be expected. 
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1.3 Using BEACH data with other national data 
Users of the BEACH data might wish to integrate information from multiple national data sources to 
gain a more comprehensive picture of the health and health care of the Australian community. It is 
therefore important that readers are aware of how the BEACH data differ from those drawn from other 
sources. This section summarises differences between BEACH and other national sources of data 
about general practice in Australia. 
The Pharmaceutical Benefits Scheme  
Prescribed medications, for which a PBS subsidy has been paid when they are dispensed, are 
recorded by Medicare Australia. 
The PBS data: 
• count the prescription each time it crosses the pharmacist’s counter (so that one GP prescription 
written with five repeats in BEACH would be counted by the PBS six times if the patient filled all 
repeats) 
• count only prescribed medications that cost: 
– more than the minimum PBS subsidy for those holding a Commonwealth concession card 
and/or who have reached the safety net threshold  
– more than the PBS threshold (which is far higher) for non-concession card holders 
• will change with each change in the PBS co-payment level for non-Commonwealth concession 
cardholders – when the co-payment level increases, those medications that then fall under the 
new level will no longer be counted in the PBS for non-Commonwealth concession cardholders10 
• hold no record of the problem being managed (with the exception of authority prescriptions, which 
require an indication and account for a small proportion of PBS data). Morbidity cannot be reliably 
assumed on the basis of medication prescribed.11,12 
In BEACH: 
• total medications include those prescribed (whether covered by the PBS or not), those supplied to 
the patient directly by the GP, and those advised for OTC purchase 
• each prescription recorded reflects the GP’s intent that the patient receives the prescribed 
medication, and the specified number of repeats; the prescription, irrespective of the number of 
repeats ordered, is counted only once 
• the medication is directly linked to the problem being managed by the GP 
• there is no information on the number of patients who do not present their prescription to be filled 
(this also applies to the PBS). 
These differences have a major impact on the numbers of prescriptions counted and also affect their 
distribution. For example, the majority of broad spectrum antibiotics, such as amoxycillin, fall under the 
non-concessional card holders’ minimum subsidy level and would not be counted in the PBS data. 
The PBS data only include those filled under the PBS by a Commonwealth concession card holder or 
by people who had reached the annual safety net threshold.10 
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Medicare Benefits Schedule 
Pathology data from the MBS 
Pathology tests undertaken by pathologists that are charged to Medicare are recorded by Medicare 
Australia. However, these Medicare data are not comparable with BEACH data. 
• MBS pathology data reflect pathology orders made by GPs and other medical specialists. About 
70% of the volume of MBS pathology claims are for pathology ordered by GPs.13 
• Each pathology company can respond differently to a specific test order label recorded by the GP. 
For example, the tests completed by a pathologist in response to a GP order for a full blood count, 
may differ between companies. 
• The pathology companies can charge through the MBS only for the three most expensive items 
undertaken, even when more were actually done. This is called ‘coning’ and is part of the DoH 
pathology payment system. This means that the tests recorded in the MBS include only those 
charged for, not all those that were done. Coning applies only to GP pathology orders, not to 
those generated by other medical specialists. 
• Pathology MBS items contain pathology tests that have been grouped on the basis of cost (for 
example, ‘any two of the following … tests’). Therefore, an MBS item often does not give a clear 
picture of the precise tests performed. 
• This means that the MBS data reflect those tests billed to the MBS after interpretation of the order 
by the pathologist, and after selection of the three most expensive MBS items. 
In BEACH, the pathology data: 
• include details of pathology tests ordered by the participating GPs; however, each GP was limited 
to recording five tests or batteries of tests at each encounter. The number of tests/batteries 
ordered on any single occasion has been increasing.14 However, this measure is likely to be an 
underestimate because no more than five tests/batteries can be recorded per encounter in 
BEACH. 
• reflect the terms used by GPs in their orders to pathologists, which for reporting purposes have 
been grouped by the MBS pathology groups for comparability. 
The distributions of the two data sets will therefore differ, reflecting on the one hand the GP order, and 
on the other the MBS-billed services from the pathologist. 
Pathology ordering by GPs is described in Chapter 12 of this report. Those interested in pathology test 
ordering by GPs should also view the following publications: 
• Evaluation of pathology ordering by general practitioners in Australia (Doctoral thesis).15 
• Are rates of pathology test ordering higher in general practices co-located with pathology 
collection centres?16 This publication investigated the independent effect of general practice 
co-location with pathology collection centres on GP pathology test ordering in Sydney and 
Melbourne metropolitan areas. 
• Evidence-practice gap in GP pathology test ordering: a comparison of BEACH pathology data and 
recommended testing.17 
Imaging data from the MBS 
Some of the issues discussed regarding pathology data also apply to imaging data. Although coning is 
not an issue for imaging, radiologists can decide whether the test ordered by the GP is the most 
suitable and whether to undertake other or additional tests of their choosing. The MBS data therefore 
reflect the tests that are actually undertaken by the radiologist, whereas the BEACH data reflect those 
ordered by the GP. Those interested in GP ordering of imaging tests should also see Evaluation of 
imaging ordering by general practitioners in Australia.18 
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The Australian Health Survey 
The 2011–13 Australian Health Survey, conducted by the Australian Bureau of Statistics (ABS), 
includes the National Health Survey, the National Nutrition and Physical Activity Survey and the 
National Health Measures Survey. The National Health Survey provides estimates of population 
prevalence of some diseases, and a measure of the problems taken to the GP by people in the two 
weeks before they were surveyed. The National Health Measures Survey includes biomedical 
measures related to chronic disease and nutritional biomarkers.19  
• Prevalence estimates from the National Health Survey are based on self-reported morbidity from 
a representative sample of the Australian population, using a structured interview to elicit 
health-related information from participants. Prevalence estimates from the National Health 
Measures Survey are based on biomedical measures of diagnosed and undiagnosed disease. 
• The National Health Survey has the advantage of accessing people who do not go to a GP as 
well as those who do. They can, therefore, provide an estimate of population prevalence of 
disease and a point estimate of incidence of disease. However, self-report has been 
demonstrated to be susceptible to misclassification because of a lack of clinical corroboration of 
diagnoses.20 
• Prevalence estimates based on biomedical measures have the advantage of measuring 
diagnosed and undiagnosed disease. 
Management rates of health problems in general practice represent GP workload for a health problem. 
BEACH can be used to estimate the period incidence of diagnosed disease presenting in general 
practice through the number of new cases of that disease. The management rates of individual health 
problems and management actions can be extrapolated to national management rates. 
The general practice patient population sits between the more clinical hospital-based population and 
the general population, with 86.9% of Australians visiting a GP at least once in in 2015–16 (personal 
communication, Australian Government DoH, May 2016]). Disease management rates are a product 
of both the prevalence of the disease/health problem in the population and the frequency with which 
patients visit GPs for the treatment of that problem. Those who are older and/or have more chronic 
disease are, therefore, likely to visit more often, and have a greater chance of being sampled in the 
encounter data. 
Prevalence of selected diseases among the patient population seen at least once in general practice 
can be investigated using the Supplementary Analysis of Nominated Data method (see Section 2.6). 
Those interested in the prevalence of disease and multimorbidity should refer to the following papers: 
Estimating prevalence of common chronic morbidities in Australia,21 Prevalence and patterns of 
multimorbidity in Australia,22 Prevalence of chronic conditions in Australia,23 Examining different 
measures of multimorbidity, using a large prospective cross-sectional study in Australian general 
practice,24 and The prevalence of complex multimorbidity in Australia.25 
1.4 Access to BEACH data 
Public domain 
This annual publication provides a comprehensive view of general practice activity in Australia. The 
BEACH program has generated many papers on a wide variety of topics in journals and professional 
magazines. All published material from BEACH is available at 
<sydney.edu.au/medicine/fmrc/publications>. 
Throughout the 18 years of the program, a section at the bottom of each encounter form has been 
used to investigate aspects of patient health or healthcare delivery not covered by general practice 
consultation-based information. These substudies are referred to as SAND (Supplementary Analysis 
of Nominated Data). The SAND methods are described in Section 2.6. Abstracts of results and the 
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research tools used in all SAND substudies from April 1998 to March 2016 have been published. 
Those from: 
• April 1998 to March 1999 were published in Measures of health and health care delivery in 
general practice in Australia26 
• April 1999 to July 2006 were published in Patient-based substudies from BEACH: abstracts and 
research tools 1999–200627 
• August 2006 to March 2015 were published in each of the BEACH annual reports28-36 
• April 2015 to March 2016 are included in Chapter 15 of this report. 
Abstracts of results for all SAND substudies are also available on the Family Medicine Research 
Centre’s (FMRC) website <sydney.edu.au/medicine/fmrc/publications/sand-abstracts> where you can 
search by topic. 
Purchasing reports 
Following closure of the BEACH program, individuals and organisations will continue to be able to 
purchase standard reports or other ad hoc analyses. Charges are outlined at 
<sydney.edu.au/medicine/fmrc/beach/data-reports/for-purchase>. Contact details are provided at the 
front of this publication. 
Analysis of the BEACH data is a complex task. The FMRC designed standard reports that cover most 
aspects of a subject under investigation. Examples of a problem-based standard report, a group report 
and a pharmacological-based standard report for a single year’s data, are available at 
<sydney.edu.au/medicine/fmrc/beach/data-reports/for-purchase>. Customised data analyses can be 
done where the specific research question is not adequately answered through standard reports.  
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 2 Methods  
In summary: 
• each year, BEACH involved a new random sample of about 1,000 GPs 
• each GP recorded details of about 100 doctor–patient encounters of all types  
• the GP sample was a rolling (ever-changing) sample, with about 20 GPs participating in any one 
week, 50 weeks a year (with two weeks break over Christmas) 
• each GP could be selected only once per Quality Improvement & Continuing Professional 
Development (QI & CPD) Program triennium (that is, once in each 3-year period) 
• the encounter information was recorded by the GPs on structured paper encounter forms 
(Appendix 1) 
• GP participants also completed a questionnaire about themselves and their practice (Appendix 2). 
2.1 Sampling methods 
The source population included all vocationally registered GPs and all general practice registrars who 
claimed a minimum of 375 Medicare general practice items of service in the most recently available  
3-month Medicare data period (which equates to 1,500 such claims in a year). This ensured inclusion 
of the majority of part-time GPs, while excluding those who are not in private practice but claim for a 
few consultations a year. 
The Medicare statistics section of the Department of Health (DoH) updated the sample frame quarterly 
from the Medicare claims data. They then removed from the sample frame any GPs already randomly 
sampled in the current triennium, and drew a new sample from those remaining in the sample frame. 
This ensured the timely addition of new entries to the profession, and timely exclusion of those GPs 
who have stopped practising, have already participated or been approached in the current triennium. 
2.2 Recruitment methods 
The randomly selected GPs were approached by letter, posted to the address provided by DoH. 
• Over the following 10 days, the telephone numbers generated from the Medicare data were 
checked using the electronic white and yellow pages. This was necessary because many of the 
telephone numbers provided from the Medicare data were incorrect. 
• The GPs were then telephoned in the order they were approached and, referring to the approach 
letter, asked whether they will participate. 
• This initial telephone contact with the practice often indicated that the selected GP had moved 
elsewhere, but was still in practice. Where a new address and/or telephone number could be 
obtained, these GPs were followed up at their new address. 
• GPs who agreed to participate were set an agreed recording date several weeks ahead. 
• A research pack was sent to each participant before the planned start date. 
• Each GP received a telephone reminder early in the agreed recording period – this also provided 
the GP with an opportunity to ask questions about the recording process. 
• GPs could use a ‘freecall’ (1800) number to ring the research team with any questions during their 
recording period. 
• Non-returns were followed up by regular telephone calls for 3 months. 
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• Participating GPs earned clinical audit points towards their QI & CPD requirements through the 
Royal Australian College of General Practitioners (RACGP) and/or the Australian College of Rural 
and Remote Medicine (ACRRM). As part of this QI process, each GP received an analysis of his 
or her results compared with those of nine other de-identified GPs who recorded at about the 
same time. Comparisons with the national average and with targets relating to the National Health 
Priority Areas were also provided. In addition, GPs received some educational material related to 
the identification and management of patients who smoke or consume alcohol at hazardous 
levels. Additional points could be earned if the participant chose to do a follow-up audit of smoking 
and alcohol consumption among a sample of patients about 6 months later. 
2.3 Ethics approval and informed patient consent 
Ethics approval for this study in 2015–16 was obtained from the Human Ethics Committee of the 
University of Sydney.  
Although the data collected by the GPs were not sufficient to identify an individual patient, informed 
consent for GP recording of the encounter details was required from each patient. GPs were 
instructed to ensure that all patients who presented during their recording period were provided with a 
Patient Information Card (Appendix 3), and asked if they were happy for their data to be included in 
the study. If the patient refused, details of the encounter were not recorded. This is in accordance with 
the ethics requirements for the BEACH program. 
2.4 Data elements 
BEACH includes three interrelated data collections: GP characteristics, encounter data and patient 
health status. An example of the form used to collect the encounter data and the data on patient 
health status is included in Appendix 1. The GP characteristics questionnaire is provided in 
Appendix 2. The GP characteristics and encounter data collected are summarised below. Patient 
health status data are described in Section 2.6. 
GP profile form (Appendix 2) 
• GP characteristics: age and sex, years in general practice, number of direct patient care hours 
worked per week, country of graduation, general practice registrar status, Fellow of the RACGP 
status, Fellow of the ACRRM status, use of computers at work for clinical purposes, work 
undertaken in other clinical settings, number of practice locations worked in a regular week. 
• Practice characteristics: postcode of major practice, number of individual and number of full-
time equivalent (FTE) GPs working in the practice, number of individual and number of FTE 
practice nurses working in the practice, usual after-hours care arrangements, other health services 
located at the major practice. 
Encounter recording form (Appendix 1) 
• Encounter data: date of consultation, type of consultation (direct/indirect) (tick box options), up to 
three Medicare Benefits Schedule (MBS)/Department of Veterans’ Affairs (DVA) item numbers 
(where applicable), and other payment source (where applicable) (tick box options). 
• Patient data: date of birth, sex and postcode of residence. Tick boxes (yes/no options) were 
provided for Commonwealth concession card holders, holders of a Repatriation Health Card (from 
DVA), non-English-speaking background (patient self-reported that a language other than English 
is the primary language at home), Aboriginal person (self-identification), and Torres Strait Islander 
person (self-identification). Space is provided for up to three patient reasons for encounter (RFEs) 
(see Glossary). 
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• The problems managed at encounter (at least one and up to four). Tick boxes were provided to 
denote the status of each problem as new or continuing for the patient. 
• Management of each problem, including: 
– medications prescribed, supplied by the GP and advised for over-the-counter (OTC) purchase 
including brand name, form (where required), strength, regimen, status (new or continuing 
medication for this problem), number of repeats 
– other treatments provided for each problem, including counselling, advice and education, and 
procedures undertaken, and whether the recorded other treatment was provided by a practice 
nurse (tick box) 
– new referrals to medical specialists, allied health services, emergency departments, and 
hospital admissions 
– investigations, including pathology tests, imaging, and other investigations ordered.  
2.5 The BEACH relational database 
The BEACH relational database is described diagrammatically in Figure 2.1. Note that:  
• all variables can be directly related to the encounter, the GP and the patient characteristics 
• all types of management are directly related to the problem being managed  
• RFEs have only an indirect relationship with problems managed, as a patient may have described 
one RFE (such as ‘repeat prescriptions’) that relates to multiple problems managed, or several 
RFEs (such as ‘runny nose’ and ‘cough’) that relate to a single problem managed (such as upper 
respiratory tract infection) (see Section 6.3). 
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The encounter 
 date 
 direct (face to face) 
— Medicare/DVA item 
number(s) claimable 
— workers compensation 
— other paid 
— no charge 
 indirect (e.g. telephone) 
Patient substudies (SAND) 
 risk factors 
— body mass 
— smoking status 
— alcohol consumption  
 other topics 
Management of each problem 
Medications (up to four per problem) 
 prescribed 
 over-the-counter advised 
 provided by GP 
— drug class 
— drug group 
— generic 
— brand name 
— strength 
— regimen 
— number of repeats  
— drug status (new/continued) 
 
Other treatments (up to two per 
problem) 
 procedural treatments 
 clinical treatments (e.g. advice, 
counselling) 
 practice nurse involvement 
 
Other management 
 referrals (up to two) 
— to specialists 
— to allied health professionals 
— to emergency departments 
— hospital admissions 
 pathology tests ordered (up to five) 
 imaging ordered (up to three) 
GP characteristics 
 age and sex 
 years in general practice 
 country of graduation 
 direct patient care hours/week 
 FRACGP status (yes/no) 
 FACRRM status (yes/no) 
 currently a registrar (yes/no) 
 clinical use of computers  
 
Practice characteristics 
 practice size (no. & FTE GPs) 
 practice nurse(s) (no. & FTE) 
 after-hours arrangements 
 postcode  
 presence of other health services 
Problems managed 
 diagnosis/problem label 
 problem status (new/old) 
 work-related problem status 
The patient 
 age and sex 
 practice status (new/old) 
 Commonwealth concession 
card status 
 Repatriation Health Card status 
 postcode of residence 
 NESB/Indigenous status 
 reasons for encounter 
Note: FRACGP – Fellow of the Royal Australian College of General 
Practitioners; FACRRM – Fellow of the Australian College of 
Rural and Remote Medicine; FTE – full-time equivalent;  
DVA – Department of Veterans’ Affairs; NESB – non-English-
speaking background; SAND – Supplementary Analysis of 
Nominated Data. 
Figure 2.1: The BEACH relational database 
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2.6 Supplementary Analysis of Nominated Data  
A section at the bottom of each recording form investigated aspects of patient health or health care 
delivery in general practice not covered by the consultation-based data. These additional substudies 
are referred to as SAND, Supplementary Analysis of Nominated Data. 
• Each year, the 12-month data period was divided into 10 blocks, each of 5 weeks, with three 
substudies per block. The research team aimed to include data from about 100 GPs in each 
block. 
• Each GP’s pack of 100 forms included 40 forms that ask for the start and finish times of the 
encounter, and included questions about patient risk factors: patient height and weight (used to 
calculate body mass index, BMI), alcohol intake and smoking status (patient self-report). The 
methods and results of topics in the SAND substudies for alcohol consumption, smoking status 
and BMI are reported in Chapter 13. The start and finish times collected for these encounters are 
used to calculate length of consultation. The length of consultation for Medicare-claimable 
encounters is reported in Section 5.3. 
• The remaining 60 forms in each pack were divided into two blocks of 30, so each of these other 
SAND studies includes about 3,000 records (30 x 100 GPs). Different questions were asked of 
the patient in each block and these varied throughout the year. Some topics were repeated to 
increase sample size. 
• The order of SAND sections was rotated in the GP recording pack, so that 40 patient risk factor 
forms may appear first, second or third in the pad. Rotation of ordering ensures there was no 
order effect on the quality of the information collected. 
Abstracts of results and the research tools used in all SAND substudies from April 1998 to March 2016 
have been published. Those: 
• from April 1998 to March 1999 were published in Measures of health and health care delivery in 
general practice in Australia26 
• from April 1999 to July 2006 were published in Patient-based substudies from BEACH: abstracts 
and research tools 1999–200627 
• conducted between August 2006 and March 2015 have been published in each of the general 
practice activity annual reports28-36 
• conducted in the 2015–16 BEACH year are provided in Chapter 15 of this publication. 
Abstracts of results for all SAND substudies are also available on the FMRC’s website 
<sydney.edu.au/medicine/fmrc/publications/sand-abstracts>. 
2.7 Statistical methods 
The analysis of the 2015–16 BEACH data was conducted with Statistical Analysis System (SAS) 
version 9.3,37 and the encounter is the primary unit of inference. Proportions are used only when 
describing the distribution of an event that can arise only once at a consultation (for example, patient 
or GP age and sex), or to describe the distribution of events within a class of events (for example, 
problem A as a percentage of total problems). Due to rounding, proportions may not always add to 
exactly 100%. 
Calculations are made in SAS using the precise data with multiple decimal points. Therefore, if a 
reader recalculates the result from the reported rounded numbers presented in tables, their result may 
differ from that presented by 0.1.  
Rates per 100 encounters are used when an event can occur more than once at the consultation (for 
example, RFEs, problems managed or medications). 
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Rates per 100 problems are also used when a management event can occur more than once per 
problem managed. In general, the results present the number of observations (n), the rate per 100 
encounters, and (in the case of management actions) the rate per 100 problems managed, and the 
95% confidence interval. 
BEACH is a single stage cluster sample study design, each 100 encounters forming a cluster around 
each GP participant. In cluster samples, variance needs to be adjusted to account for the correlation 
between observations within clusters. Procedures in SAS version 9.3 were used to calculate 
intracluster correlation, and adjust the confidence intervals accordingly.37  
Post-stratification weighting of encounter data adjusts for: any difference in the age–sex distribution of 
the participating GPs and those GPs in the sample frame from which the samples were drawn; and for 
the varying activity level of each GP (measured by the number of claims each has made in the 
previous 12 months from Medicare Australia) (see Chapter 3). 
Statistical significance is tested by chi-square statistic for GP characteristics. However, where 
changes over time are investigated in the companion report, the significance of differences in rates is 
judged by non-overlapping confidence intervals (CIs) of the results being compared. The magnitude of 
this difference can be described as at least p < 0.05. Assessment using non-overlapping confidence 
intervals is a conservative measure of significance,38-40 particularly when differences are assessed by 
comparing results from independent random samples, as is the case when changes over time are 
investigated using BEACH data. Due to the number of comparisons made, we believe this 
conservative approach is warranted. 
2.8 Classification of data 
The following data elements are classified according to the International Classification of Primary Care 
– Version 2 (ICPC-2), of the World Organization of Family Doctors (Wonca):9 
• patient reasons for encounter (RFEs) 
• problems managed 
• clinical treatments (for example, counselling, advice) 
• procedural treatments 
• referrals 
• investigations ordered (including pathology, imaging and other investigations). 
The ICPC-2 is used in more than 45 countries as the standard for data classification in primary care. 
It is accepted by the WHO in the WHO Family of International Classifications,41 and is the declared 
national standard in Australia for reporting of health data from general practice and patient 
self-reported health information.42 
The ICPC-2 has a biaxial structure, with 17 chapters on one axis (each with an alphabetic code) and 
seven components on the other (numeric codes) (Figure 2.2). Chapters are based on body systems, 
with additional chapters for psychological and social problems. Component 1 includes symptoms and 
complaints. Component 7 covers diagnoses – it can also be expanded to provide data about 
infections, injuries, neoplasms, congenital anomalies and ‘other’ diagnoses. 
Component 2 (diagnostic, screening and prevention) is often applied in describing the problem 
managed (for example, check-up, immunisation). Components 3 to 6 cover other processes of care, 
including referrals, other (non-pharmacological) treatments and orders for pathology and imaging. The 
components are standard and independent throughout all chapters. The updated component 
groupings of ICPC-2 codes, released by the Wonca International Classification Committee in 200443 
have been used in this report. 
The ICPC-2 is an excellent epidemiological tool. The diagnostic and symptom rubrics have been 
selected for inclusion on the basis of their relative frequency in primary care settings, or because of 
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their relative importance in describing the health of the community. ICPC has about 1,370 rubrics and 
these are sufficient for meaningful analyses. However, reliability of data entry, using ICPC-2 alone, 
requires a thorough knowledge of the classification for correct classification of a concept to be 
ensured. 
In 1995, recognising a need for a coding and classification system for general practice electronic 
health records, the FMRC (then the Family Medicine Research Unit, FMRU) developed an extended 
clinical terminology classified according to the ICPC, now called ICPC-2 PLUS.44 This is an interface 
terminology, developed from all the terms used by GPs in studies such as The Australian Morbidity 
and Treatment Survey 1990–91 (113,468 encounters),45 A comparison of country and metropolitan 
general practice 1990–91 (51,277 encounters),46 The Morbidity and Therapeutic Index 1992–1998 (a 
clinical audit tool that was available to GPs; approximately 400,000 encounters), and BEACH  
1998–2016 (about 1.8 million encounters). Together, these make up about 2.4 million encounter 
records, involving about 3.5 million free text descriptions of problems managed and a further 
3.5 million descriptions of patient reasons for encounter. These terms are classified according to 
ICPC-2 to ensure data can be compared internationally. Readers interested in seeing how coding 
works can download the ICPC-2 PLUS Demonstrator at <sydney.edu.au/health-sciences/ncch/icpc-2-
plus/demonstrator.shtml>.  
When the free-text data are received from the GPs, trained secondary coders (who are undergraduate 
students), code the data in specific terms using ICPC-2 PLUS. This ensures high coder reliability and 
automatic classification of the concept, and allows us to ‘ungroup’ such ICPC-2 rubrics as ‘other 
diseases of the circulatory system’ and select a specific disease from the terms within it. 
 
 
                    
 Components A B D F H K L N P R S T U W X Y Z  
 1. Symptoms, complaints                    
 2. Diagnostic, screening, prevention                   
 3. Treatment, procedures, medication                   
 4. Test results                   
 5. Administrative                   
 6. Other                   
 7. Diagnoses, disease                   
 A General and unspecified L Musculoskeletal U Urinary 
 B Blood & blood-forming organs N Neurological W Pregnancy, family planning 
 D Digestive P Psychological X Female genital  
 F Eye R Respiratory Y Male genital  
 H Ear S Skin Z Social  
 K Circulatory T Endocrine, nutritional & metabolic   
 
Figure 2.2: The structure of the International Classification of Primary Care – Version 2 (ICPC-2) 
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Presentation of data classified in ICPC-2 
Statistical reporting is usually at the level of the ICPC-2 classification (for example, acute otitis 
media/myringitis is ICPC-2 code H71). However, there are some exceptions where data are grouped 
either above the ICPC-2 level or across the ICPC-2 level. These grouped morbidity, pathology and 
imaging codes are defined in Appendix 4 available at: <hdl.handle.net/2123/15514>. 
Reporting morbidity with groups of ICPC-2 codes 
When recording problems managed, GPs may not always be very specific. For example, in recording 
the management of hypertension, they may simply record the problem as ‘hypertension’. In ICPC-2, 
‘unspecified hypertension’ is classified as ‘uncomplicated hypertension’ (code K86). There is another 
code for ‘complicated hypertension’ (K87). In some cases, the GP may simply have failed to specify 
that the patient had hypertension with complications. The research team therefore feels that for 
national data reporting, it is more reliable to group the codes K86 and K87 and label this 
‘Hypertension*’ – the asterisk indicating that multiple ICPC-2 codes (as in this example), or ICPC-2 
PLUS codes (see below), are included. Appendix 4, Table A4.1 lists the codes included in these 
groups.  
Reporting morbidity with groups of ICPC-2 PLUS codes 
In other cases, a concept can be classified within (but be only part of) multiple ICPC-2 codes. For 
example, osteoarthritis is classified in ICPC-2 in multiple broader codes according to site, such as 
L92 – shoulder syndrome (includes bursitis, frozen shoulder, osteoarthritis of shoulder, rotator cuff 
syndrome). When reporting osteoarthritis in this publication, all the more specific osteoarthritis ICPC-2 
PLUS terms classified within all the appropriate ICPC-2 codes are grouped. This group is labelled 
‘Osteoarthritis*’ – the asterisk again indicating multiple codes, but in this case they are PLUS codes 
rather than ICPC-2 codes. Appendix 4, Table A4.1 lists the codes included in these groups. 
Reporting chronic morbidity 
Chronic conditions are medical conditions characterised by a combination of the following 
characteristics: duration that has lasted or is expected to last 6 months or more, a pattern of 
recurrence or deterioration, a poor prognosis, and consequences or sequelae that affect an 
individual’s quality of life. 
To identify chronic conditions, a chronic condition list47 classified according to ICPC-2 was applied to 
the BEACH data set. Chronic and non-chronic conditions (for example, diabetes and gestational 
diabetes) are often grouped together when reporting (for example, diabetes – all*). When reporting 
chronic morbidity, only problems regarded as chronic have been included in the analysis. Where the 
group used for the chronic analysis differs from that used in other analyses in this report, they are 
marked with a double asterisk. Codes included in the chronic groups are provided in Appendix 4, 
Table A4.2. 
Reporting pathology and imaging test orders 
All the pathology and imaging tests are coded very specifically in ICPC-2 PLUS, but ICPC-2 classifies 
pathology and imaging tests very broadly (for example, a test of cardiac enzymes is classified in  
K34 – Blood test associated with the circulatory system; a CT scan of the lumbar spine is classified as 
L41 – Diagnostic radiology/imaging of the musculoskeletal system). In Australia, the MBS classifies 
pathology and imaging tests in groups that are relatively well recognised. The team therefore 
regrouped all pathology and imaging ICPC-2 PLUS codes into MBS standard groups. This allows 
comparison of data between data sources. The groups are marked with an asterisk, and inclusions are 
provided in Appendix 4, Tables A4.7 and A4.8. 
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Classification of pharmaceuticals 
Pharmaceuticals that are prescribed, provided by the GP, or advised for over-the-counter purchase, 
are coded and classified according to an in-house classification, the Coding Atlas for Pharmaceutical 
Substances (CAPS). 
This is a hierarchical structure that facilitates analysis of data at a variety of levels, such as medication 
class, medication group, generic name/composition, and brand name. 
The generic name of a medication is its non-proprietary name, which describes the pharmaceutical 
substance(s) or active pharmaceutical ingredient(s). 
When strength and regimen are combined with the CAPS code, we can derive the prescribed daily 
dose for any prescribed medication or group of medications. 
CAPS is mapped to the Anatomical Therapeutic Chemical (ATC)48 classification, which is the 
Australian standard for classifying medications at the generic level.42 The ATC has a hierarchical 
structure with five levels. For example: 
• Level 1: C – Cardiovascular system 
• Level 2: C10 – Serum lipid reducing agents 
• Level 3: C10A – Cholesterol and triglyceride reducers 
• Level 4: C10AA – HMG CoA reductase inhibitors 
• Level 5: C10AA01 – Simvastatin (the generic drug). 
CAPS is now in the care of the National Centre for Classification in Health. Further information about 
CAPS is available from <sydney.edu.au/health-sciences/ncch/caps.shtml>.  
Use of the pharmaceutical classifications in reporting 
For pharmaceutical data, there is the choice of reporting in terms of the CAPS coding scheme or the 
ATC. They each have advantages in different circumstances. 
In the CAPS system, a new drug enters at the product and generic level, and is immediately allocated 
a generic code. Therefore, the CAPS classification uses a bottom-up approach. 
In the ATC, a new generic may initially enter the classification at any level (1 to 5), not always at the 
generic level. Reclassification to lower ATC levels may occur later. Therefore, the ATC uses a 
top-down approach. 
When analysing medications across time, a generic medication that is initially classified to a higher 
ATC level will not be identifiable in that data period and may result in under-enumeration of that drug 
during earlier data collection periods. 
There are some differences in the labels applied to generic medications in the two classifications. For 
example, the medication combination of paracetamol and codeine is labelled as ‘Paracetamol/codeine’ 
in CAPS and as ‘Codeine combinations excluding psycholeptics’ in the ATC. 
• When reporting annual results for pharmaceutical data, the CAPS database is used in tables of 
the ‘most frequent medications’ (Tables 9.2 to 9.4). 
• When reporting the annual results for pharmaceuticals in terms of the ATC hierarchy (Table 9.1), 
ATC levels 1, 3, and 5 are used. The reader should be aware that the results reported at the 
generic level (Level 5) may differ slightly from those reported in the ‘most frequent medication’ 
tables for the reasons described above. 
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2.9 Quality assurance 
All morbidity and therapeutic data elements were secondarily coded by staff entering key words or 
word fragments, and selecting the required term or label from a pick list. This was then automatically 
coded and classified by the computer. To ensure reliability of data entry, we used computer-aided 
error checks (‘locks’) at the data entry stage, and a physical check of samples of data entered versus 
those on the original recording form. Further logical data checks were conducted through SAS 
regularly. 
2.10 Validity and reliability 
A discussion of the reliability and validity of the BEACH program has been published elsewhere.49 This 
section touches on some aspects of reliability and validity of active data collection from general 
practice that should be considered by the reader. 
In the development of a database such as BEACH, data gathering moves through specific stages: GP 
sample selection, cluster sampling around each GP, GP data recording, secondary coding and data entry. 
At each stage the data can be invalidated by the application of inappropriate methods. The methods 
adopted to ensure maximum reliability of coding and data entry have been described above. The 
statistical techniques adopted to ensure valid analysis and reporting of recorded data are described in 
Section 2.7. Previous work has demonstrated the extent to which a random sample of GPs recording 
information about a cluster of patients represents all GPs and all patients attending GPs,50 the degree to 
which GP-reported patient RFEs and problems managed accurately reflect those recalled by the patient,51 
and reliability of secondary coding of RFEs52 and problems managed.45 The validity of ICPC as a tool with 
which to classify the data has also been investigated in earlier work.53 
2.11 Extrapolated national estimates 
A section at the end of each chapter highlights changes that have occurred over the decade 2006–07 
to 2015–16. These sections summarise results published in the companion publication, A decade of 
Australian general practice activity 2006–07 to 2015–16.1 Where the results demonstrate a significant 
change over time, the estimated national change across total GP Medicare services from 2006–07 to 
2015–16 can be calculated using the method detailed below. 
Note that extrapolations are always based on rate per 100 encounters rather than rate per 100 
problems because there is no independent measure of the total number of problems managed in 
Australian general practice. In contrast, the number of national encounters can be drawn from 
Medicare claims data. 
In this report, we also occasionally extrapolate data for a single year (usually 2015–16) to give the 
reader some feeling of the real size of the issue across Australian general practice. 
When extrapolating from a single time point we: 
• divide the ‘rate per 100 encounters’ of the selected event by 100, and then multiply by the total 
number of GP service items claimed through Medicare in that year, (for example, 143.0 million in 
2015–16, rounded to the nearest 100,000, see Table 2.1), to give the estimated number of the 
selected event across Australia in that year. 
When extrapolating measured change over the decade to national estimates, we: 
• divide the ‘rate per 100 encounters’ of the selected event for 2006–07 by 100, and then multiply 
by the total number of GP service items claimed through Medicare in that year, (103.4 million, 
rounded to the nearest 100,000, see Table 2.1), to give the estimated national number of events 
in 2006–07 
• repeat the process using data for 2015–16. 
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The difference between the two estimates gives the estimated national change in the frequency of that 
event over the decade. Estimates are rounded to the nearest 100,000 if more than 1 million, and to the 
nearest 10,000 if below 1 million. 
Change is expressed as the estimated increase or decrease over the study period (from 2006–07 to 
2015–16), in the number of general practice contacts for that event (for example, an increase or 
decrease in the number of GP management contacts with a certain problem), or an increase or 
decrease in the number of times a particular medication type was prescribed in Australia. 
Table 2.1 provides the rounded number of GP service items claimed from Medicare in each 
financial year from 2006–07 to 2015–16. 
 
Table 2.1: Rounded number of general practice professional services claimed from Medicare Australia 
each financial year, 2006–07 to 2015–16 (million) 
 2006–07 2007–08 2008–09 2009–10 2010–11 2011–12 2012–13 2013–14 2014–15 2015–16(a) 
Rounded number of 
Medicare GP items 
of service claimed 
103.4 109.5 113.0 116.6 119.2 123.9 128.7 134.2 139.4 143.0 
(a) Medicare data for the 2015–16 year included data from the April 2015 to March 2016 quarters because the 2015–16 financial year data 
were not available at the time of preparation of this report. 
Source: Medicare Statistics.3,4  
 
Examples of extrapolation 
Example 1: Number of GP encounters at which depression was managed nationally in 
2015–16 
Depression was managed at a rate of 4.2 per 100 GP encounters (95% CI: 4.0–4.4) in 2015–16 
(shown in Table 7.4). How many times does this suggest that depression was managed in GP 
encounters across Australia in 2015–16?  
Our best estimate is: 
6.0 million times [(4.2/100) x 143.0 million], but we are 95% confident that the true number 
lies between 5.7 million [(4.0/100) x 143.0 million] and 6.3 million [(4.4/100) x 143.0 million]. 
Using the management rate per 100 encounters as the basis for extrapolation, works very well 
when estimating total national GP encounters at which a single concept (symptom/complaint, or 
diagnosis/disease) is managed. However, if you wish to estimate how many GP–patient 
encounters involve management of any psychological problem, you need to use a different 
approach (see example 2 below). 
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Example 2: Number of GP encounters which involve management of psychological 
problems 
The concept ‘psychological problems’ includes many different individual concepts (for example, 
depression, dementia, anorexia nervosa, etc). In BEACH, GPs record at least one and up to four 
problems managed, per encounter. It is therefore possible that at a single encounter, a GP can 
manage more than one of the many problems classified as ‘psychological problems’ in the 
International Classification of Primary Care. 
If you use the management rate per 100 encounters to estimate the national number of 
encounters at which at least one psychological problem was managed in 2015–16, you will 
overestimate the true number of encounters, because more than one of these problems can be 
managed at a single encounter. 
To overcome this problem, we have a column on the right hand side of Table 6.4 (Patient reasons 
for encounter by ICPC-2 chapter and most frequent individual reasons for encounter within 
chapter) and Table 7.3 (Problems managed by ICPC-2 chapter and frequent individual problems 
within chapter), which gives you the proportion of all BEACH encounters at which at least one 
problem of each chapter type was managed. 
In the example provided, we use this column to answer the question: At how many encounters 
across Australia did GPs manage at least one psychological problem in 2015–16? 
Using the far right column of Table 7.3, our best estimate is: 
17.7 million times (12.4% of 143.0 million), but we are 95% confident that the true number 
lies between 17.0 million (11.9% of 143.0 million) and 18.4 million (12.9% of 143.0 million). 
 
Example 3: National increase in the number of problems managed from 2006–07 to  
2015–16 
There was a statistically significant increase in the number of problems managed at GP–patient 
encounters, from 148.5 per 100 encounters in 2006–07 to 154.3 in 2015–16 (see Table 7.2 in A 
decade of Australian general practice activity 2006–07 to 2015–16).1 The calculation used to 
extrapolate the effect of this change across Australia is:  
(148.5/100) x 103.4 million = 153.5 million problems managed nationally in 2006–07, and 
(154.3/100) x 143.0 million = 220.6 million problems managed nationally in 2015–16. 
This suggests there were 67.1 million (220.6 million minus 153.5 million) more problems managed 
at GP–patient encounters in Australia in 2015–16 than in 2006–07. This is the result of the 
compound effect of the increase in the number of problems managed by GPs at encounters plus 
the far higher number of visits across Australia in 2015–16 than in 2006–07. 
Considerations and limitations in extrapolations 
The extrapolations to the total events occurring nationally in any one year are only estimates. They 
may provide: 
• an underestimate of the true ‘GP workload’ of a condition/treatment because the extrapolations 
are made to GP Medicare items claimed, not to the total number of GP encounters per year – an 
additional 5% or so of BEACH encounters annually include encounters paid by sources other than 
Medicare, such as DVA, state governments, workers compensation insurance, and employers, or 
not charged to anyone. 
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• an underestimate of activities of relatively low frequency with a skewed distribution across 
individual GPs. Where activity is so skewed across the practising population, a national random 
sample will provide an underestimate of activity because the sample reflects the population rather 
than the minority. 
Further, the base numbers used in the extrapolations are rounded to the nearest 100,000, and 
extrapolation estimates are rounded to the nearest 100,000 if more than a million, and to the nearest 
10,000 if below a million, so can only be regarded as approximations. However, the rounding has 
been applied to all years, so the effect on measures of change will be very small. Therefore, the 
extrapolation still provides an indication of the size of the effect of measured change nationally. 
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 3 The sample 
This chapter describes the GP sample and sampling methods used in the BEACH program. The 
sampling and recruitment methods are only summarised in this chapter. A more detailed explanation 
of the BEACH methods is provided in Chapter 2. A summary of the BEACH data sets is reported for 
each year from 2006–07 to 2015–16 in the companion report, A decade of Australian general practice 
activity 2006–07 to 2015–16.1  
3.1 Response rate 
A random sample of GPs who claimed at least 375 general practice Medicare items of service in the 
previous 3 months was regularly drawn from Medicare claims data by the Australian Government 
Department of Health (see Chapter 2). 
In 2015–16, contact was attempted with 4,530 GPs, but 23.4% could not be contacted. A third of these 
had moved (and were untraceable), or had retired or died (Table 3.1), but more than half (53.8%) were 
those with whom contact could not be established after five calls. Younger GPs were harder to 
contact. In previous years, these have largely been registrars moving through practices during 
training, who were no longer at the nominated practice and could not be traced. We were not able to 
measure the proportion of ‘no contact’ GPs who were registrars as, owing to changes in 2013 to the 
privacy requirements for data provided by DoH, information relating to any GPs who do not participate 
in BEACH must be destroyed quarterly. 
The final participating sample for 2015–16, consisted of 921 practitioners, representing 25.6% of those 
who were contacted and available (Table 3.1). The announcement of the suspension of the BEACH 
program in early April will have influenced the response rate for the year as some GPs who 
commenced recording in the last weeks of March elected not to complete data recording where they 
might otherwise have done so.  
Further, there were 44 GPs who commenced recording in the first few weeks of April and decided to 
complete the task – these would have been participants for the 2016–17 BEACH year. As they were 
approached from the same DoH sample batch as the final participants from the 2015–16 year, we felt 
it appropriate to include them in the 2015–16 analysis.  
It was not possible to determine the response rate for these 44 participants as they were recruited with 
many others who had no opportunity to respond to the recruitment invitation. Therefore, for clarity, we 
have calculated the response rate for the year on the total sample for 2015–16, and included the extra 
44 participants into the subsequent analyses in recognition of the valuable contribution made by these 
GPs. 
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Table 3.1: Recruitment and participation rates 2015–16 
Type of contact Number 
Per cent of  
approached  
(n = 4,530) 
Per cent of contacts 
established  
(n = 3,470) 
Letter sent and phone contact attempted 4,530 100.0 — 
No contact  1,060 23.4 — 
 No phone number could be established 13 0.3 — 
 Moved & untraceable/retired/deceased 400 8.8 — 
 Unavailable (overseas, maternity leave, etc.) 77 1.7 — 
 No contact after five calls 570 12.6 — 
Telephone contact established 3,470 76.6 100.0 
 Declined to participate 2,221 49.0 64.0 
 Agreed but withdrew 328 7.2 9.4 
 Agreed and completed 921 20.3 26.5 
April 2016 participants – completed (a) 44 — — 
Total participant sample 965 — — 
(a) Includes 44 GPs from the intended 2016–17 participant sample 
 
3.2 Representativeness of the GP sample 
Whenever possible, the study group of GPs should be compared with the population from which the 
GPs were drawn (the sample frame) to identify and, if necessary, adjust for any sample bias that may 
affect the findings of the study. Comparisons between characteristics of the final GP sample and those 
of the GPs in the sample frame are provided below. The method by which weightings are generated 
as a result of these comparisons and applied to the data, are described in Section 3.3. 
Statistical comparisons, using the chi-square statistic (2) (significant at the 5% level), were made 
between BEACH participants and all recognised GPs in the sample frame during the study period 
(Table 3.2). The GP characteristics data for BEACH participants were drawn from their GP profile 
questionnaire. DoH provided the grouped data for all GPs in the sample frame, from Medicare data. 
Table 3.2 demonstrates there were no significant differences in characteristics of GPs in the final 
sample of BEACH participants and those of all GPs in the sample frame, in terms of sex, proportion of 
GPs who had graduated from their primary medical degree in Australia (place of graduation), 
State/Territory and practice location as classified by the Australian Standard Geographical 
Classification (ASGC). In the final BEACH GP sample, there was a slight over-representation of GPs 
in the 55+ years age group, compared with GPs in the sample frame.  
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Table 3.2: Comparison of BEACH participants and all active recognised GPs in Australia who satisfied the 
selection criteria (the sample frame) 
Variable 
BEACH(a)(b)(c)  Australia(a)(d) 
Number 
Per cent of GPs 
(n = 965)  Number 
Per cent of GPs 
(n = 25,761)  
Sex (2 = 1.8, p = 0.176)      
 Males 532 55.1  14,768 57.3 
 Females 433 44.9  10,993 42.7 
Age (2 = 8.0, p = 0.046)      
 < 35 years 80 8.3  2,560 9.9 
 35–44 years 210 21.9  5,941 23.1 
 45–54 years 236 24.6  6,709 26.0 
 55+ years 435 45.3  10,551 41.0 
 Missing 4 —  — — 
Place of graduation (2 = 0.19, p = 0.662)      
 Australia 584 60.8  15,474 60.1 
 Overseas 377 39.2  10,287 39.9 
 Missing 4 —  — — 
State (2 = 13.9, p = 0.052)      
 New South Wales 305 31.6  8,250 32.0 
 Victoria 236 24.5  6,332 24.6 
 Queensland 180 18.7  5,364 20.8 
 South Australia 79 8.2  2,016 7.8 
 Western Australia 111 11.5  2,527 9.8 
 Tasmania 36 3.7  648 2.5 
 Australian Capital Territory 14 1.5  398 1.6 
 Northern Territory 3 0.3  226 0.9 
 Missing 1 —  — — 
ASGC (2 = 7.2, p = 0.127)      
 Major Cities of Australia 661 68.6  17,918 69.6 
 Inner Regional Australia 215 22.3  5,025 19.5 
 Outer Regional Australia 72 7.5  2,275 8.8 
 Remote Australia 12 1.2  347 1.4 
 Very Remote Australia 4 0.4  189 0.7 
 Missing 1 —  7 — 
(a) Missing data removed. 
(b) Data drawn from the BEACH GP profile completed by each participating GP. 
(c) Includes 44 GPs from the intended 2016–17 participant sample. 
(d) All GPs who satisfied the sample selection criteria of at least 375 MBS-claimed GP consultation service items during the most recent  
3-month Medicare Australia data period prior to their being sampled. Data provided by the Australian Government Department of Health. 
Note: ASGC – Australian Standard Geographical Classification.54 
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GP activity in the previous year 
Data on the number of MBS general practice service items claimed in the previous year were also 
provided by DoH for each GP in the drawn samples, and for all GPs (as a group) in the sample frame. 
These data were used to determine the ‘activity level’ of each participating GP, and to compare the 
activity level of the final participants with that of GPs in the sample frame. 
When comparing GP activity level in the previous 12 months, the proportion of GPs in the final 
participant sample who had claimed fewer than 1,500 services in the previous year was about half that 
of GPs in the sample frame. This may suggest that those GPs who we could not contact were more 
likely to be low service providers. A slightly larger proportion of participants had claimed 1,501–3,000 
services and 3001–4,500 services, but there was a less than one percentage point difference in the 
proportion claiming 4,501–6,000 and claiming 6,001–10,000 services. GPs who claimed the highest 
number of service items represented small proportions of both the participant and sample frame 
groups.  
A clearer comparison using the mean number of claims shows that the mean for the participating GPs 
was slightly lower than that for the GP sample frame. Participants in the 2015–16 BEACH year 
conducted on average 92.1 fewer services per year, or 1.8 consultations per week (on a 52-week 
year, or 2 per week on a 48-week year, assuming 4 weeks leave) (Table 3.3). As the mean number of 
claims for the sample frame sat within the 95% CIs around the mean for BEACH participants, there 
was no statistically significant difference in activity levels between the two groups. 
Table 3.3: Activity level in the previous 12 months of participating GPs and GPs in the sample frame 
(measured by the number of GP service items claimed) 
Variable 
Participants(a)  
(n = 965)  
Australia(b) 
(n = 25,761) 
Number of GPs Per cent  Number of GPs Per cent 
Activity (2 = 37.3, p < 0.0001)      
 1–1,500 services in previous year 44 4.6  2,200 8.9 
 1,501–3,000 services in previous year 222 23.0  4,873 19.8 
 3,001–4,500 services in previous year 255 26.4  5,729 23.2 
 4,501–6,000 services in previous year 167 17.3  4,321 17.5 
 6,001–10,000 services in previous year 227 23.5  5,611 22.8 
 > 10,000 services in previous year 50 5.2  1,909 7.7 
 Number of claims 95% CI  Number of claims  
Mean activity level  4,890.73 4,712.1–5,069.4  4,982.83 — 
Standard deviation 2,827.7 —  — — 
Median activity level 4,248.0 —  — — 
(a) Includes 44 GPs from the intended 2016–17 participant sample. 
(b) Number of GPs in the sample frame for whom these data were provided. 
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3.3 Weighting the data 
Age–sex weights  
As described in Section 3.2, comparisons are made annually to test how representative BEACH 
participants are of the GPs in the original Australian sample frame. Where participants in a particular 
age or sex group are over-represented or under-represented, GP age–sex weights need to be applied 
to the data sets in post-stratification weighting to achieve comparable estimates and precision. 
Because there are always slight (even if not statistically significant) differences, even in years where 
the BEACH participants are representative in all age and sex categories, post-stratification weighting 
for GP age and sex is applied for consistency over recording years. 
Activity weights  
In BEACH, each GP provided details of 100 encounters. There was considerable variation among 
GPs in the number of services each provides in a given year. Encounters were therefore assigned an 
additional weight directly proportional to the activity level of the recording GP. GP activity level was 
measured as the number of MBS general practice service items claimed for services by the GP in the 
previous 12 months (data supplied by DoH). Because the measure is based on annual activity, 
estimates could only be provided for GPs who had claimed service items during the whole year. Those 
entering or leaving the sample frame part way through the year will have met the eligibility criteria for 
inclusion in the BEACH sample (that is, claiming a minimum of 375 MBS GP consultation services 
during the most recent 3-month Medicare Australia data period at sampling date) but would not have 
an annual activity level. 
Total weights  
The final weighted estimates were calculated by multiplying raw rates by the GP age–sex weight and 
the GP sampling fraction of services (‘activity’) in the previous 12 months. Table 3.4 shows the 
precision ratio calculated before and after weighting the encounter data. 
3.4 Representativeness of the encounter sample 
In the BEACH program, we aimed to gain a representative sample of GP–patient encounters each 
year. To assess the representativeness of the final weighted sample of encounters, the age–sex 
distribution of patients at weighted BEACH encounters with GP consultation service items claimed 
(excluding those with Department of Veterans’ Affairs [DVA] patients) was compared with that of 
patients at all encounters claimed as GP consultation service items through Medicare in the 2015–16 
study period (data provided by DoH). 
As shown in Table 3.4, there is an excellent fit of the age–sex distribution of patients at the weighted 
MBS-claimed BEACH encounters with that of the MBS claims distribution, with all precision ratios 
within the range 0.87–1.08. This indicates that the BEACH sample is a good representation of 
Australian GP–patient encounters, as no age–sex category varied by more than 13% from the 
population distribution, and only one by 13%. 
The age–sex distribution of patients at BEACH encounters and for MBS GP consultation service item 
claims, is shown graphically for all patients in Figure 3.1, for males in Figure 3.2, and for females in 
Figure 3.3. 
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Table 3.4: Age–sex distribution of patients at BEACH and MBS GP consultation service items 
 
BEACH–raw(a)  BEACH–weighted(b)  Australia(c)  
Precision ratios 
(Australia = 1.00) 
Sex/age 
Number 
Per cent  
(n = 80,624)  Number 
Per cent 
(n = 80,907)  
Per cent 
(n = 118,502,966)  Raw(a) Weighted(c) 
All           
 < 1 year 1,583 2.0  1,471 1.8  1.8  1.11 1.00 
 1–4 years 3,558  4.4   3,750  4.6  4.9  0.90 0.94 
 5–14 years  4,417  5.5   4,575  5.7  6.3  0.87 0.90 
 15–24 years  6,401  7.9   6,395  7.9  8.3  0.95 0.95 
 25–44 years  17,916  22.2   18,265  22.6  22.5  0.99 1.00 
 45–64 years  21,884  27.1   21,942  27.1  26.0  1.04 1.04 
 65–74 years  11,952  14.8   11,937  14.8  13.7  1.08 1.08 
 75+ years  12,913  16.0   12,573  15.5  16.4  0.98 0.95 
Male           
 < 1 year 808 1.0  748 0.9  1.0  1.00 0.90 
 1–4 years  1,870  2.3  1,932 2.4  2.6  0.88 0.92 
 5–14 years  2,219  2.8  2,360  2.9  3.2  0.88 0.91 
 15–24 years  2,267  2.8  2,424  3.0  3.1  0.90 0.97 
 25–44 years  6,080  7.5  6,877  8.5  8.5  0.88 1.00 
 45–64 years  8,824  10.9  9,489  11.7  11.2  0.97 1.04 
 65–74 years  5,177  6.4  5,501  6.8  6.3  1.02 1.08 
 75+ years  5,317  6.6  5,438  6.7  7.0  0.94 0.96 
Female           
 < 1 year 775 1.0  723 0.9  0.9  1.11 1.00 
 1–4 years  1,688  2.1  1,818  2.2  2.3  0.91 0.96 
 5–14 years  2,198  2.7  2,215  2.7  3.1  0.87 0.87 
 15–24 years  4,134  5.1  3,971  4.9  5.2  0.98 0.94 
 25–44 years  11,836  14.7  11,388  14.1  14.1  1.04 1.00 
 45–64 years  13,060  16.2  12,452  15.4  14.8  1.09 1.04 
 65–74 years  6,775  8.4  6,436  8.0  7.4  1.14 1.08 
 75+ years  7,596  9.4  7,135  8.8  9.4  1.00 0.94 
(a) Unweighted Medicare-claimed GP consultation service items only, excluding encounters with patients who hold a DVA Repatriation Health 
Card. 
(b) Calculated from BEACH weighted data, excluding encounters with patients who hold a DVA Repatriation Health Card. 
(c) Age–sex distribution of patients at MBS-claimed GP consultation services; data provided by the Australian Government Department of 
Health. 
Note: GP consultation services – see ‘Glossary’. Only encounters with valid patient age and sex recorded are included in the comparison. 
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 Figure 3.1: Age distribution of all patients at BEACH and MBS GP consultation services, 2015–16 
 
 
 
 
 
 Figure 3.2: Age distribution of male patients at BEACH and MBS GP consultation services, 2015–16 
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 Figure 3.3: Age distribution of female patients at BEACH and MBS GP consultation services, 2015–16 
3.5 The weighted data set 
The final unweighted data set from the 18th year of collection contained encounters, reasons for 
encounters, problems managed and management/treatments. Most variables decreased after 
weighting. Raw and weighted totals for each data element are shown in Table 3.5. The weighted data 
set is used for all analyses in the remainder of this report. 
Table 3.5: The BEACH data set, 2015–16 
Variable Raw Weighted 
General practitioners 965 965 
Encounters 96,500 97,398 
Reasons for encounter 148,681 149,084 
Problems managed 153,643 150,279 
Medications 98,965 99,398 
Other treatments(a) 56,241 54,744 
Referrals 16,322 15,671 
Pathology 49,501 46,315 
Imaging 10,878 10,733 
Other investigations 899 829 
(a) Other treatments excludes injections for immunisations/vaccinations (raw n = 3,986,  
weighted n = 3,850) (see Chapter 10). 
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 4 The participating GPs 
This chapter reports data collected between April 2015 and March 2016 (the 18th year of the BEACH 
program) about the participating GPs and their practices. Details of GP and practice characteristics 
are reported for each year from 2006–07 to 2015–16 in the 10-year summary report, A decade of 
Australian general practice activity 2006–07 to 2015–16.1  
4.1 Characteristics of the GP participants 
All participants returned a GP profile questionnaire, although some were incomplete. The results are 
provided in Tables 4.1 and 4.2 (median results not tabled). Of the 965 participants: 
• 55.1% were male, and 45.3% were aged 55 years and over (mean age 52.0 years; median age 
53 years) 
• 57.1% had been in general practice for more than 20 years 
• 60.8% had graduated in Australia and 15.2% in Asia 
• 61.8% spent 21–40 hours on average per week on direct patient care services (mean hours 
worked was 36.7; median was 37.5 hours) 
• 62.6% were Fellows of the RACGP, and 6.7% were Fellows of the ACRRM 
• 48.8% had provided care in a residential aged care facility in the previous month 
• 90.1% worked in an accredited practice 
• 68.6% practised in Major cities (using ASGC54) 
• 76.7% worked at only one practice location in a regular week, and 18.8% worked in two. 
At their major practice address: 
• 32.6% were in practices of fewer than five individual GPs, and 28.8% were in practices of 10 or 
more individual GPs. On average, there were 7.5 individual GPs per practice, with a median of 
6 per practice 
• 50.2% were in practices of fewer than five full-time-equivalent (FTE) GPs. On average, there were 
5.5 FTE GPs per practice, with a median of 4.6 FTE GPs per practice 
• 84.7% of the GPs worked in a practice that employed practice nursing staff. Of these GPs, more 
than one-third (35.7%) worked at practices employing fewer than two FTE practice nurses (where 
one FTE is 35–45 hours per week). On average, there were 0.3 FTE practice nurses per FTE GP 
• four in five GPs (80.9%) had a co-located pathology laboratory or collection centre in, or within 50 
metres of, the practice, and more than half (60.3%) had a co-located psychologist  
• 37.8% worked in a practice that provided their own or cooperative after-hours care, and 56.8% in 
a practice that used a deputising service for after-hours patient care (multiple responses allowed). 
Those interested in the clinical activity of overseas trained doctors will find more information in Bayram 
et al. (2007) Clinical activity of overseas trained doctors practising in general practice in Australia.55 
Readers interested in the effects of GP age on clinical practice will find more information in Charles et 
al. (2006) The independent effect of age of general practitioner on clinical practice.56 For more 
information about the effect of the sex of the GP on clinical practice see Harrison et al. (2011) Sex of 
the GP – 20 years on.57   
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Table 4.1: Characteristics of participating GPs and their practices 
GP characteristic Number(a)(b) 
Per cent of GPs(a)(b) 
(n = 965) 
Sex (missing n = 0)   
 Male 532 55.1 
 Female 433 44.9 
Age (missing n = 4)   
 < 35 years 80 8.3 
 35–44 years 210 21.9 
 45–54 years 236 24.6 
 55+ years 435 45.3 
Years in general practice (missing n = 8)   
 < 2 years 8 0.8 
 2–5 years 118 12.3 
 6–10 years 140 14.6 
 11–19 years 145 15.2 
 20+ years 546 57.1 
Place of graduation (missing n = 4)   
 Australia 584 60.8 
 Overseas 377 39.2 
  Asia 146 15.2 
  United Kingdom/Ireland 94 9.8 
  Africa and Middle East 66 6.9 
  Europe 44 4.6 
  New Zealand 14 1.5 
  Other 13 1.4 
Direct patient care hours (worked) per week (missing n = 22)   
 ≤ 10 hours 3 0.3 
 11–20 hours 95 10.1 
 21–40 hours 583 61.8 
 41–60 hours 243 25.8 
 61+ hours 19 2.0 
GP Registrar (in training) (missing n = 12) 46 4.8 
Fellow of RACGP (missing n = 8) 599 62.6 
Fellow of ACRRM (missing n = 29) 63 6.7 
Patient care provided in previous month(c)    
 In a residential aged care facility (missing n = 8) 467 48.8 
 As a salaried/sessional hospital medical officer (missing n = 9) 109 11.4 
(continued) 
30
  
Table 4.1 (continued): Characteristics of participating GPs and their practices 
GP characteristic Number(a)(b) 
Per cent of GPs(a)(b) 
 (n = 965) 
Accredited practice (missing n = 11) 867 90.1 
Practice location by ASGC remoteness structure (missing n = 1)   
 Major cities 661 68.6 
 Inner regional 215 22.3 
 Outer regional 72 7.5 
 Remote 12 1.2 
 Very remote 4 0.4 
Number of practice locations worked at in a regular week (missing n = 16)   
 1 728 76.7 
 2 178 18.8 
 3 37 3.9 
 4+ 6 0.6 
Size of practice – number of individual GPs (missing n = 33)   
 Solo 77 8.3 
 2–4  226 24.3 
 5–9  360 38.6 
 10–14 167 17.9 
 15+  102 10.9 
Size of practice – full-time equivalent GPs (missing n = 143)   
 < 1 4 0.5 
 1.0– <2 81 9.9 
 2.0– <3 91 11.1 
 3.0– <4 117 14.2 
 4.0– <5 120 14.6 
 5.0– <10 294 35.8 
 10.0– <15 87 10.6 
 15+ 28 3.4 
Practice nurse at major practice address (missing n = 12) 807 84.7 
Number of individual practice nurses (missing n = 31)   
 0 146 15.6 
 1 153 16.4 
 2  183 19.6 
 3 152 16.3 
 4–5  198 21.2 
 6+ 102 10.9 
(continued) 
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Table 4.1 (continued): Characteristics of participating GPs and their practices 
GP characteristic Number(a)(b) 
Per cent of GPs(a)(b) 
 (n = 965) 
Number of full-time equivalent practice nurses (missing n = 141)   
 0 146 17.7 
 < 1 57 6.9 
 1.0– <2 237 28.8 
 2.0– <3 206 25.0 
 3.0– <4 106 12.9 
 4.0+ 72 8.7 
Co-located services(d) (missing n = 19)   
 Pathology laboratory/collection centre 765 80.9 
 Psychologist 570 60.3 
 Physiotherapist 495 52.3 
 Medical specialist 292 30.9 
 Imaging/radiology services 284 30.0 
 Dietitian 475 50.2 
 Podiatrist 459 48.5 
 Other service 164 17.3 
 None 58 6.1 
After-hours arrangements(c) (missing n = 8)   
 Practice does own and/or cooperative with other practices 362 37.8 
  Practice does its own 281 29.4 
  Cooperative with other practices 94 9.8 
 Deputising service 544 56.8 
 Other arrangement 95 9.9 
 None 52 5.4 
(a) Missing data removed. 
(b) Includes 44 GPs from the intended 2016–17 participant sample. 
(c) Multiple responses allowed. 
(d) Services located/available in the practice, in the same building or within 50 metres, available on a daily or regular basis. 
Note: ASGC – Australian Standard Geographical Classification; RACGP – Royal Australian College of General Practitioners;  
ACRRM – Australian College of Rural and Remote Medicine. 
Table 4.2: Means of selected characteristics of participating GPs and their practices 
Characteristic 
Mean 
(n = 965) (a)(b) 95% LCL 95% UCL 
Mean age of participating GPs (missing n = 4) 52.0 51.2 52.7 
Mean hours worked per week on direct patient care (missing n = 22) 36.7 35.9 37.4 
Mean number of individual GPs at major practice address (missing n = 33) 7.5 7.2 7.8 
Mean number of FTE GPs at major practice address (missing n = 143) 5.5 5.3 5.8 
FTE practice nurse: FTE GP ratio (missing n = 141) 0.3 0.3 0.4 
(a) Missing data removed. 
(b) Includes 44 GPs from the intended 2016–17 participant sample  
Note: LCL – lower confidence limit; UCL – upper confidence limit; FTE – full-time equivalent. 
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4.2 Changes in characteristics of the GPs over the
 decade 2006–07 to 2015–16 
Changes over the decade 2006–07 to 2015–16, are described in detail in Chapter 4 of the 
accompanying report, A decade of Australian general practice activity 2006–07 to 2015–16.1 Briefly, 
the major changes in the characteristics of the participating GPs were: 
• the proportion of participants who were female increased over time 
• the proportion who were younger than 45 years did not change significantly, whereas the 
proportions aged 45–54 years, and 55 years or more, increased over the decade 
• the proportion of GPs working 21–40 hours per week on direct patient care significantly increased, 
though the proportion working 41–60 hours, and the proportion working more than 60 hours, 
significantly decreased 
• the mean number of hours spent on direct patient care significantly decreased 
• the proportion of participants holding Fellowship of the RACGP increased over the decade 
• the proportion of GPs in smaller practices of 2–4 GPs decreased over time, and the proportion in 
practices with 10 or more individual GPs almost doubled 
• fewer practices are providing after-hours care on their own, or in cooperation with other practices, 
but more practices are using deputising services for after-hours care than a decade ago. 
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 5 The encounters 
This chapter describes the content and types of encounters recorded in the 2015–16 BEACH year. 
Data about the encounters are reported for each year from 2006–07 to 2015–16 in the 10-year report, 
A decade of Australian general practice activity 2006–07 to 2015–16.1 
5.1 Content of the encounters 
In 2015–16, details of 97,398 encounters (weighted data) were available from 965 GPs. A summary of 
these encounters is provided in Table 5.1. Reasons for encounter (RFEs) and problems managed are 
expressed as rates per 100 encounters. Each management action is presented in terms of both a rate 
per 100 encounters and a rate per 100 problems managed, with 95% confidence limits. 
• On average, patients gave 153 RFEs, and GPs managed about 154 problems per 
100 encounters. 
• Chronic problems accounted for 34.6% of all problems managed, and an average of 53.3 chronic 
problems were managed per 100 encounters. 
• New problems accounted for 38.9% of all problems, and on average 60.1 new problems were 
managed per 100 encounters. 
• Medications were the most common treatment choice (102.1 per 100 encounters). Most 
medications were prescribed (82.0 per 100 encounters) rather than supplied by the GP (9.1 per 
100) or advised for over-the-counter purchase (10.9 per 100). 
• For an ‘average’ 100 GP–patient encounters, GPs provided 102 medications and 39 clinical 
treatments (such as advice and counselling), undertook 18 procedures, made 10 referrals to 
medical specialists and 6 to allied health services, and placed 48 pathology test orders and 
11 imaging test orders (Table 5.1). 
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Table 5.1: Summary of morbidity and management at GP–patient encounters 
Variable Number 
Rate per 100 
encounters 
(n = 97,398) 
95% 
LCL 
95% 
UCL 
Rate per 100 
problems  
(n = 150,279) 
95% 
LCL 
95% 
UCL 
General practitioners 965 — — — — — — 
Encounters 97,398 — — — — — — 
Reasons for encounter 149,084 153.1 151.2 155.0 — — — 
Problems managed 150,279 154.3 152.0 156.6 — — — 
 New problems 58,501 60.1 58.5 61.6 38.9 37.9 39.9 
 Chronic problems 51,929 53.3 51.4 55.3 34.6 33.6 35.5 
Medications 99,398 102.1 99.6 104.5 66.1 64.8 67.5 
 Prescribed 79,871 82.0 79.8 84.2 53.1 51.9 54.4 
 GP-supplied 8,869 9.1 8.3 9.9 5.9 5.4 6.4 
 Advised OTC 10,658 10.9 10.1 11.8 7.1 6.6 7.6 
Other treatments(a) 54,744 56.2 53.4 59.0 36.4 34.8 38.1 
 Clinical 37,563 38.6 36.1 41.0 25.0 23.5 26.5 
 Procedural 17,181 17.6 16.6 18.7 11.4 10.8 12.1 
Referrals 15,671 16.1 15.4 16.7 10.4 10.0 10.8 
 Medical specialist* 9,242 9.5 9.1 9.9 6.2 5.9 6.4 
 Allied health services* 5,452 5.6 5.2 6.0 3.6 3.4 3.9 
 Hospital* 305 0.3 0.3 0.4 0.2 0.2 0.2 
 Emergency department* 261 0.3 0.2 0.3 0.2 0.1 0.2 
 Other referrals* 410 0.4 0.3 0.5 0.3 0.2 0.3 
Pathology 46,315 47.6 45.5 49.6 30.8 29.7 32.0 
Imaging 10,733 11.0 10.6 11.5 7.1 6.9 7.4 
Other investigations(b) 829 0.9 0.8 0.9 0.6 0.5 0.6 
(a) Other treatments includes treatment given by practice nurses or Aboriginal health workers in the context of the GP–patient encounter and 
treatment given by GPs. 
(b) Other investigations reported here include only those ordered by the GP. Other investigations in Chapter 12 include those ordered by the 
GP and those done by the GP or practice staff. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, <hdl.handle.net/2123/15514>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; OTC – over-the-counter. 
5.2 Encounter type 
Of the 87,727 encounters where a payment source was recorded, 96.1% related to MBS/DVA 
GP items of service. Items with other health professionals, for example, practice nurse item numbers 
not accompanied by a GP item of service were recorded infrequently. 
Table 5.2 reports the breakdown of encounter type by payment source, counting a single Medicare 
item number per encounter (where applicable). 
• Indirect encounters (where the patient was not seen by the GP) accounted for 1.4%, and direct 
encounters (where the patient was seen by the GP) accounted for 98.6% of encounters at which a 
payment source was recorded. 
• The vast majority of all direct encounters (97.4%) were claimable through Medicare or the DVA. 
• Sixteen indirect encounters were claimed as chronic disease management or case conference 
items. 
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• Direct encounters where the GP indicated that no charge was made were rare, accounting for 
0.4% of encounters. 
• Encounters claimable through workers compensation accounted for 1.4% of all encounters. 
• Encounters claimable through other sources (for example, hospital-paid encounters) accounted 
for 0.8% of all encounters. 
Table 5.2: Type of encounter and a source of payment recorded for the encounter  
Type of encounter Number 
Per cent of 
encounters(a) 
(n = 87,727) 
95% 
LCL 
95% 
UCL 
Per cent of direct 
encounters 
(n = 86,523) 
Indirect encounters (patient not seen by GP)(b) 1,204  1.4 1.2 1.6   
Direct encounters (patient seen by GP) 86,523  98.6 98.4 98.8 100.0  
 MBS/DVA items of service (direct encounters only)(c) 84,300  96.1 95.8 96.4 97.4  
 Workers compensation 1,243  1.4 1.3 1.5 1.4  
 Other paid (hospital, state, etc) 667  0.8 0.6 0.9 0.8  
 No charge 313  0.4 0.3 0.4 0.4  
Total 87,727 100.0 — — — 
(a) Missing data (no payment source specified) removed from analysis (n = 9,671). 
(b) Sixteen encounters involving chronic disease management or case conference items were recorded as indirect encounters. 
(c) Includes direct encounters at which either a GP item or an item with an other health professional (or both) was recorded. 
Note: LCL – lower confidence limit; UCL – upper confidence limit; MBS – Medicare Benefits Schedule; DVA – Australian Government Department 
of Veterans’ Affairs. 
 
Table 5.3 provides an overview of the MBS/DVA item numbers recorded in BEACH in 2015–16. 
At least one MBS/DVA item number was recorded at 84,318 encounters. A single item number was 
recorded at 96.1% of BEACH encounters said to be claimable from the MBS/DVA. 
Table 5.3: Number of MBS/DVA items recorded 
Variable Number 
Per cent of MBS/DVA encounters 
(n = 84,318)(a) 
Encounters at which one MBS/DVA item was recorded 81,055  96.1 
Encounters at which two MBS/DVA items were recorded 2,969  3.5 
Encounters at which three MBS/DVA items were recorded 294  0.3 
Total encounters at which at least one item was recorded 84,318  100.0 
(a) Total includes 84,300 direct encounters and 18 indirect, including 16 for chronic disease items and 2 practice nurse only items. 
Note: MBS – Medicare Benefits Schedule; DVA – Department of Veterans’ Affairs. 
 
GPs could record up to three MBS/DVA item numbers per encounter. For comparability with 
earlier years, in Table 5.4 only one item number per MBS/DVA-claimable encounter has been 
counted. Selection of one item number was undertaken on a priority basis: consultation item numbers 
overrode incentive item numbers, which overrode procedural item numbers, which overrode other 
Medicare item numbers. 
• Standard surgery consultations accounted for 77.3% of MBS/DVA-claimable GP consultations, 
and for 74.2% of all encounters for which a payment source was recorded. 
• 11.8% of MBS/DVA-claimable encounters were claimable as long or prolonged surgery 
consultations. 
• Home or institution visits, and visits at residential aged care facilities were all relatively rare, 
together accounting for 2.6% of MBS/DVA-claimable encounters. 
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• About 1.6% of encounters were claimable as GP mental health care items, 2.4% as chronic 
disease management items, and 0.4% as health assessments. 
• There was a decrease in home visits in the decade to 201058 and this has important implications 
for ageing patients wishing to be managed at home rather than in institutional care. The changes 
to the Medicare schedule in May 2010 mean that it is no longer possible to separate home visits 
from institutional visits using Medicare item numbers. The BEACH collection form was altered 
from the 2012–13 BEACH data year onwards, to include a tick box to identify home visits. In 
2015–16, there were 454 encounters identified as home visits at a rate of 0.5 per 100 encounters 
(95% CI: 0.3–0.7) (results not tabled). An MBS/DVA GP item was recorded at 453 home visit 
encounters, or 0.5% (95% CI: 0.3–0.7) of encounters at which an MBS/DVA item was recorded 
(results not tabled). 
Table 5.4: Summary of GP only MBS/DVA items recorded (counting one item per encounter) 
MBS/DVA item Number 
Rate per 100 
encounters(a) 
(n = 87,727) 
95% 
LCL 
95% 
UCL 
Per cent of 
MBS/DVA  
GP items  
(n = 84,313) 
Short surgery consultations 1,711 2.0 1.7 2.2 2.0 
Standard surgery consultations 65,132 74.2 73.0 75.4 77.3 
Long surgery consultations 9,367 10.7 10.0 11.3 11.1 
Prolonged surgery consultations 594 0.7 0.5 0.8 0.7 
Residential aged care facility (RACF) visits 1,412 1.6 1.2 2.1 1.7 
Home or institution visits (excluding RACF) 778 0.9 0.6 1.1 0.9 
GP mental health care 1,441 1.6 1.5 1.8 1.7 
Chronic disease management items 2,098 2.4 2.1 2.7 2.5 
Health assessments 380 0.4 0.4 0.5 0.5 
Case conferences 14 0.0Ŧ 0.0Ŧ 0.0Ŧ 0.0Ŧ 
Attendances associated with Practice 
Incentives Program payments 
201 0.2 0.2 0.3 0.2 
Other items 1,187 1.4 1.1 1.7 1.4 
 Therapeutic procedures 367 0.4 0.3 0.5 0.4 
 Surgical operations 371 0.4 0.3 0.5 0.4 
 Acupuncture 108 0.1 0.0Ŧ 0.2 0.1 
 Other items 341 0.4 0.1 0.6 0.4 
Total MBS/DVA items of service (GPs only) 84,313 96.1 95.8 96.4 100.0 
(a) Encounters with missing payment source were removed from analysis (n = 9,671). Denominator used for analysis n = 87,727. 
Ŧ Rates are reported to one decimal place. This indicates that the rate is less than 0.05 per 100 encounters. 
Note: LCL – lower confidence limit; UCL – upper confidence limit; MBS – Medicare Benefits Schedule; DVA – Australian Government Department 
of Veterans’ Affairs; GP – general practitioner; RACF – residential aged care facility. 
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Table 5.5 provides the distribution of all MBS/DVA item numbers recorded across Medicare item 
number groups and the number of encounters at which at least one of each type of item number was 
recorded. Overall, there were 87,875 item numbers recorded at 84,318 MBS/DVA-claimable 
encounters in 2015–16, an average of 1.0 item per encounter claimable through MBS/DVA. 
Surgery consultations (including short, standard, long and prolonged) were the most commonly 
recorded type of item number, accounting for 87.4% of all MBS items, and at least one of these items 
was recorded at 91.1% of MBS/DVA claimable encounters. 
Items for hospital, residential aged care and home visits together accounted for 2.5% of all MBS items. 
Items for other practice nurse, Aboriginal health worker and allied health services accounted for 0.6% 
of all MBS items, and were recorded at 0.7% of claimable encounters at which at least one MBS item 
was recorded. 
 
Table 5.5: Distribution of MBS/DVA service item numbers recorded, across item number groups and 
encounters 
Items/encounters 
All MBS/ 
DVA items(a) 
(n = 87,875)  
Encounters with at least 
one item recorded(b) 
(n = 84,318) 
Number Per cent  Number Per cent  
95% 
LCL 
95% 
UCL 
Surgery consultations 76,804 87.4   76,804 91.1 90.3 91.9 
Home, institution and residential aged care visits 2,190 2.5   2,190 2.6 2.0 3.2 
Chronic disease management items (including 
case conferences) 
3,000 3.4   2,179 2.6 2.3 2.9 
Other practice nurse/Aboriginal health 
worker/allied health worker services 
551 0.6   551 0.7 0.4 0.9 
GP mental health care items 1,758 2.0   1,758 2.1 1.9 2.3 
Surgical operations 1,240 1.4   1,183 1.4 1.2 1.6 
Diagnostic procedures and investigations 507 0.6   478 0.6 0.5 0.7 
Health assessments 461 0.5   460 0.5 0.5 0.6 
Therapeutic procedures 472 0.5   458 0.5 0.4 0.7 
Acupuncture 110 0.1   110 0.1 0.0Ŧ 0.2 
Pathology services 152 0.2   146 0.2 0.1 0.2 
Diagnostic imaging services 4 0.0Ŧ   4 0.0Ŧ 0.0Ŧ 0.0Ŧ 
Attendances associated with Practice Incentives 
Program payments 
249 0.3   249 0.3 0.2 0.4 
Other items 378 0.4   378 0.4 0.2 0.7 
Total items 87,875 100.0   — — — — 
(a) Up to three MBS/DVA items could be recorded at each encounter. 
(b) Identifies encounters where at least one item from the MBS group was recorded. 
Ŧ Rates are reported to one decimal place. This indicates that the rate is less than 0.05 per 100 encounters. 
Note: MBS – Medicare Benefits Schedule; DVA – Australian Government Department of Veterans’ Affairs; LCL – lower confidence limit; UCL –
upper confidence limit. 
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5.3 Consultation length 
In a subsample of 32,191 BEACH MBS/DVA-claimable encounters at which start and finish times 
were recorded by the GP, the mean length of consultation in 2015–16 was 14.9 minutes (95% CI: 
14.6–15.2). The median length was 13.0 minutes (results not tabled). 
For A1 MBS/DVA-claimable encounters (n = 29,041), the mean length of consultation in 2015–16 was 
14.5 minutes (95% CI: 14.2–14.8), and the median length was 13.0 minutes (results not tabled). 
The methods of the substudy from which data on consultation length are collected, are described in 
Section 2.6. 
The determinants of consultation length were investigated by Britt et al. (2004) in Determinants of GP 
billing in Australia: content and time59 and Britt et al. (2005) in Determinants of consultation length in 
Australian general practice.60 Length of GP consultations is also discussed in a ‘Byte from BEACH’ 
published on the FMRC website (2014): Britt H, Valenti L, Miller G. Debunking the myth of general 
practice as ‘6 minute medicine’.61 
5.4 Changes in the encounters over the decade
 2006–07 to 2015–16 
Chapter 5 of the companion report, A decade of Australian general practice activity 2006–07 to 
2015–16,1 provides an overview of changes in general practice encounters over the past decade. 
The major changes between 2006–07 and 2015–16 are summarised below. 
• There was a 4% increase in the average number of problems managed at encounter, from 149 
per 100 encounters in 2006–07 to 154 in 2015–16. 
• The number of clinical treatments provided in general practice increased by 30%, from 30 per 100 
encounters in 2006–07 to 39 per 100 encounters in 2015–16. 
• The number of procedures undertaken per 100 encounters increased by 20%, from 15 to 18 per 
100 encounters. 
• There was an increased rate of referrals, which was reflected in referrals to allied health services 
and to medical specialists. 
• Pathology test/test battery order rates increased by 12%. Orders for imaging tests also increased. 
Of the encounters claimable from MBS/DVA: 
• short surgery consultations as a proportion of all MBS/DVA-claimed consultations increased over 
the study period and standard surgery consultations decreased significantly 
• the proportion claimable as chronic disease management items, health assessments and GP 
mental health care all increased significantly 
• the mean length of A1 MBS/DVA-claimable GP–patient encounters in 2015–16 was marginally 
longer than in 2006–07, increasing from 14.0 to 14.5 minutes. The mean length of all 
MBS/DVA-claimable encounters increased significantly over the decade from 14.1 minutes to 
14.9 minutes. The median length of both groups of MBS/DVA-claimable encounters increased 
from 12 to 13 minutes. 
The changes in management actions are expressed in terms of rates per 100 encounters. As there 
was a significant increase in the number of problems managed at encounters, it may be more 
informative to consider changes in management actions in terms of rates per 100 problems managed. 
Rates per 100 problems are reported in the individual chapters dealing with these items in the 10-year 
companion report. 
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 6 The patients 
This chapter reports data collected from April 2015 to March 2016 (the 18th year of the BEACH 
program) about the characteristics of patients at GP encounters and their reasons for encounter. Data 
on patient characteristics and reasons for encounter are reported for each year from 2006–07 to 
2015–16 in the 10-year report, A decade of Australian general practice activity 2006–07 to 2015–16.1 
6.1 Age–sex distribution of patients at encounter 
The age–sex distribution of patients at encounters is shown in Figure 6.1. Females accounted for the 
greater proportion (56.6%) of encounters (Table 6.1). This was reflected across all age groups except 
among children aged less than 15 years (Figure 6.1). 
Patients aged less than 25 years accounted for 19.3% of encounters, those aged 25–44 years for 
22.8%, those aged 45–64 years for 27.2%, and those aged 65 years and over for 30.7% of encounters 
(Table 6.1). Readers interested in changes in the care of middle-aged people in general practice 
should see Chapter 14. 
 
  
 
Note: Missing data removed. The distributions will not agree perfectly with those in Table 6.1 because of missing data in either age or  
sex fields. 
 Figure 6.1: Age–sex distribution of patients at encounters, 2015–16 
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0
5
10
15
20
25
30
Per cent of encounters 
Age group (years) 
40
  
6.2 Other patient characteristics 
Table 6.1 presents other characteristics of the patients at GP encounters. In summary: 
• the patient was new to the practice at 7.3% of encounters 
• nearly half of the encounters were with patients who held a Commonwealth concession card 
(46.2%) and/or a Repatriation Health Card (1.8%) 
• at 1 in 10 encounters (10.5%) the patient was from a non-English-speaking background (see 
glossary) 
• at 1.5% of encounters the patient identified themselves as an Aboriginal and/or Torres Strait 
Islander person. 
Table 6.1: Characteristics of the patients at encounters 
Patient characteristics Number 
Per cent of encounters 
(n = 97,398) 
95% 
LCL 
95%  
UCL 
Sex (missing)(a) 828    
 Males 41,894 43.4 42.5 44.2 
 Females 54,676 56.6 55.8 57.5 
Age group (missing)(a) 847    
 < 1 year 1,683 1.7 1.6 1.9 
 1–4 years 4,188 4.3 4.0 4.6 
 5–14 years 5,162 5.3 5.0 5.6 
 15–24 years 7,619 7.9 7.5 8.3 
 25–44 years 22,033 22.8 21.9 23.7 
 45–64 years 26,228 27.2 26.6 27.8 
 65–74 years 14,203 14.7 14.1 15.3 
 75+ years 15,435 16.0 15.0 16.9 
New patient to practice (missing)(a) 1,719    
 New patient to practice 6,949 7.3 6.5 8.0 
 Patient seen previously 88,730 92.7 92.0 93.5 
Commonwealth concession card status (missing)(a) 9,096    
 Has a Commonwealth concession card 40,788 46.2 44.4 47.9 
 No Commonwealth concession card 47,514 53.8 52.1 55.6 
Repatriation Health Card status (missing)(a) 10,465    
 Has a Repatriation Health Card 1,595 1.8 1.7 2.0 
 No Repatriation Health Card 85,339 98.2 98.0 98.3 
Language status (missing)(a) 10,443    
 Non-English-speaking background(b) 9,154 10.5 8.5 12.5 
 English-speaking background 77,801 89.5 87.5 91.5 
Indigenous status (missing)(a) 10,254    
 Aboriginal and/or Torres Strait Islander(c) 1,308 1.5 1.2 1.8 
 Non-Indigenous 85,835 98.5 98.2 98.8 
(a) Missing data removed. 
(b) Speaks a language other than English as their primary language at home. 
(c) Self-identified. 
Note: LCL – lower confidence limit; UCL – upper confidence limit. 
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6.3 Patient reasons for encounter 
Patient reasons for encounter (RFEs) reflect the patient’s demand for care and can provide an 
indication of service use patterns. Patient demand for care can be influenced by interventions aimed at 
the general population (for example, health awareness campaigns in popular media and print). 
RFEs are those concerns and expectations that patients bring to the GP. Participating GPs were 
asked to record at least one, and up to three, patient RFEs in words as close as possible to those 
used by the patient, before the diagnostic or management process had begun. These reflect the 
patient’s view of their reasons for consulting the GP. RFEs can be expressed in terms of one or more 
symptoms (for example, ‘itchy eyes’, ‘chest pain’), in diagnostic terms (for example, ‘about my 
diabetes’, ‘for my hypertension’), a request for a service (‘I need more scripts’, ‘I want a referral’), an 
expressed fear of disease or a need for a check-up. 
The patient may describe a single RFE that relates to a single problem managed at the encounter, a 
single RFE that relates to multiple problems, multiple RFEs that relate to a single problem managed, 
or multiple RFEs that relate to multiple problems managed at the encounter. GPs may also manage a 
problem that is unrelated to the patient’s RFE (for example, a patient presents about her diabetes but 
while she is there the GP also provides a vaccination and performs a Pap smear). 
Number of reasons for encounter 
There were 149,084 RFEs recorded at 97,398 encounters in 2015–16 (Table 6.3). At 58.7% of 
encounters only one RFE was recorded, at 29.6% two RFEs were recorded and at 11.7% of 
encounters three RFEs were recorded (Table 6.2). On average, patients presented with 153.1 RFEs 
per 100 encounters, or about one-and-a-half RFEs per encounter (Table 6.3). 
Table 6.2: Number of patient reasons for encounter  
Number of RFEs at encounter 
Number of encounters 
(n = 97,398) 
Per cent of 
encounters 
95% 
LCL 
95% 
UCL 
One RFE 57,136 58.7 57.4 60.0 
Two RFEs 28,838 29.6 28.8 30.5 
Three RFEs 11,424 11.7 11.1 12.4 
Total 97,398 100.0 — — 
Note: RFEs – reasons for encounter; LCL – lower confidence limit; UCL – upper confidence limit. 
Reasons for encounter by ICPC-2 component 
The distribution of patient RFEs by ICPC-2 component is presented in Table 6.3, expressed as a 
percentage of all RFEs and as a rate per 100 encounters with 95% confidence limits. In the ‘diagnosis, 
diseases’ group we provide data about infections, injuries, neoplasms, congenital anomalies and 
‘other’ diagnoses and diseases. 
Approximately 4 out of 10 (41.7%) patient RFEs were expressed in terms of a symptom or complaint 
(for example, ‘tired’, ‘fever’). RFEs described in diagnostic terms (for example, ‘about my diabetes’, ‘for 
my depression’) accounted for 18.0% of RFEs. The remaining 40.3% of RFEs were described in terms 
of processes of care, such as requests for a health check, prescriptions, referrals, test results or 
medical certificates. 
At an ‘average’ 100 encounters, patients described 63.8 ‘symptom or complaint’ RFEs, 27.6 
diagnosis/disease RFEs, 24.0 procedural RFEs and made 16.1 requests for medications, treatments 
and/or therapeutics. 
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Table 6.3: Patient reasons for encounter by ICPC-2 component 
ICPC-2 component Number 
Per cent of  
total RFEs 
(n = 149,084) 
Rate per 100 
encounters 
(n = 97,398) 
95%  
LCL 
95%  
UCL 
Symptoms and complaints 62,112 41.7 63.8 61.8 65.8 
Diagnosis, diseases 26,904 18.0 27.6 26.2 29.1 
 Infections 6,430 4.3 6.6 6.2 7.0 
 Injuries 4,191 2.8 4.3 4.1 4.5 
 Neoplasms 962 0.6 1.0 0.9 1.1 
 Congenital anomalies 213 0.1 0.2 0.2 0.3 
 Other diagnoses, diseases 15,108 10.1 15.5 14.4 16.6 
Diagnostic and preventive procedures 23,329 15.6 24.0 23.0 24.9 
Medications, treatments and therapeutics 15,678 10.5 16.1 15.4 16.8 
Test results 9,952 6.7 10.2 9.7 10.7 
Referrals and other RFEs 7,404 5.0 7.6 7.2 8.0 
Administrative 3,705 2.5 3.8 3.5 4.1 
Total RFEs 149,084 100.0 153.1 151.2 155.0 
Note: RFEs – reasons for encounter; LCL – lower confidence limit; UCL – upper confidence limit. 
Reasons for encounter by ICPC-2 chapter  
The distribution of patient RFEs by ICPC-2 chapter and the most common RFEs within each chapter 
are presented in Table 6.4. Each chapter and individual RFE is expressed as a percentage of all RFEs 
and as a rate per 100 encounters with 95% confidence limits. 
RFEs of a general and unspecified nature were presented at a rate of 46.3 per 100 encounters, with 
requests for prescriptions, test results and general check-ups the most frequently recorded of these. 
RFEs related to the respiratory system occurred at a rate of 20.2 per 100 encounters, those related to 
the musculoskeletal system at a rate of 15.3 per 100, and those relating to skin at a rate of 15.3 per 
100 encounters (Table 6.4). 
The far right column of Table 6.4 shows the proportion of patient encounters where there was at least 
one RFE within an ICPC-2 chapter (representing body systems). Patients may describe multiple RFEs 
that are classified within the same ICPC-2 chapter (for example, depression and anxiety; or 
rheumatoid arthritis and osteoporosis), however this column reports only one instance per chapter. 
RFEs classified as ‘General and unspecified’ were described at least once at 40.4% of encounters in 
2015–16. At least one respiratory RFE was recorded at 17.1% of encounters, while one or more RFEs 
related to the musculoskeletal system were recorded at 14.1% of encounters. 
It is possible to extrapolate the ‘rate per 100 encounters’ and the ‘per cent of encounters’ results to the 
143.0 million MBS-claimed GP encounters in 2015–16 (see section 2.9). This allows calculation of the 
estimated number of times an RFE was presented at GP encounters as well as the number of 
encounters where an RFE was presented. Using respiratory-related RFEs as an example, we 
estimate that nationally in 2015–16, patients described 28.9 million RFEs related to the respiratory 
system at 24.5 million GP–patient encounters. 
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Table 6.4: Patient reasons for encounter by ICPC-2 chapter and most frequent individual reasons for 
encounter within chapter  
Reasons for encounter Number 
Per cent of 
total RFEs(a) 
(n = 149,084) 
Rate per 100 
encounters 
 (n = 97,398) 
95%  
LCL 
95%  
UCL 
Per cent of 
encounters(b)  
(95% CI) 
(n = 97,398)  
General and unspecified 45,089 30.2 46.3 45.0 47.6 
40.4  
(39.4–41.5) 
 Prescription NOS 9,764 6.5 10.0 9.4 10.6 — 
 Results tests/procedures NOS 8,420 5.6 8.6 8.2 9.1 — 
 General check-up* 4,451 3.0 4.6 4.1 5.0 — 
 Administrative procedure NOS 3,278 2.2 3.4 3.1 3.6 — 
 Immunisation/vaccination NOS 2,293 1.5 2.4 2.1 2.6 — 
 Fever 2,102 1.4 2.2 1.9 2.4 — 
 Other referrals NEC 1,403 0.9 1.4 1.3 1.6 — 
 Weakness/tiredness 1,397 0.9 1.4 1.3 1.6 — 
 Blood test NOS 1,068 0.7 1.1 0.9 1.2 — 
 Clarify or discuss patient’s RFE 893 0.6 0.9 0.8 1.0 — 
 Observation/health education/advice/ 
 diet NOS 
855 0.6 0.9 0.8 1.0 
— 
 Follow-up encounter unspecified NOS 832 0.6 0.9 0.7 1.0 — 
 Other reason for encounter NEC 730 0.5 0.7 0.6 0.9 — 
 Chest pain NOS 710 0.5 0.7 0.7 0.8 — 
 Trauma/injury NOS 683 0.5 0.7 0.6 0.8 — 
Respiratory 19,710 13.2 20.2 19.3 21.2 
17.1 
(16.4–17.8) 
 Cough 6,074 4.1 6.2 5.8 6.6 — 
 Throat symptom/complaint 2,659 1.8 2.7 2.5 3.0 — 
 Immunisation/vaccination – respiratory 2,423 1.6 2.5 2.0 3.0  
 Upper respiratory tract infection 1,638 1.1 1.7 1.5 1.9 — 
 Sneezing/nasal congestion 1,474 1.0 1.5 1.3 1.7 — 
Musculoskeletal 14,923 10.0 15.3 14.8 15.9 
14.1 
(13.7–14.6) 
 Back complaint* 3,023 2.0 3.1 2.9 3.3 — 
 Knee symptom/complaint 1,379 0.9 1.4 1.3 1.5 — 
 Shoulder symptom/complaint 1,143 0.8 1.2 1.1 1.3 — 
 Foot/toe symptom/complaint 1,109 0.7 1.1 1.0 1.2 — 
 Leg/thigh symptom/complaint 784 0.5 0.8 0.7 0.9 — 
 Neck symptom/complaint 762 0.5 0.8 0.7 0.9 — 
 Musculoskeletal injury NOS 726 0.5 0.7 0.7 0.8 — 
(continued) 
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Table 6.4 (continued): Patient reasons for encounter by ICPC-2 chapter and most frequent individual 
reasons for encounter within chapter  
Reasons for encounter Number 
Per cent of 
total RFEs(a) 
(n = 149,084) 
Rate per 100 
encounters 
 (n = 97,398) 
95%  
LCL 
95%  
UCL 
Per cent of 
encounters(b)  
(95% CI) 
(n = 97,398)  
Skin 14,893 10.0 15.3 14.7 15.9 
14.5 
(14.0–15.0) 
 Rash* 2,659 1.8 2.7 2.5 2.9 — 
 Skin symptom/complaint, other 1,589 1.1 1.6 1.5 1.8 — 
 Skin check-up* 1,233 0.8 1.3 1.1 1.5 — 
 Swelling (skin)* 1,054 0.7 1.1 1.0 1.2 — 
 Laceration/cut 858 0.6 0.9 0.8 1.0 — 
Digestive 9,031 6.1 9.3 8.9 9.6 
8.2 
(7.9–8.5) 
 Abdominal pain* 1,848 1.2 1.9 1.7 2.0 — 
 Diarrhoea 1,086 0.7 1.1 1.0 1.2 — 
 Vomiting 735 0.5 0.8 0.7 0.9 — 
Psychological 8,814 5.9 9.0 8.6 9.5 
8.1 
(7.7–8.5) 
 Depression* 1,933 1.3 2.0 1.8 2.1 — 
 Anxiety* 1,429 1.0 1.5 1.3 1.6 — 
 Sleep disturbance 1,066 0.7 1.1 1.0 1.2 — 
 Acute stress reaction 691 0.5 0.7 0.6 0.8 — 
Circulatory 7,967 5.3 8.2 7.7 8.6 
7.9 
(7.4–8.3) 
 Cardiovascular check-up* 3,222 2.2 3.3 3.0 3.6 — 
 Hypertension/high blood pressure* 1,456 1.0 1.5 1.3 1.7 — 
Endocrine and metabolic 5,757 3.9 5.9 5.5 6.3 
5.7 
(5.3–6.0) 
 Diabetes (non-gestational)* 1,140 0.8 1.2 1.0 1.3 — 
 Prescription – endocrine/metabolic 954 0.6 1.0 0.9 1.1 — 
Female genital system 4,435 3.0 4.6 4.2 4.9 
4.2 
(3.9–4.5) 
 Female genital check-up/Pap smear* 1,566 1.1 1.6 1.4 1.8 — 
 Menstrual problems* 675 0.5 0.7 0.6 0.8 — 
Neurological 4,321 2.9 4.4 4.2 4.7 
4.3 
(4.1–4.5) 
 Headache* 1,614 1.1 1.7 1.5 1.8 — 
 Vertigo/dizziness 997 0.7 1.0 0.9 1.1 — 
Ear 3,220 2.2 3.3 3.1 3.5 
3.2 
(3.0–3.3) 
 Ear pain/earache 1,211 0.8 1.2 1.1 1.3 — 
Pregnancy and family planning 2,884 1.9 3.0 2.7 3.2 
2.9 
(2.6–3.1) 
(continued)  
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Table 6.4 (continued): Patient reasons for encounter by ICPC-2 chapter and most frequent individual 
reasons for encounter within chapter  
Reasons for encounter Number 
Per cent of 
total RFEs(a) 
(n = 149,084) 
Rate per 100 
encounters 
 (n = 97,398) 
95%  
LCL 
95%  
UCL 
Per cent of 
encounters(b)  
(95% CI) 
(n = 97,398)  
Urology 2,595 1.7 2.7 2.5 2.8 
2.4 
(2.3–2.5) 
Eye 2,053 1.4 2.1 2.0 2.2 
1.9 
(1.8–2.1) 
Blood and blood-forming organs 1,325 0.9 1.4 1.2 1.5 
1.4 
(1.2–1.5) 
 Blood test – blood and blood 
 forming organs 
805 0.5 0.8 0.7 1.0 — 
Male genital system 1,110 0.7 1.1 1.0 1.2 
1.1 
(1.0–1.2) 
Social 958 0.6 1.0 0.9 1.1 
1.0 
(0.9–1.1) 
Total RFEs 149,084 100.0 153.1 151.2 155.0 — 
(a) Only individual RFEs accounting for  0.5% of total RFEs are included. 
(b) The proportion of all encounters at which the patient described at least one reason for encounter that was classified in the chapter. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1 <hdl.handle.net/2123/15514>). 
Note: RFEs – reasons for encounter; LCL – lower confidence limit; UCL – upper confidence limit; CI – confidence interval; NEC – not elsewhere 
classified; NOS – not otherwise specified. 
Most frequent patient reasons for encounter 
The 30 most commonly recorded RFEs (Table 6.5), accounted for more than half (59.5%) of all RFEs. 
In this analysis, the specific ICPC-2 chapter to which an across-chapter concept belongs was 
disregarded, so that, for example, ‘check-up – all’ includes all check-ups from all ICPC-2 chapters, 
irrespective of whether or not the body system was specified. 
Of the top 30 RFEs (Table 6.5), most were either symptom or disease descriptions such as cough, 
back complaint, throat complaint or rash. However, the top three RFEs reflected requests for a 
process of care (that is, requests for prescription, check-up and test results), and together accounted 
for nearly one-quarter of all RFEs (23.5%). 
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 Table 6.5: Thirty most frequent patient reasons for encounter 
Patient reason for encounter Number 
Per cent of 
total RFEs(a) 
(n = 149,084) 
Rate per 100 
encounters 
 (n = 97,398) 
95%  
LCL 
95%  
UCL 
Prescription – all* 13,113 8.8 13.5 12.8 14.1 
Check-up – all* 12,014 8.1 12.3 11.7 13.0 
Test results* 9,952 6.7 10.2 9.7 10.7 
Cough 6,074 4.1 6.2 5.8 6.6 
Immunisation/vaccination – all* 4,884 3.3 5.0 4.4 5.6 
Administrative procedure – all* 3,705 2.5 3.8 3.5 4.1 
Back complaint* 3,023 2.0 3.1 2.9 3.3 
Rash* 2,659 1.8 2.7 2.5 2.9 
Throat symptom/complaint 2,659 1.8 2.7 2.5 3.0 
Blood test – all* 2,184 1.5 2.2 2.0 2.5 
Fever 2,102 1.4 2.2 1.9 2.4 
Depression* 1,933 1.3 2.0 1.8 2.1 
Abdominal pain* 1,848 1.2 1.9 1.7 2.0 
Upper respiratory tract infection 1,638 1.1 1.7 1.5 1.9 
Headache* 1,614 1.1 1.7 1.5 1.8 
Skin symptom/complaint, other 1,589 1.1 1.6 1.5 1.8 
Sneezing/nasal congestion 1,474 1.0 1.5 1.3 1.7 
Hypertension/high blood pressure* 1,456 1.0 1.5 1.3 1.7 
Anxiety* 1,429 1.0 1.5 1.3 1.6 
Other referrals NEC 1,403 0.9 1.4 1.3 1.6 
Weakness/tiredness 1,397 0.9 1.4 1.3 1.6 
Knee symptom/complaint 1,379 0.9 1.4 1.3 1.5 
Observation/health education/advice/diet – all* 1,370 0.9 1.4 1.3 1.5 
Ear pain/earache 1,211 0.8 1.2 1.1 1.3 
Diabetes – all* 1,148 0.8 1.2 1.0 1.3 
Shoulder symptom/complaint 1,143 0.8 1.2 1.1 1.3 
Foot/toe symptom/complaint 1,109 0.7 1.1 1.0 1.2 
Diarrhoea 1,086 0.7 1.1 1.0 1.2 
Sleep disturbance 1,066 0.7 1.1 1.0 1.2 
Swelling* 1,054 0.7 1.1 1.0 1.2 
Subtotal 88,719 59.5 — — — 
Total RFEs 149,084 100.0 153.1 151.2 155.0 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1, <hdl.handle.net/2123/15514>). 
Note: RFEs – reasons for encounter; LCL – lower confidence limit; UCL – upper confidence limit; NEC – not elsewhere classified. 
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6.4 Changes in patients and their reasons for
 encounter over the decade 2006–07 to 2015–16 
An overview of changes in the characteristics of patients at encounters and their reasons for 
encounter over the decade 2006–07 to 2015–16, can be found in Chapter 6 of the companion report, 
A decade of Australian general practice activity 2006–07 to 2015–16.1 Major changes are summarised 
below. 
From 2006–07 to 2015–16, the proportion of BEACH encounters with patients aged 65–74 years 
increased from 12.7% to 14.7%. When extrapolated, this change (in combination with the increased 
number of encounters nationally) means that in 2015–16 there were 7.9 million more encounters with 
patients aged 65–74 years nationally than a decade earlier. 
The proportion of patients holding a Repatriation Health Card nearly halved, from 3.4% in 2006–07 to 
1.8% in 2015–16. This is probably due to a decline in the number of World War 2 veterans and their 
partners. 
Over the decade, there was no significant change in the number of reasons for encounter recorded 
per 100 encounters, from 150.8 in 2006–07 to 153.1 in 2015–16. However, there was a significant 
increase in the proportion providing two RFEs. There was a significant increase in the rate of RFEs 
describing processes of care, particularly requests for ‘medications, treatments and therapeutics’ and 
for test results. 
There was a large increase in requests for administrative procedures such as sickness certificates, 
wellness certificates and care plans. This increase is due to the introduction of many care and 
management plans for specific chronic conditions over the decade. Another factor that may have 
influenced this increase is the expectation by employers and schools that workers provide sickness 
certificates to claim sick days and for children to stay at home from school. 
The rate of RFEs describing an infection decreased across the decade. This continues a trend that 
has been seen particularly among children at GP encounters.62 
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 7 Problems managed 
A ‘problem managed’ is a formal statement of the provider’s understanding of a health problem 
presented by the patient, family or community, and can be described in terms of a disease, symptom 
or complaint, social problem or ill-defined condition managed at the encounter. GPs were instructed to 
record each problem at the most specific level possible from the information available. As a result, the 
problem managed may, at times, be limited to the level of a presenting symptom. 
At each patient encounter, up to four problems could be recorded by the GP. A minimum of one 
problem was compulsory. The status of each problem to the patient – new (first presentation to a 
medical practitioner) or old (follow-up of previous problem) – was also indicated. The concept of a 
principal diagnosis, which is often used in hospital statistics, is not adopted in studies of general 
practice where multiple problem management is the norm rather than the exception. Further, the 
range of problems managed at the encounter often crosses multiple body systems and may include 
undiagnosed symptoms, psychosocial problems or chronic disease, which makes the designation of a 
principal diagnosis difficult. Thus, the order in which the problems were recorded by the GP is not 
significant.  
There are two ways to describe the frequency of problems managed: as a percentage of all problems 
managed in the study or as a rate at which problems are managed per 100 encounters. Where groups 
of problems are reported (for example, circulatory problems) it must be remembered that more than 
one of that type of problem (such as hypertension and heart failure) may have been managed at a 
single encounter. We therefore report these data in a variety of ways to aid interpretation and 
reporting. 
For a single ungrouped problem that can only be managed once per encounter, the rate per 100 
encounters can also be regarded as equivalent to the percentage of encounters at which that problem 
was managed. For example, ‘asthma was managed at a rate of 2.0 per 100 encounters’, can also be 
regarded as ‘asthma was managed at 2.0% of encounters’. The reader must be mindful that such a 
statement cannot be made for grouped concepts (ICPC-2 chapters and those marked with asterisks in 
the tables), as more than one problem within that group could have been managed at a single 
encounter. 
The last column in Table 7.3 describes the proportion of encounters during which at least one problem 
within each ICPC-2 chapter was managed. This allows users to make the following types of 
statements: ‘at least one psychological problem was managed at 12.4% of encounters’; or (using the 
extrapolation methods described in Chapter 2) ‘at least one digestive problem was managed at 
17.7 million general practice encounters in 2015–16.’ 
Changes in the problems managed in Australian general practice from the BEACH study are reported 
for each year from 2006–07 to 2015–16 in the 10-year report, A decade of Australian general practice 
activity 2006–07 to 2015–16.1  
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7.1 Number of problems managed at encounter 
In 2015–16, there were 150,279 problems managed, at a rate of 154.3 per 100 encounters 
(Table 7.2). Table 7.1 shows that one problem was managed at 61.4% of encounters and two 
problems were managed at 26.1% of encounters. Approximately 10% of encounters involved the 
management of three problems (9.4%), and four problems were managed at 3.2% of encounters. 
Table 7.1: Number of problems managed at an encounter 
Number of problems managed at encounter Number of encounters Per cent 95% LCL 95% UCL 
One problem 59,804 61.4 60.1 62.7 
Two problems 25,385 26.1 25.3 26.8 
Three problems 9,132 9.4 8.9 9.9 
Four problems 3,077 3.2 2.8 3.5 
Total 97,398 100.0 — — 
Note: LCL – lower confidence limit; UCL – upper confidence limit. 
 
Figure 7.1 shows the age–sex-specific rates of problems managed. The number of problems 
managed at encounter increased steadily with the age of the patient from young adulthood up to those 
aged 65–74 years, and this rate remained steady for those aged 75 years or more. 
Significantly more problems were managed overall at encounters with female patients (156.9 per 100 
encounters, 95% CI: 154.5–159.2) than at those with male patients (151.2 per 100 encounters,  
95% CI: 148.7–153.7) (results not tabled). Figure 7.1 demonstrates that this difference was evident in 
the 15–24 and 25–44 year age groups. There was no difference in the average number of problems 
managed between males and females for those aged 45–64, 65–74 and 75 years and over.  
 
 
 
Note: Missing data removed. 
Figure 7.1: Age–sex-specific rates of problems managed per 100 encounters, 2015–16 
(95% confidence intervals) 
<1 1–4 5–14 15–24 25–44 45–64 65–74 75+
Male 118.9 115.5 118.9 126.3 135.0 159.6 174.2 173.4
Female 124.2 116.3 117.8 138.3 143.4 164.8 179.3 179.1
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7.2 Problems managed by ICPC-2 component 
A broad view of the types of problems managed in general practice can be seen by examining 
problems managed from the perspective of the component structure of the ICPC-2 classification (as 
described in Section 2.8). Table 7.2 lists the distribution of problems managed by ICPC-2 component. 
Nearly two-thirds (65.1%) of problems were described as diagnoses or diseases. Of these, the 
majority were ‘other diagnoses’ (accounting for 42.3% of all problems managed), followed by 
infections (14.9%), injuries (4.5%) and neoplasms (2.9%). 
Nearly 1 in 5 problems (19.3%) were expressed as a symptom or complaint. In some situations, rather 
than providing clinical descriptions of the problem under management, processes of care were 
recorded. The processes recorded most often were diagnostic and preventive procedures (for 
example, check-ups), accounting for 9.5% of problems managed. 
At an ‘average’ 100 encounters GPs managed 100 diagnoses/diseases: 23 infections, 7 injuries, and 4 
neoplasms. They also managed an average 30 symptoms and complaints, and 15 problems described 
as a diagnostic or preventive procedure. 
Table 7.2: Problems managed by ICPC-2 component 
ICPC-2 component Number 
Per cent of 
total problems 
(n = 150,279) 
Rate per 100 
encounters 
(n = 97,398) 
95% 
 LCL 
95% 
 UCL 
Diagnosis, diseases 97,801 65.1 100.4 98.4 102.4 
 Infections 22,412 14.9 23.0 22.3 23.8 
 Injuries 6,808 4.5 7.0 6.7 7.3 
 Neoplasms 4,327 2.9 4.4 4.1 4.7 
 Congenital anomalies 627 0.4 0.6 0.6 0.7 
 Other diagnoses 63,627 42.3 65.3 63.4 67.3 
Symptoms and complaints 29,048 19.3 29.8 29.0 30.7 
Diagnostic and preventive procedures 14,301 9.5 14.7 13.9 15.4 
Medications, treatments and therapeutics 4,168 2.8 4.3 3.9 4.7 
Test results 2,243 1.5 2.3 2.0 2.6 
Administrative 1,549 1.0 1.6 1.4 1.8 
Referrals and other RFEs 1,170 0.8 1.2 1.1 1.3 
Total problems  150,279 100.0 154.3 152.0 156.6 
Note: LCL – lower confidence limit; UCL – upper confidence limit; RFE – reason for encounter. 
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7.3 Problems managed by ICPC-2 chapter 
The frequency and the distribution of problems managed are presented in Table 7.3 by ICPC-2 
chapter (equivalent to body systems, as described in Chapter 2). Rates per 100 encounters and the 
proportion of total problems are provided at the ICPC-2 chapter level, and for frequent individual 
problems within each chapter. Individual problems accounting for at least 0.5% of all problems 
managed are listed in the table, in decreasing order of frequency within the chapter. 
The most common problems managed were: 
• problems of a general and unspecified nature (20.0 per 100 encounters and 13.0% of all 
problems), particularly general check-ups, prescriptions and general immunisations (usually 
multisystem childhood immunisations) 
• respiratory problems (19.5 per 100 encounters), in particular upper respiratory tract infections, 
respiratory immunisation/vaccinations, asthma, and acute bronchitis/bronchiolitis  
• those classified as musculoskeletal (18.1 per 100 encounters), such as arthritis and back 
complaints 
• skin problems (17.4 per 100 encounters), with contact dermatitis and ‘other’ skin disease the most 
common 
• circulatory problems (15.1 per 100), led by hypertension and atrial fibrillation/flutter 
• endocrine and metabolic problems (13.5 per 100), such as diabetes and lipid disorder. 
The last column in Table 7.3 describes the proportion of encounters at which at least one problem 
within an ICPC-2 chapter was managed. GPs may manage more than one problem within an ICPC-2 
chapter (for example, depression and anxiety, rheumatoid arthritis and osteoporosis), but this column 
reports only one instance per chapter. 
At least one general and unspecified problem was managed at 18.5% of encounters in 2015–16, 
equating to approximately 26.4 million encounters at which at least one general and unspecified 
problem was managed in 2015–16. At least one respiratory problem was managed at 18.9% of 
encounters, which extrapolates to 27.0 million encounters at which at least one respiratory problem 
was managed nationally in 2015–16 (Table 7.3). 
Table 7.3: Problems managed by ICPC-2 chapter and most frequent individual problems within chapter  
Problem managed  Number 
Per cent total 
problems(a)  
(n = 150,279) 
Rate per 100 
encounters 
(n = 97,398) 
95%  
LCL 
95%  
UCL 
Per cent of 
encounters(b)  
(95% CI)  
(n = 97,398)  
General and unspecified 19,467 13.0 20.0 19.2 20.8 
18.5  
(17.8–19.1) 
 General check-up* 2,852 1.9 2.9 2.7 3.1 — 
 Immunisation/vaccination NOS 1,949 1.3 2.0 1.8 2.2 — 
 Prescription NOS 1,736 1.2 1.8 1.5 2.0 — 
 Results tests/procedures NOS 1,688 1.1 1.7 1.5 2.0 — 
 Administrative procedure NOS 1,396 0.9 1.4 1.3 1.6 — 
 Abnormal result/investigation NOS 1,127 0.8 1.2 1.0 1.3 — 
 Viral disease, other/NOS 1,113 0.7 1.1 1.0 1.3 — 
 Weakness/tiredness, general 739 0.5 0.8 0.7 0.8 — 
Respiratory 19,018 12.7 19.5 18.8 20.3 
18.9  
(18.2–19.6) 
 Upper respiratory tract infection 5,313 3.5 5.5 5.1 5.8 — 
 (continued) 
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Table 7.3 (continued): Problems managed by ICPC-2 chapter and frequent individual problems within 
chapter 
Problem managed  Number 
Per cent total 
problems(a)  
(n = 150,279) 
Rate per 100 
encounters 
(n = 97,398) 
95%  
LCL 
95%  
UCL 
Per cent of 
encounters(b)  
(95% CI)  
(n = 97,398) 
 Immunisation/vaccination – 
 respiratory 
2,946 2.0 3.0 2.5 3.6 — 
 Asthma 1,942 1.3 2.0 1.8 2.1 — 
 Acute bronchitis/bronchiolitis 1,935 1.3 2.0 1.8 2.2 — 
 Sinusitis acute/chronic  1,229 0.8 1.3 1.1 1.4 — 
 Chronic obstructive pulmonary 
 disease 
863 0.6 0.9 0.8 1.0 — 
 Tonsillitis* 750 0.5 0.8 0.7 0.9 — 
Musculoskeletal 17,597 11.7 18.1 17.5 18.6 
17.1  
(16.6–17.6) 
 Arthritis – all* 3,438 2.3 3.5 3.3 3.7 — 
  Osteoarthritis* 2,548 1.7 2.6 2.4 2.8 — 
 Back complaint* 3,045 2.0 3.1 2.9 3.3 — 
 Bursitis/tendonitis/synovitis NOS 1,277 0.8 1.3 1.2 1.4 — 
 Sprain/strain* 1,205 0.8 1.2 1.1 1.4 — 
 Osteoporosis 977 0.7 1.0 0.9 1.1 — 
 Fracture* 843 0.6 0.9 0.8 0.9 — 
 Injury musculoskeletal NOS 805 0.5 0.8 0.7 0.9 — 
Skin 16,961 11.3 17.4 16.8 18.1 
16.4  
(15.8–16.9) 
 Contact dermatitis 1,721 1.1 1.8 1.6 1.9 — 
 Skin disease, other 1,144 0.8 1.2 1.0 1.3 — 
 Laceration/cut 1,084 0.7 1.1 1.0 1.2 — 
 Solar keratosis/sunburn 1,067 0.7 1.1 1.0 1.2 — 
 Malignant neoplasm, skin 1,042 0.7 1.1 0.9 1.2 — 
 Skin symptom/complaint, other 806 0.5 0.8 0.7 0.9 — 
Circulatory 14,678 9.8 15.1 14.4 15.8 
14.1  
(13.5–14.7) 
 Hypertension* 7,289 4.9 7.5 7.0 7.9 — 
 Atrial fibrillation/flutter 1,234 0.8 1.3 1.1 1.4 — 
 Ischaemic heart disease* 868 0.6 0.9 0.8 1.0 — 
 Cardiovascular check-up* 833 0.6 0.9 0.7 1.0 — 
Endocrine and metabolic 13,151 8.8 13.5 12.9 14.1 
12.3  
(11.7–12.8) 
 Diabetes (non-gestational)* 3,896 2.6 4.0 3.7 4.3 — 
 Lipid disorder 2,956 2.0 3.0 2.8 3.3 — 
 Vitamin/nutritional deficiency 1,419 0.9 1.5 1.3 1.6 — 
 Hypothyroidism/myxoedema  909 0.6 0.9 0.8 1.0 — 
 Obesity (BMI > 30) 736 0.5 0.8 0.6 0.9  
 (continued)  
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Table 7.3 (continued): Problems managed by ICPC-2 chapter and frequent individual problems within 
chapter 
Problem managed  Number 
Per cent total 
problems(a)  
(n = 150,279) 
Rate per 100 
encounters 
(n = 97,398) 
95%  
LCL 
95%  
UCL 
Per cent of 
encounters(b)  
(95% CI)  
(n = 97,398) 
Psychological 12,778 8.5 13.1 12.6 13.7 
12.4  
(11.9–12.9) 
 Depression* 4,103 2.7 4.2 4.0 4.4 — 
 Anxiety* 2,126 1.4 2.2 2.0 2.3 — 
 Sleep disturbance 1,549 1.0 1.6 1.5 1.7 — 
 Acute stress reaction 740 0.5 0.8 0.7 0.8 — 
Digestive 10,797 7.2 11.1 10.7 11.4 
10.7  
(10.3–11.0) 
 Gastro-oesophageal reflux disease* 2,487 1.7 2.6 2.4 2.7 — 
 Gastroenteritis* 1,321 0.9 1.4 1.2 1.5 — 
 Abdominal pain* 756 0.5 0.8 0.7 0.9 — 
Female genital system 5,303 3.5 5.4 5.1 5.8 
5.0  
(4.7–5.3) 
 Female genital check-up/Pap smear* 1,515 1.0 1.6 1.4 1.7 — 
 Menopausal symptom/complaint 683 0.5 0.7 0.6 0.8 — 
Neurological 3,867 2.6 4.0 3.8 4.1 
3.9  
(3.7–4.1) 
 Headache* 1,126 0.7 1.2 1.1 1.3 — 
Ear 3,523 2.3 3.6 3.4 3.8 
3.6  
(3.4–3.7) 
 Acute otitis media/myringitis 864 0.6 0.9 0.8 1.0 — 
 Excessive ear wax 797 0.5 0.8 0.7 0.9 — 
Pregnancy and family planning 3,500 2.3 3.6 3.3 3.9 
3.5  
(3.2–3.7) 
 Pregnancy* 1,118 0.7 1.1 1.0 1.3 — 
 Oral contraception* 1,006 0.7 1.0 0.9 1.1 — 
Urology 3,403 2.3 3.5 3.3 3.7 
3.4  
(3.3–3.6) 
 Urinary tract infection* 1,754 1.2 1.8 1.7 1.9 — 
Eye 2,182 1.5 2.2 2.1 2.4 
2.2  
(2.1–2.3) 
Male genital system 1,748 1.2 1.8 1.7 1.9 
1.8  
(1.7–1.9) 
Blood and blood-forming organs 1,562 1.0 1.6 1.5 1.7 
1.6  
(1.5–1.7) 
Social 744 0.5 0.8 0.7 0.8 
0.8  
(0.7–0.8) 
Total problems 150,279 100.0 154.3 152.0 156.6 — 
(a) Only those individual problems accounting for ≥ 0.5% of total problems are included in the table. 
(b) The proportion of all encounters at which at least one problem classified in this chapter was managed. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1 <hdl.handle.net/2123/15514>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; CI – confidence interval; NOS – not otherwise specified; BMI – body mass 
index. 
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7.4 Most frequently managed problems 
Table 7.4 shows the most frequently managed individual problems in general practice, in decreasing 
order of frequency. These 35 problems accounted for 53.4% of all problems managed, and the top 10 
problems accounted for 29.4%. 
In this analysis, the specific chapter to which ‘across chapter concepts’ (for example, check-ups, 
immunisation/vaccination and prescriptions) apply is ignored, and the concept is grouped with all 
similar concepts regardless of body system. For example, immunisation/vaccination includes 
vaccinations for influenza, childhood diseases, hepatitis and many others. 
Hypertension was the most common problem managed (7.5 per 100 encounters), followed by 
check-ups (6.3 per 100), upper respiratory tract infection (URTI) (5.5 per 100), immunisation/ 
vaccination (5.3 per 100), and depression (4.2 per 100) (Table 7.4). 
The percentage of each problem that was ‘new’ is listed in the far right column in Table 7.4. If a 
problem was a new chronic problem to the patient, or a new episode of a recurrent problem and the 
patient had not been treated for that problem or episode by any medical practitioner before the 
encounter, it was considered a new problem (see Glossary). This can provide a measure of general 
practice incidence. For example, only 5.3% of all contacts with hypertension were new diagnoses. In 
contrast, 77.3% of URTI problems were new to the patient, suggesting that the majority of people with 
URTIs who attend the GP, do so only once per episode. 
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Table 7.4: Most frequently managed problems 
Problem managed Number 
Per cent of 
total problems 
(n = 150,279) 
Rate per 100 
encounters 
(n = 97,398) 
95% 
LCL 
95% 
UCL 
New as per 
cent of all 
problems(a) 
Hypertension* 7,289 4.9 7.5 7.0 7.9 5.3 
Check-up – all* 6,121 4.1 6.3 5.9 6.6 47.2 
Upper respiratory tract infection 5,313 3.5 5.5 5.1 5.8 77.3 
Immunisation/vaccination – all* 5,194 3.5 5.3 4.8 5.9 66.1 
Depression* 4,103 2.7 4.2 4.0 4.4 13.0 
Diabetes – all* 3,939 2.6 4.0 3.8 4.3 5.5 
Arthritis – all* 3,438 2.3 3.5 3.3 3.7 18.0 
Back complaint* 3,045 2.0 3.1 2.9 3.3 23.9 
Lipid disorder 2,956 2.0 3.0 2.8 3.3 10.8 
Prescription – all* 2,849 1.9 2.9 2.6 3.3 7.1 
Gastro-oesophageal reflux disease* 2,487 1.7 2.6 2.4 2.7 13.2 
Test results* 2,243 1.5 2.3 2.0 2.6 34.9 
Anxiety* 2,126 1.4 2.2 2.0 2.3 16.9 
Asthma 1,942 1.3 2.0 1.8 2.1 22.7 
Acute bronchitis/bronchiolitis 1,935 1.3 2.0 1.8 2.2 72.8 
Urinary tract infection* 1,754 1.2 1.8 1.7 1.9 65.2 
Contact dermatitis 1,721 1.1 1.8 1.6 1.9 45.4 
Sleep disturbance 1,549 1.0 1.6 1.5 1.7 23.1 
Administrative procedure – all* 1,549 1.0 1.6 1.4 1.8 38.0 
Vitamin/nutritional deficiency 1,419 0.9 1.5 1.3 1.6 33.2 
Abnormal test results* 1,348 0.9 1.4 1.3 1.5 45.4 
Gastroenteritis* 1,321 0.9 1.4 1.2 1.5 79.6 
Bursitis/tendonitis/synovitis NOS 1,277 0.8 1.3 1.2 1.4 58.4 
Atrial fibrillation/flutter 1,234 0.8 1.3 1.1 1.4 7.4 
Sinusitis acute/chronic 1,229 0.8 1.3 1.1 1.4 66.1 
Sprain/strain* 1,205 0.8 1.2 1.1 1.4 66.0 
Skin disease, other 1,144 0.8 1.2 1.0 1.3 58.9 
Headache* 1,126 0.7 1.2 1.1 1.3 35.2 
Pregnancy* 1,118 0.7 1.1 1.0 1.3 39.9 
Viral disease, other/NOS  1,113 0.7 1.1 1.0 1.3 74.0 
Laceration/cut 1,084 0.7 1.1 1.0 1.2 43.9 
Solar keratosis/sunburn 1,067 0.7 1.1 1.0 1.2 49.6 
Malignant neoplasm, skin 1,042 0.7 1.1 0.9 1.2 51.2 
Oral contraception* 1,006 0.7 1.0 0.9 1.1 18.7 
Osteoporosis 977 0.7 1.0 0.9 1.1 16.9 
Subtotal  80,263 53.4 — — — — 
Total problems 150,279 100.0 154.3 152.0 156.6 38.9 
(a) The proportion of total contacts with this problem that were accounted for by new problems. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1 <hdl.handle.net/2123/15514>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; NOS – not otherwise specified.  
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7.5 Most common new problems 
For each problem managed, participating GPs were asked to indicate whether the problem under 
management was a new problem for the patient (see Glossary). Table 7.5 lists the most common new 
problems managed in general practice, in decreasing order of frequency. Overall, 58,501 problems 
(38.9% of all problems) were specified as new, and were managed at a rate of 60.1 per 100 
encounters. 
New problems were often acute in nature, such as URTI (4.2 per 100 encounters), acute 
bronchitis/bronchiolitis (1.4 per 100) and urinary tract infection (1.2 per 100). Preventive activities were 
also frequently recorded, including immunisation/vaccination (3.5 per 100) and check-ups (3.0 per 100 
encounters) (Table 7.5). 
The far right column of this table shows the new cases of this problem as a proportion of total contacts 
with this problem. This provides an indication of the incidence of each problem. For example, the 729 
new cases of arthritis represented only 18% of all GP contacts with diagnosed arthritis, suggesting 
that by far the majority of contacts for arthritis were for ongoing management. In contrast, 73% of 
acute bronchitis/bronchiolitis contacts were first consultations with a medical practitioner for this 
episode, indicating that the balance (27%) were follow-up consultations for this episode. This suggests 
that most patients only require one visit to a GP for the management of an episode of acute 
bronchitis/bronchiolitis. 
Table 7.5: Most frequently managed new problems 
New problem managed Number 
Per cent of total 
 new problems 
(n = 58,501) 
Rate per 100 
encounters 
(n = 97,398) 
95% 
 LCL 
95% 
UCL 
New as per 
cent of all 
problems(a) 
Upper respiratory tract infection 4,105 7.0 4.2 3.9 4.6 77.3 
Immunisation/vaccination – all* 3,435 5.9 3.5 3.1 3.9 66.1 
Check-up – all* 2,887 4.9 3.0 2.7 3.2 47.2 
Acute bronchitis/bronchiolitis 1,410 2.4 1.4 1.3 1.6 72.8 
Urinary tract infection* 1,144 2.0 1.2 1.1 1.3 65.2 
Gastroenteritis* 1,052 1.8 1.1 1.0 1.2 79.6 
Viral disease, other/NOS 824 1.4 0.8 0.7 1.0 74.0 
Sinusitis acute/chronic  812 1.4 0.8 0.7 0.9 66.1 
Sprain/strain* 795 1.4 0.8 0.7 0.9 66.0 
Test results* 783 1.3 0.8 0.7 0.9 34.9 
Contact dermatitis  782 1.3 0.8 0.7 0.9 45.4 
Bursitis/tendonitis/synovitis NOS 746 1.3 0.8 0.7 0.8 58.4 
Back complaint* 729 1.2 0.7 0.7 0.8 23.9 
Skin disease, other 674 1.2 0.7 0.6 0.8 58.9 
Acute otitis media/myringitis 639 1.1 0.7 0.6 0.7 73.9 
Arthritis – all* 617 1.1 0.6 0.6 0.7 18.0 
Abnormal test results* 612 1.0 0.6 0.6 0.7 45.4 
Administrative procedure – all* 588 1.0 0.6 0.5 0.7 38.0 
Tonsillitis* 562 1.0 0.6 0.5 0.7 74.9 
Malignant neoplasm, skin 534 0.9 0.5 0.5 0.6 51.2 
Depression* 532 0.9 0.5 0.5 0.6 13.0 
(continued) 
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Table 7.5 (continued): Most frequently managed new problems 
New problem managed Number 
Per cent of total 
 new problems 
(n = 58,501) 
Rate per 100 
encounters 
(n = 97,398) 
95% 
 LCL 
95% 
UCL 
New as per 
cent of all 
problems(a) 
Solar keratosis/sunburn 529 0.9 0.5 0.5 0.6 49.6 
Excessive ear wax 497 0.8 0.5 0.5 0.6 62.3 
Laceration/cut 476 0.8 0.5 0.4 0.5 43.9 
Skin symptom/complaint 475 0.8 0.5 0.4 0.6 58.9 
Vitamin/nutritional deficiency 471 0.8 0.5 0.4 0.6 33.2 
Pregnancy* 447 0.8 0.5 0.4 0.5 39.9 
Asthma 440 0.8 0.5 0.4 0.5 22.7 
Respiratory infection, other 433 0.7 0.4 0.3 0.6 76.8 
Abdominal pain* 432 0.7 0.4 0.4 0.5 57.2 
Subtotal 28,462 48.7 — — — — 
Total new problems 58,501 100.0 60.1 58.5 61.6 — 
(a) The proportion of total contacts with this problem that were accounted for by new problems. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1 <hdl.handle.net/2123/15514>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; NOS – not otherwise specified. 
7.6 Most frequently managed chronic problems 
To identify chronic conditions, a list classified according to ICPC-2, based on work undertaken by 
O’Halloran et al. in 200447 and regularly updated (see ‘Chronic conditions’ grouper G84 in the 
‘Analysis and reporting’ section of the ICPC-2 PLUS Demonstrator63), was applied to the BEACH data 
set. More than one-third (34.6%) of the problems managed in general practice were chronic. At least 
one chronic problem was managed at 40.3% of encounters (95% CI: 39.2–41.5) (results not tabled), 
and chronic problems were managed at an average rate of 53.3 per 100 encounters (Table 7.6). 
In other parts of this chapter, both chronic and non-chronic conditions (for example, diabetes and 
gestational diabetes) may have been grouped together when reporting (for example, diabetes – all*, 
Table 7.4). In this section, only problems regarded as chronic have been included in the analysis. For 
this reason, the condition labels and figures in this analysis may differ from those in Table 7.4. Where 
the group used for the chronic analysis differs from that used in other analyses in this report, the labels 
are marked with a double asterisk (for example, Diabetes [non-gestational]**). Codes included in 
asterisked concepts are presented in Appendix 4, Table A4.2. 
Table 7.6 shows the most frequently managed chronic problems. Together, these 30 chronic problems 
accounted for 78.7% of all chronic problems managed, and for 27.2% of all problems managed. Half 
of all chronic problems managed (50.2%) were accounted for by the top seven chronic problems: 
non-gestational hypertension (14.0% of chronic conditions), depressive disorder (7.8%), 
non-gestational diabetes (7.5%), chronic arthritis (6.6%), lipid disorder (5.7%), oesophageal disease 
(4.9%) and asthma (3.7%) (Table 7.6). 
The far right column of Table 7.6 shows the proportion of each chronic problem that was new to the 
patient (as defined in Section 7.4). Overall, 16.1% of chronic problems managed were new diagnoses, 
though just 5.3% of non-gestational diabetes problems were new, and 51.2% of malignant skin 
neoplasms managed were new problems. 
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Table 7.6: Most frequently managed chronic problems 
Chronic problem managed Number 
Per cent of 
total chronic 
problems 
(n = 51,929) 
Rate per 100 
encounters 
(n = 97,398) 
95% 
 LCL 
95% 
UCL 
New as per 
cent of all 
chronic 
problems 
Hypertension (non-gestational)** 7,279 14.0 7.5 7.0 7.9 5.3 
Depressive disorder** 4,064 7.8 4.2 3.9 4.4 12.7 
Diabetes (non-gestational)** 3,896 7.5 4.0 3.7 4.3 5.3 
Chronic arthritis** 3,429 6.6 3.5 3.3 3.7 17.9 
Lipid disorder 2,956 5.7 3.0 2.8 3.3 10.8 
Oesophageal disease 2,521 4.9 2.6 2.4 2.8 13.5 
Asthma 1,942 3.7 2.0 1.8 2.1 22.7 
Atrial fibrillation/flutter 1,234 2.4 1.3 1.1 1.4 7.4 
Malignant neoplasm, skin 1,042 2.0 1.1 0.9 1.2 51.2 
Osteoporosis 977 1.9 1.0 0.9 1.1 16.9 
Hypothyroidism/myxoedema 909 1.7 0.9 0.8 1.0 10.5 
Back syndrome with radiating pain** 880 1.7 0.9 0.8 1.0 22.5 
Ischaemic heart disease** 868 1.7 0.9 0.8 1.0 9.6 
Chronic obstructive pulmonary disease 863 1.7 0.9 0.8 1.0 15.1 
Obesity (BMI > 30) 736 1.4 0.8 0.6 0.9 12.4 
Shoulder syndrome (excluding 
arthritis)** 
659 1.3 0.7 0.6 0.7 45.1 
Gout 612 1.2 0.6 0.6 0.7 20.5 
Chronic skin ulcer (including varicose 
ulcer) 
591 1.1 0.6 0.5 0.7 21.9 
Migraine 589 1.1 0.6 0.5 0.7 20.0 
Heart failure 535 1.0 0.5 0.5 0.6 13.8 
Chronic back pain** 530 1.0 0.5 0.5 0.6 2.5 
Schizophrenia 527 1.0 0.5 0.5 0.6 3.3 
Dementia (including senile, Alzheimer’s) 515 1.0 0.5 0.4 0.6 10.8 
Chronic pain NOS 482 0.9 0.5 0.4 0.6 1.1 
Anxiety disorder** 457 0.9 0.5 0.4 0.5 13.8 
Chronic acne** 420 0.8 0.4 0.4 0.5 26.7 
Chronic kidney disease** 370 0.7 0.4 0.3 0.4 8.3 
Vertiginous syndrome 361 0.7 0.4 0.3 0.4 52.6 
Back syndrome without radiating pain 
(excluding arthritis, sprains and 
strains)** 
309 0.6 0.3 0.3 0.4 14.8 
Neck syndrome (excluding arthritis and 
sprains/strains)** 
309 0.6 0.3 0.3 0.4 32.3 
Subtotal 40,862 78.7 — — — — 
Total chronic problems 51,929 100.0 53.3 51.4 55.3 16.1 
** Includes multiple ICPC-2 or ICPC-2 PLUS codes and indicates that this group differs from that used for analysis in other sections of this 
chapter, as only chronic conditions have been included in this analysis (see Appendix 4, Table A4.2 <hdl.handle.net/2123/15514>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; BMI – body mass index; NOS – not otherwise specified. 
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7.7 Changes in problems managed over the decade
 2006–07 to 2015–16 
Data about the problems managed in general practice from each of the past 10 years of the BEACH 
study, 2006–07 to 2015–16 are reported in Chapter 7 of the companion report, A decade of Australian 
general practice activity 2006–07 to 2015–16.1 Major changes that occurred over the decade are 
summarised below. 
Overall, the number of problems managed at general practice encounters increased from 148.5 per 
100 encounters in 2006–07 to 154.3 in 2015–16. When this result is extrapolated to estimate national 
figures, this represents 67.1 million more problems managed at general practice encounters in  
2015–16 than in 2006–07. A rise in GP attendances over the decade also contributed to this increase. 
The increased numbers of problems managed was reflected in a significant increase over the decade 
in the management of new problems (56.5 to 60.1 per 100 encounters). 
Changes in some of the most common individual problems managed in general practice are 
summarised below. 
• The management rate of hypertension decreased from 9.6 per 100 encounters in 2006–07 to 
7.5 per 100 in 2015–16. Due to the overall increase in the number of general practice encounters 
nationally, there were still an additional 800,000 encounters at which hypertension was managed 
in 2015–16 than in 2006–07. 
• General check-ups were managed more often in 2015–16 than in 2006–07, increasing from 2.4 to 
2.9 per 100 encounters. This represents 1.7 million more occasions where general check-ups 
were managed in 2015–16 than in 2006–07. 
• The management rate of depression increased from 3.7 per 100 encounters to 4.2 per 100 
between 2006–07 and 2015–16, suggesting about 2.2 million more occasions where depression 
was managed in 2015–16 than in 2006–07. 
• The management rate of immunisation/vaccination did not change significantly over the decade. 
However, there were numerous fluctuations in the management rate, with a significant spike in 
2009–10 (7.3 per 100 encounters) that coincided with the H1N1 influenza pandemic, and a 
significant decrease in 2014–15 (3.6 per 100) which may be explained by a delay in supply of the 
influenza vaccine in 2015. The 2015–16 rate of immunisation/vaccination (5.3 per 100) was 
similar to that of 2013–14. 
The management rate of chronic conditions did not differ in 2015–16 (53.3 per 100 encounters) from 
that of 2006–07 (53.3 per 100 encounters). However, due to the increase in the number of GP visits 
nationally, we estimate that GPs managed 21.1 million more chronic problems in 2015–16 than they 
did a decade earlier. 
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 8 Overview of management 
The BEACH survey form allows GPs to record several aspects of patient management for each 
problem managed at an encounter. Pharmaceutical management is recorded in detail. All modes of 
treatment, including clinical treatments (for example, counselling) and procedures, recorded briefly in 
the GP’s own words, are related to a single problem. The form allows referrals, hospital admissions, 
pathology and imaging test orders to be related to a single or multiple problems (see Appendix 1). 
A summary of management at GP encounters from 2006–07 to 2015–16 is reported for each year in 
the 10-year report, A decade of Australian general practice activity 2006–07 to 2015–16.1  
At the 97,398 encounters, GPs undertook 227,690 management activities in total. The most common 
management type was medication, either prescribed, GP-supplied, or advised for over-the-counter 
purchase. ‘Other treatments’ were the second most common management activity, with clinical 
treatments more frequent than procedural treatments (Table 8.1). 
For an ‘average’ 100 patient problems managed, GPs provided 53 prescriptions and 25 clinical 
treatments, undertook 11 procedures, made 6 referrals to medical specialists and 4 to allied health 
services, and placed 31 pathology test/battery orders and 7 imaging test orders. 
At an ‘average’ 100 encounters, they prescribed 82 medications, supplied 9, and advised the 
purchase of 11. They undertook 39 clinical treatments, 18 procedures, referred 10 patients to 
specialists and 6 to allied health services, and placed orders for 48 pathology and 11 imaging tests. 
Table 8.1: Summary of management 
Management type Number 
Rate per 100 
encounters 
(n = 97,398) 
95% 
LCL 
95% 
UCL 
Rate per 100 
problems  
(n = 150,279) 
95% 
LCL 
95% 
UCL 
Medications 99,398 102.1 99.6 104.5 66.1 64.8 67.5 
 Prescribed 79,871 82.0 79.8 84.2 53.1 51.9 54.4 
 GP-supplied 8,869 9.1 8.3 9.9 5.9 5.4 6.4 
 Advised OTC 10,658 10.9 10.1 11.8 7.1 6.6 7.6 
Other treatments 54,744 56.2 53.4 59.0 36.4 34.8 38.1 
 Clinical 37,563 38.6 36.1 41.0 25.0 23.5 26.5 
 Procedural 17,181 17.6 16.6 18.7 11.4 10.8 12.1 
Referrals and admissions 15,671 16.1 15.4 16.7 10.4 10.0 10.8 
 Medical specialist* 9,242 9.5 9.1 9.9 6.2 5.9 6.4 
 Allied health services* 5,452 5.6 5.2 6.0 3.6 3.4 3.9 
 Hospital* 305 0.3 0.3 0.4 0.2 0.2 0.2 
 Emergency department* 261 0.3 0.2 0.3 0.2 0.1 0.2 
 Other referrals* 410 0.4 0.3 0.5 0.3 0.2 0.3 
Pathology 46,315 47.6 45.5 49.6 30.8 29.7 32.0 
Imaging 10,733 11.0 10.6 11.5 7.1 6.9 7.4 
Other investigations(a) 829 0.9 0.8 0.9 0.6 0.5 0.6 
Total management activities 227,690 233.9 — — 151.4 — — 
(a) Other investigations reported here include only those ordered by the GP. Other investigations in Chapter 12 include those ordered by the  
GP and those done by the GP or practice staff. 
* Includes multiple ICPC-2 and ICPC-2 PLUS codes (see Appendix 4, <hdl.handle.net/2123/15514>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; OTC – over-the-counter.  
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The number of encounters or problems for which at least one form of management was recorded by 
the GPs gives us another perspective (Table 8.2). At least one management action was recorded at 
91.6% of encounters, for 86.0% of problems managed. 
• At least one medication or other treatment was given for 71.8% of the problems managed. 
• At least one medication (most commonly prescribed) was prescribed, supplied or advised for 
more than half (51.9%) of the problems managed. 
• At least one other treatment (most commonly clinical) was provided for nearly one-third (32.2%) of 
problems managed. 
• At least one referral (most commonly to a medical specialist) was made for 10.3% of problems 
managed. 
• At least one investigation (most commonly pathology) was requested for 19.2% of problems 
managed (Table 8.2). 
When extrapolated nationally based on the total number of MBS claims for GP consultation items of 
service (see Section 2.11), which in 2015–16 was 143.0 million: 
• at least one medication was prescribed, advised for over-the-counter purchase, or supplied by the 
GP at approximately 89.7 million (95% CI: 88.4–90.9 million) GP–patient encounters across the 
country in 2015–16 
• at least one procedure was undertaken at 22.6 million (95% CI: 21.5–23.6 million) encounters 
nationally 
• at least one referral to a specialist, allied health professional, hospital or emergency department 
was provided by GPs at 21.0 million (95% CI: 20.2–21.9 million) encounters nationally 
• at least one pathology, imaging or other investigation was ordered at 36.6 million (95% CI:  
35.6–37.6 million) encounters across Australia in 2015–16. 
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The combinations of management types related to each problem were investigated. The majority of 
treatments occurred as a single component, or in combination with one other component. 
Management was provided: 
• as a single component for almost two-thirds (59.3%) of the problems managed (Table 8.3) 
• as a double component for 20.2% of problems managed 
• less often (6.5%) with more than two components (results not tabled). 
Table 8.3 lists the most common management combinations, where management action(s) were 
recorded. Medication alone was the most common management, followed by a clinical treatment 
alone, and the combination of a medication and a clinical treatment. When a problem was referred it 
was most likely that no other treatments were given for that problem at the encounter. 
Table 8.3: Most common management combinations 
1+ 
medication 
1+ clinical 
treatment 
1+ procedural  
treatment 
1+  
referral 
1+ imaging 
order 
1+ pathology 
order 
Per cent of total 
problems  
(n = 97,398) 
Per cent  
of total 
encounters 
 (n = 150,279) 
No recorded management 14.0 8.4 
1+ management recorded   
      32.2 27.1 
      10.0 7.2 
      6.9 10.6 
      5.2 3.9 
      5.0 2.9 
      4.3 3.6 
      2.9 4.5 
      2.8 4.4 
      2.6 1.9 
      1.5 3.1 
      1.3 1.4 
      1.2 2.1 
      1.2 1.3 
      1.2 1.5 
      0.6 1.9 
      0.5 0.7 
      0.4 1.3 
      0.4 0.7 
      0.4 1.3 
      0.3 0.5 
Note: 1+ – at least one specified management type. 
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8.1 Changes in management over the decade 
 2006–07 to 2015–16 
Changes in management over the decade 2006–07 to 2015–16 are described in detail in Chapter 8 of 
the accompanying report, A decade of Australian general practice activity 2006–07 to 2015–16.1 In 
that publication, changes over time are largely reported in terms of changes in management actions 
as a rate per 100 problems. This reflects change in how GPs are managing problems and accounts for 
the significant increase in the number of problems managed per encounter over the decade. 
The major changes in management actions over the 10 years to 2015–16 are summarised below. 
• There was a significant decrease in the rate of prescribed medications, from 56.1 per 100 
problems managed in 2006–07 to 53.1 per 100 problems in 2015–16. 
• The rate of other treatments increased significantly, from 30.1 to 36.4 per 100 problems. Both 
clinical and procedural treatments increased significantly. Clinical treatments increased from 19.9 
to 25.0 per 100 problems, and the rate of GP-provided procedures increased from 10.2 to 11.4 per 
100 problems over the decade. 
• The rate of referrals to other health providers significantly increased, from 8.2 to 10.4 per 100 
problems managed between 2006–07 and 2015–16, influenced by a 15% increase in referrals to 
medical specialists (from 5.4 to 6.2 per 100 problems managed) and a 71% increase in referrals to 
allied health services over the period (from 2.1 to 3.6 per 100 problems managed). It was further 
influenced by a marginal increase in referrals to emergency departments (from 0.1 to 0.2 per 100 
problems managed).  
• The rate at which pathology tests/test batteries were ordered significantly increased by 8%, from 
28.6 tests/batteries per 100 problems managed in 2006–07 to 30.8 per 100 in 2015–16. 
• The rate at which imaging was ordered increased significantly from 6.0 imaging orders per 
100 problems managed in 2006–07 to 7.1 per 100 in 2015–16, an increase of 18%. 
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 9 Medications 
GPs could record up to four medications for each of four problems managed – a maximum of 
16 medications per encounter. Each medication could be recorded as prescribed (the default), 
supplied by the GP, or recommended for over-the-counter (OTC) purchase. The generic name of a 
medication is its non-proprietary name, which describes the pharmaceutical substance(s) or active 
pharmaceutical ingredient(s). 
• GPs were asked to: 
– record the generic or brand name, the strength, regimen and number of repeats ordered for 
each medication 
– designate this as a new or continued medication for this patient for this problem. 
• Generic or brand names were entered into the database in the manner recorded by the GP. 
• Medications were coded using the Coding Atlas of Pharmaceutical Substances (CAPS) system 
developed by the FMRC, a hierarchical classification system which captures details of 
medications from generic to brand and product level. Every medication in the CAPS coding 
system is mapped to the international Anatomical Therapeutic Chemical (ATC) classification 
index.64 
• The reporting of results at drug group, subgroup and generic level uses ATC levels 1, 3 and 5. 
The most frequently prescribed, supplied or advised individual medications are reported at the 
CAPS generic level (equivalent to ATC level 5) because ATC does not include many of the  
over-the-counter medications that arise in BEACH. Further, some ATC level 5 labels are not 
sufficiently specific for clarity. 
Data on medications are reported for each year from 2006–07 to 2015–16 in the companion 10-year 
summary report, A decade of Australian general practice activity 2006–07 to 2015–16.1  
Readers interested in adverse drug events will find more detailed information from the BEACH 
program in Drugs causing adverse events in patients aged 45 or older: a randomised survey of 
general practice patients.65 
9.1 Source of medications 
As reported in Chapter 8, a total of 99,398 medications were recorded, at rates of 102.1 per 100 
encounters and 66.1 per 100 problems managed. We can derive from Table 8.1 that: 
• approximately 4 out of 5 medications (80.4%) were prescribed 
• 8.9% of medications were supplied to the patient by the GP 
• 10.7% of medications were recommended by the GP for OTC purchase. 
When medication rates per 100 encounters are extrapolated to the 143 million general practice 
Medicare-claimed encounters in Australia from April 2015 to March 2016, we estimate that GPs in 
Australia: 
• prescribed, supplied or advised at least one medication at 89.7 million encounters (62.7% of 
encounters, Table 8.2) 
• wrote a prescription (with/without repeats) for more than 117.3 million medications 
• supplied 13 million medications directly to the patient 
• recommended 15.6 million medications for OTC purchase (Table 8.1). 
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9.2 Prescribed medications 
Prescribed medications accounted for 80.4% of all medications. There were 79,871 prescriptions 
recorded, at rates of 82.0 per 100 encounters and 53.1 per 100 problems managed (Table 8.1). 
GPs recorded 76.1% of prescribed medications by brand (proprietary) name and 23.9% by their 
generic (non-proprietary) name. Medications most likely to be recorded by generic name were 
paracetamol, amoxycillin, and prednisolone (results not tabled). 
As shown in Table 8.2, at least one prescription was given at 51.9% of encounters. Extrapolated to the 
143 million general practice Medicare-claimed encounters, we estimate that GPs prescribed at least 
one medication at 74.2 million encounters. 
At least one prescription was given for 42.4% of problems managed. 
• No prescription was given for 57.6% of problems managed. 
• One prescription was given for 34.4% of problems managed. 
• Two prescriptions were given for 6.0% of problems managed. 
• Three or four prescriptions were given for 2.0% of problems managed (Figure 9.1). 
 
 
 
 Figure 9.1: Number of medications prescribed per problem, 2015–16 
Number of repeats 
For 62,958 prescriptions (78.8% of all prescriptions), the GPs recorded ‘number of repeats’. The 
distribution of the specified number of repeats (from nil to more than five) is provided in Figure 9.2. For 
37.4% of these prescriptions, the GP specified that no repeats had been prescribed, and for 36.1% 
five repeats were ordered. The latter proportion reflects the Pharmaceutical Benefits Scheme (PBS) 
provision of one month’s supply and five repeats for many medications used for chronic conditions 
such as hypertension. The ordering of one repeat was also quite common (14.0%). 
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Note: Percentages are based on the 62,958 prescriptions for which number of repeats was known. 
Figure 9.2: Number of repeats ordered per prescription, 2015–16 
Age–sex-specific rates of prescribed medications 
Age–sex-specific analysis showed similar prescription rates for male (83 per 100 encounters) and 
female patients (82 per 100), and the well-described tendency for the number of prescriptions written 
at each encounter to rise with the advancing age of the patient. 
The rate of prescribing almost doubled from 53 per 100 encounters for patients aged less than 
25 years, to 104 per 100 encounters for patients aged 65 years and over (results not tabled). 
However, Figure 9.3 demonstrates that this age-based increase lessens if the prescription rate is 
considered in terms of the number of problems managed in each age group. This suggests that a 
substantial part of the higher prescription rate for older patients is due to the increased number of 
health problems they have managed at an encounter. The remaining increase in prescription rate 
associated with patient age is probably a reflection of the problems under management, as the rate of 
chronic problem management increases with patient age.66 
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 Figure 9.3: Age–sex-specific prescription rates per 100 problems managed, 2015–16 
Types of medications prescribed 
Table 9.1 shows the distribution of prescribed medications using the WHO ATC classification.48 This 
allows comparison with other data sources such as those produced from PBS data. The table lists 
medications in frequency order within ATC levels 1, 3 and 5, which are: drug group (mainly 
anatomical), subgroup, and non-proprietary drug name. Prescriptions are presented as a percentage 
of total prescriptions, as a rate per 100 encounters, and as a rate per 100 problems managed, each 
with 95% confidence intervals. 
Drugs acting on the nervous system accounted for almost one-quarter (23.6%) of all prescribed 
medications. Most common were opioids (7.6% of prescribed medications), which include analgesics 
containing high-dose (at least 30 mg) codeine. The inclusion of analgesic combinations with 30 mg of 
codeine aligns with the Poisons Regulations of the Therapeutic Goods Administration,67 which 
stipulates that high-dose codeine combinations are Schedule 4 (prescription only) medications. 
Oxycodone was prescribed at a similar rate to the codeine combinations. Antidepressants were also 
common nervous system medications, as were other analgesics, in particular, plain paracetamol. 
Anti-infectives for systemic use, a group including antibiotics and antivirals, accounted for 17.8% of 
prescribed medications. Cardiovascular system medications made up 17.7%, and lipid-modifying 
agents were the most common of these.  
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Table 9.1: Prescribed medications by ATC levels 1, 3 and 5  
  
ATC Classification level 
Number 
Per cent of 
prescribed 
medications 
(n = 79,871)(a) 
Rate per 100 
encounters 
 (95% CI) 
(n = 97,398) 
Rate per 100 
problems 
 (95% CI)  
(n = 150,279) 1 3 5 
Nervous system  18,861 23.6 19.4 (18.5–20.2) 12.6 (12.0–13.1) 
  Opioids 6,072 7.6 6.2 (5.9–6.6) 4.0 (3.8–4.3) 
 Codeine, combinations excl. psycholeptics 1,513 1.9 1.6 (1.4–1.7) 1.0 (0.9–1.1) 
 Oxycodone 1,423 1.8 1.5 (1.3–1.6) 0.9 (0.9–1.0) 
  Tramadol 928 1.2 1.0 (0.8–1.1) 0.6 (0.5–0.7) 
  Oxycodone, combinations 760 1.0 0.8 (0.7–0.9) 0.5 (0.4–0.6) 
 Buprenorphine 582 0.7 0.6 (0.5–0.7) 0.4 (0.3–0.4) 
  Antidepressants 4,171 5.2 4.3 (4.0–4.5) 2.8 (2.6–2.9) 
  Escitalopram 593 0.7 0.6 (0.5–0.7) 0.4 (0.4–0.4) 
  Sertraline  571 0.7 0.6 (0.5–0.7) 0.4 (0.3–0.4) 
 Amitriptyline 544 0.7 0.6 (0.5–0.6) 0.4 (0.3–0.4) 
 Venlafaxine 412 0.5 0.4 (0.4–0.5) 0.3 (0.2–0.3) 
 Mirtazepine 397 0.5 0.4 (0.4–0.5) 0.3 (0.2–0.3) 
  Other analgesics and antipyretics 1,823 2.3 1.9 (1.7–2.1) 1.2 (1.1–1.3) 
  Paracetamol, plain 1,680 2.1 1.7 (1.5–1.9) 1.1 (1.0–1.2) 
  Anxiolytics 1,694 2.1 1.7 (1.6–1.9) 1.1 (1.0–1.2) 
  Diazepam 1,128 1.4 1.2 (1.0–1.3) 0.8 (0.7–0.8) 
 Oxazepam 389 0.5 0.4 (0.3–0.5) 0.3 (0.2–0.3) 
  Hypnotics and sedatives 1,393 1.7 1.4 (1.3–1.5) 0.9 (0.9–1.0) 
  Temazepam 862 1.1 0.9 (0.8–1.0) 0.6 (0.5–0.6) 
  Antipsychotics 1,263 1.6 1.3 (1.2–1.4) 0.8 (0.8–0.9) 
 Prochlorperazine 473 0.6 0.5 (0.4–0.5) 0.3 (0.3–0.4) 
  Antiepileptics 1,262 1.6 1.3 (1.2–1.4) 0.8 (0.8–0.9) 
 Pregabalin 733 0.9 0.8 (0.7–0.8) 0.5 (0.4–0.5) 
  Drugs used in addictive disorders 498 0.6 0.5 (0.4–0.6) 0.3 (0.3–0.4) 
Anti-infective for systemic use 14,224 17.8 14.6 (14.1–15.2) 9.5 (9.1–9.9) 
  Beta-lactam antibacterials, penicillins 5,623 7.0 5.8 (5.4–6.1) 3.7 (3.5–4.0) 
 Amoxycillin 2,686 3.4 2.8 (2.5–3.0) 1.8 (1.6–1.9) 
 Amoxycillin and enzyme inhibitor 2,011 2.5 2.1 (1.9–2.3) 1.3 (1.2–1.5) 
 Flucloxacillin 431 0.5 0.4 (0.4–0.5) 0.3 (0.2–0.3) 
 Other beta-lactam antibacterials 2,650 3.3 2.7 (2.5–2.9) 1.8 (1.6–1.9) 
 Cephalexin 2,341 2.9 2.4 (2.2–2.6) 1.6 (1.4–1.7) 
 Macrolides, lincosamides and streptogramins 1,905 2.4 2.0 (1.8–2.1) 1.3 (1.2–1.4) 
 Roxithromycin 733 0.9 0.8 (0.7–0.8) 0.5 (0.4–0.5) 
 Clarithromycin 508 0.6 0.5 (0.4–0.6) 0.3 (0.3–0.4) 
 Tetracyclines 812 1.0 0.8 (0.8–0.9) 0.5 (0.5–0.6) 
 Doxycycline 738 0.9 0.8 (0.7–0.8) 0.5 (0.4–0.5) 
(continued) 
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Table 9.1 (continued): Prescribed medications by ATC levels 1, 3 and 5  
 
ATC Classification level 
Number 
Per cent of 
prescribed 
medications 
(n = 79,871)(a) 
Rate per 100 
encounters 
 (95% CI) 
(n = 97,398) 
Rate per 100 
problems 
 (95% CI)  
(n = 150,279) 1 3 5 
 Sulfonamides and trimethoprim 693 0.9 0.7 (0.6–0.8) 0.5 (0.4–0.5) 
 Trimethoprim 528 0.7 0.5 (0.5–0.6) 0.4 (0.3–0.4) 
 Viral vaccines 666 0.8 0.7 (0.6–0.8) 0.4 (0.4–0.5) 
 Other antibacterials 500 0.6 0.5 (0.5–0.6) 0.3 (0.3–0.4) 
 Bacterial vaccines 446 0.6 0.5 (0.4–0.5) 0.3 (0.2–0.3) 
 Direct acting antivirals 361 0.5 0.4 (0.3–0.4) 0.2 (0.2–0.3) 
Cardiovascular system 14,167 17.7 14.5 (13.8–15.3) 9.4 (9.0–9.9) 
 Lipid modifying agents, plain 3,379 4.2 3.5 (3.2–3.7) 2.2 (2.1–2.4) 
 Atorvastatin 1,347 1.7 1.4 (1.3–1.5) 0.9 (0.8–1.0) 
 Rosuvastatin 1,281 1.6 1.3 (1.2–1.4) 0.9 (0.8–0.9) 
 Simvastatin 381 0.5 0.4 (0.3–0.4) 0.3 (0.2–0.3) 
 Angiotensin II antagonists, plain 2,019 2.5 2.1 (1.9–2.2) 1.3 (1.2–1.4) 
 Irbesartan 655 0.8 0.7 (0.6–0.8) 0.4 (0.4–0.5) 
 Telmisartan 559 0.7 0.6 (0.5–0.6) 0.4 (0.3–0.4) 
 Candesartan 557 0.7 0.6 (0.5–0.7) 0.4 (0.3–0.4) 
 ACE inhibitors, plain 1,710 2.1 1.8 (1.6–1.9) 1.1 (1.1–1.2) 
 Perindopril 1,038 1.3 1.1 (1.0–1.2) 0.7 (0.6–0.7) 
 Ramipril 482 0.6 0.5 (0.4–0.6) 0.3 (0.3–0.4) 
 Angiotensin II antagonists, combinations 1,436 1.8 1.5 (1.3–1.6) 1.0 (0.9–1.0) 
 Irbesartan and diuretics 418 0.5 0.4 (0.4–0.5) 0.3 (0.2–0.3) 
 Beta blocking agents 1,429 1.8 1.5 (1.3–1.6) 1.0 (0.9–1.0) 
 Metoprolol 476 0.6 0.5 (0.4–0.5) 0.3 (0.3–0.3) 
 Atenolol 469 0.6 0.5 (0.4–0.5) 0.3 (0.3–0.4) 
 Selective calcium channel blockers with mainly 
vascular effects 
1,027 1.3 1.1 (1.0–1.2) 0.7 (0.6–0.7) 
 Amlodipine 537 0.7 0.6 (0.5–0.6) 0.4 (0.3–0.4) 
 ACE inhibitors, combinations 609 0.8 0.6 (0.6–0.7) 0.4 (0.4–0.5) 
 High-ceiling diuretics 540 0.7 0.6 (0.5–0.6) 0.4 (0.3–0.4) 
 Frusemide 538 0.7 0.6 (0.5–0.6) 0.4 (0.3–0.4) 
Alimentary tract and metabolism 8,850 11.1 9.1 (8.7–9.5) 5.9 (5.6–6.1) 
 Drugs for peptic ulcer and gastro-oesophageal reflux 3,519 4.4 3.6 (3.4–3.8) 2.3 (2.2–2.5)  
 Esomeprazole 1,735 2.2 1.8 (1.7–1.9) 1.2 (1.1–1.2) 
 Pantoprazole 814 1.0 0.8 (0.8–0.9) 0.5 (0.5–0.6) 
 Blood glucose lowering drugs, excluding insulins 2,352 2.9 2.4 (2.2–2.6) 1.6 (1.4–1.7) 
 Metformin 1,263 1.6 1.3 (1.2–1.4) 0.8 (0.8–0.9) 
 Insulins and analogues 582 0.7 0.6 (0.5–0.7) 0.4 (0.3–0.4) 
 Propulsives 567 0.7 0.6 (0.5–0.7) 0.4 (0.3–0.4) 
 Metoclopramide 458 0.6 0.5 (0.4–0.5) 0.3 (0.3–0.3) 
(continued)  
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Table 9.1 (continued): Prescribed medications by ATC levels 1, 3 and 5  
 
ATC Classification level 
Number 
Per cent of 
prescribed 
medications 
(n = 79,871)(a) 
Rate per 100 
encounters 
 (95% CI) 
(n = 97,398) 
Rate per 100 
problems 
 (95% CI)  
(n = 150,279) 1 3 5 
 Drugs for constipation 417 0.5 0.4 (0.4–0.5) 0.3 (0.2–0.3) 
Respiratory system 4,632 5.8 4.8 (4.5–5.0) 3.1 (2.9–3.3) 
 Adrenergics, inhalants 2,485 3.1 2.6 (2.4–2.7) 1.7 (1.5–1.8) 
 Salbutamol 1,171 1.5 1.2 (1.1–1.3) 0.8 (0.7–0.9) 
 Salmeterol and fluticasone 641 0.8 0.7 (0.6–0.7) 0.4 (0.4–0.5) 
 Formoterol and budesonide 472 0.6 0.5 (0.4–0.5) 0.3 (0.3–0.4) 
 Decongestants and other nasal preparations 779 1.0 0.8 (0.7–0.9) 0.5 (0.5–0.6) 
 Other drugs for obstructive airway diseases, 
inhalants 
736 0.9 0.8 (0.7–0.8) 0.5 (0.4–0.5) 
Musculoskeletal system 4,218 5.3 4.3 (4.1–4.6) 2.8 (2.6–3.0) 
 Anti-inflammatory and antirheumatic products,  
non-steroid 
2,960 3.7 3.0 (2.8–3.3) 2.0 (1.8–2.1) 
 Meloxicam 914 1.1 0.9 (0.8–1.0) 0.6 (0.5–0.7) 
 Celecoxib 591 0.7 0.6 (0.5–0.7) 0.4 (0.3–0.5) 
 Diclofenac  483 0.6 0.5 (0.4–0.6) 0.3 (0.3–0.4) 
 Antigout preparations 507 0.6 0.5 (0.5–0.6) 0.3 (0.3–0.4) 
 Drugs affecting bone structure and mineralization 493 0.6 0.5 (0.4–0.6) 0.3 (0.3–0.4) 
Dermatologicals 3,871 4.8 4.0 (3.7–4.2) 2.6 (2.4–2.7) 
 Corticosteroids, plain 2,095 2.6 2.2 (2.0–2.3) 1.4 (1.3–1.5) 
 Betamethasone 799 1.0 0.8 (0.7–0.9) 0.5 (0.5–0.6) 
 Mometasone 526 0.7 0.5 (0.5–0.6) 0.3 (0.3–0.4) 
Genitourinary system and sex hormones 3,060 3.8 3.1 (3.0–3.3)  2.0 (1.9–2.2) 
 Hormonal contraceptives for systemic use 1,209 1.5 1.2 (1.1–1.4) 0.8 (0.7–0.9) 
 Estrogens 535 0.7 0.5 (0.5–0.6) 0.4 (0.3–0.4) 
 Urologicals 523 0.7 0.5 (0.5–0.6) 0.3 (0.3–0.4) 
Systemic hormonal preparations, excluding sex 
hormones  
2,849 3.6 2.9 (2.7–3.1) 1.9 (1.8–2.0) 
  Corticosteroids for systemic use, plain  1,657 2.1 1.7 (1.6–1.8) 1.1 (1.0–1.2) 
  Prednisolone oral [all] 1,183 1.5 1.2 (1.1–1.3) 0.8 (0.7–0.9) 
  Thyroid preparations  893 1.1 0.9 (0.8–1.0) 0.6 (0.5–0.7) 
  Levothyroxine sodium 866 1.1 0.9 (0.8–1.0) 0.6 (0.5–0.6) 
Blood and blood-forming organs 2,498 3.1 2.6 (2.4–2.8) 1.7 (1.5–1.8) 
 Antithrombotic agents 1,868 2.3 1.9 (1.7–2.1) 1.2 (1.1–1.4) 
 Warfarin 813 1.0 0.8 (0.7–1.0) 0.5 (0.5–0.6) 
Sensory organs  1,900 2.4 2.0 (1.8–2.1) 1.3 (1.2–1.3) 
  Anti-infectives ophthalmological  655 0.8 0.7 (0.6–0.7) 0.4 (0.4–0.5) 
  Chloramphenicol ophthalmological 595 0.7 0.6 (0.5–0.7) 0.4 (0.4–0.4) 
  Corticosteroids and anti-infective in combination 
otological  
540 0.7 0.6 (0.5–0.6) 0.4 (0.3–0.4) 
(continued)  
72
  
Table 9.1 (continued): Prescribed medications by ATC levels 1, 3 and 5  
 
ATC Classification level 
Number 
Per cent of 
prescribed 
medications 
(n = 79,871)(a) 
Rate per 100 
encounters 
 (95% CI) 
(n = 97,398) 
Rate per 100 
problems 
 (95% CI)  
(n = 150,279) 1 3 5 
Antineoplastic and immunomodulating agents  408 0.5 0.4 (0.4–0.5) 0.3 (0.2–0.3) 
Antiparasitic products, insecticides and repellent 155 0.2 0.2 (0.1–0.2) 0.1 (0.1–0.1) 
Various  177 0.2 0.2 (0.1–0.2) 0.1 (0.1–0.1) 
Total prescribed medications 79,871 100.0 82.0 (79.8–84.2) 53.1 (51.9–54.4) 
(a) Only those individual medications accounting for ≥ 0.5% of total prescribed medications are included in the table. 
Note: ATC – Anatomical Therapeutic Chemical classification; CI – confidence interval; ACE – angiotensin-converting enzyme.  
Most frequently prescribed medications 
The most frequently prescribed individual medications are reported at the CAPS generic level (ATC 
level 5 equivalent) in Table 9.2. Together these 30 medications made up 42.1% of all prescribed 
medications. 
Table 9.2: Most frequently prescribed medications  
Generic medication Number 
Per cent of 
prescribed 
medications 
(n = 79,871) 
Rate per 100 
encounters 
 (95% CI) 
(n = 97,398) 
Rate per 100 
problems 
 (95% CI)  
(n = 150,279) 
Amoxycillin 2,686 3.4 2.8 (2.5–3.0) 1.8 (1.6–1.9) 
Cephalexin 2,341 2.9 2.4 (2.2–2.6) 1.6 (1.4–1.7) 
Amoxycillin/potassium clavulanate 2,011 2.5 2.1 (1.9–2.3) 1.3 (1.2–1.5) 
Esomeprazole 1,735 2.2 1.8 (1.7–1.9) 1.2 (1.1–1.2) 
Paracetamol [plain] 1,680 2.1 1.7 (1.5–1.9) 1.1 (1.0–1.2) 
Paracetamol/codeine 1,507 1.9 1.5 (1.4–1.7) 1.0 (0.9–1.1) 
Oxycodone 1,423 1.8 1.5 (1.3–1.6) 0.9 (0.9–1.0) 
Atorvastatin 1,347 1.7 1.4 (1.3–1.5) 0.9 (0.8–1.0) 
Rosuvastatin 1,281 1.6 1.3 (1.2–1.4) 0.9 (0.8–0.9) 
Metformin 1,263 1.6 1.3 (1.2–1.4) 0.8 (0.8–0.9) 
Salbutamol 1,186 1.5 1.2 (1.1–1.3) 0.8 (0.7–0.9) 
Diazepam 1,128 1.4 1.2 (1.0–1.3) 0.8 (0.7–0.8) 
Perindopril 1,038 1.3 1.1 (1.0–1.2) 0.7 (0.6–0.7) 
Tramadol 928 1.2 1.0 (0.8–1.1) 0.6 (0.5–0.7) 
Meloxicam 914 1.1 0.9 (0.8–1.0) 0.6 (0.5–0.7) 
Thyroxine 866 1.1 0.9 (0.8–1.0) 0.6 (0.5–0.6) 
Temazepam 862 1.1 0.9 (0.8–1.0) 0.6 (0.5–0.6) 
Pantoprazole 814 1.0 0.8 (0.8–0.9) 0.5 (0.5–0.6) 
Warfarin sodium 813 1.0 0.8 (0.7–1.0) 0.5 (0.5–0.6) 
Betamethasone topical 799 1.0 0.8 (0.7–0.9) 0.5 (0.5–0.6) 
Prednisolone 790 1.0 0.8 (0.7–0.9) 0.5 (0.5–0.6) 
Oxycodone/naloxone 760 1.0 0.8 (0.7–0.9) 0.5 (0.4–0.6) 
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Table 9.2 (continued): Most frequently prescribed medications 
Generic medication Number 
Per cent of 
prescribed 
medications 
(n = 79,871) 
Rate per 100 
encounters 
 (95% CI) 
(n = 97,398) 
Rate per 100 
problems 
 (95% CI)  
(n = 150,279) 
Levonorgestrel/ethinyloestradiol 757 0.9 0.8 (0.7–0.9) 0.5 (0.5–0.6) 
Doxycycline 738 0.9 0.8 (0.7–0.8) 0.5 (0.4–0.5) 
Pregabalin 733 0.9 0.8 (0.7–0.8) 0.5 (0.4–0.5) 
Roxithromycin 733 0.9 0.8 (0.7–0.8) 0.5 (0.4–0.5) 
Irbesartan 655 0.8 0.7 (0.6–0.8) 0.4 (0.4–0.5) 
Fluticasone/salmeterol 641 0.8 0.7 (0.6–0.7) 0.4 (0.4–0.5) 
Chloramphenicol eye 595 0.7 0.6 (0.5–0.7) 0.4 (0.4–0.4) 
Escitalopram oxalate 593 0.7 0.6 (0.5–0.7) 0.4 (0.4–0.4) 
Subtotal 33,617 42.1 — — 
Total prescribed medications 79,871 100.0 82.0 (79.8–84.2) 53.1 (51.9–54.4) 
Note: CI – confidence interval. 
9.3 Medications supplied by GPs 
GPs supplied 8,869 medications in 2015–16, at a rate of 9.1 medications per 100 encounters, and 
5.9 per 100 problems managed. At least one medication was supplied for 4.9% of all problems 
managed, and at 7.4% of encounters, an estimated 8.4 million encounters nationally in 2015–16. The 
most frequently supplied medications are listed in Table 9.3. 
Table 9.3: Medications most frequently supplied by GPs  
Generic medication Number 
Per cent of 
supplied 
medications 
(n = 8,869) 
Rate per 100 
encounters 
 (95% CI) 
(n = 97,398) 
Rate per 100 
problems 
 (95% CI)  
(n = 150,279) 
Influenza virus vaccine 2,607 29.4 2.7 (2.1–3.2) 1.7 (1.4–2.1) 
Pneumococcal vaccine 525 5.9 0.5 (0.5–0.6) 0.3 (0.3–0.4) 
Vitamin B12 (cobalamin) 513 5.8 0.5 (0.4–0.6) 0.3 (0.3–0.4) 
Diphtheria/pertussis/tetanus/hepatitis B/polio/ 
Haemophilus influenzae B vaccine 
389 4.4 0.4 (0.3–0.5) 0.3 (0.2–0.3) 
Triple antigen (diphtheria/pertussis/tetanus) 388 4.4 0.4 (0.3–0.5) 0.3 (0.2–0.3) 
Rotavirus vaccine 321 3.6 0.3 (0.3–0.4) 0.2 (0.2–0.2) 
Measles/mumps/rubella vaccine 239 2.7 0.2 (0.2–0.3) 0.2 (0.1–0.2) 
Measles/mumps/rubella/varicella zoster vaccine 162 1.8 0.2 (0.1–0.2) 0.1 (0.1–0.1) 
Diphtheria/tetanus vaccine 152 1.7 0.2 (0.1–0.2) 0.1 (0.1–0.1) 
Denosumab 148 1.7 0.2 (0.1–0.2) 0.1 (0.1–0.1) 
Haemophilus B/Meningococcus C vaccine 123 1.4 0.1 (0.1–0.2) 0.1 (0.1–0.1) 
Hepatitis B vaccine 113 1.3 0.1 (0.1–0.1) 0.1 (0.1–0.1) 
Hepatitis A vaccine 100 1.1 0.1 (0.1–0.1) 0.1 (0.0–0.1) 
Diphtheria/pertussis/tetanus/polio vaccine 96 1.1 0.1 (0.1–0.1) 0.1 (0.0–0.1) 
Typhoid vaccine (Salmonella typhi) 93 1.1 0.1 (0.1–0.1) 0.1 (0.0–0.1) 
Hepatitis A/typhoid (Salmonella typhi) vaccine 86 1.0 0.1 (0.1–0.1) 0.1 (0.0–0.1) 
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Table 9.3 (continued): Medications most frequently supplied by GPs 
Generic medication Number 
Per cent of 
supplied 
medications 
(n = 8,869) 
Rate per 100 
encounters 
 (95% CI) 
(n = 97,398) 
Rate per 100 
problems 
 (95% CI)  
(n = 150,279) 
Immunisation NEC 85 1.0 0.1 (0.1–0.1) 0.1 (0.0–0.1) 
Allergen treatment 80 0.9 0.1 (0.1–0.1) 0.1 (0.0–0.1) 
Medroxyprogesterone 78 0.9 0.1 (0.1–0.1) 0.1 (0.0–0.1) 
Metoclopramide 66 0.7 0.1 (0.0–0.1) 0.0 (0.0–0.1) 
Testosterone 51 0.6 0.1 (0.0–0.1) 0.0 (0.0–0.0) 
Steroid injection NEC 50 0.6 0.1 (0.0–0.1) 0.0 (0.0–0.0) 
Local anaesthetic injection 47 0.5 0.0 (0.0–0.1) 0.0 (0.0–0.0) 
Papillomavirus (HPV) vaccine 44 0.5 0.0 (0.0–0.1) 0.0 (0.0–0.0) 
Chickenpox (varicella zoster) vaccine 43 0.5 0.0 (0.0–0.1) 0.0 (0.0–0.0) 
Hepatitis A and B vaccine 42 0.5 0.0 (0.0–0.1) 0.0 (0.0–0.0) 
Betamethasone systemic 42 0.5 0.0 (0.0–0.1) 0.0 (0.0–0.0) 
Lignocaine 42 0.5 0.0 (0.0–0.1) 0.0 (0.0–0.0) 
Salbutamol 41 0.5 0.0 (0.0–0.1) 0.0 (0.0–0.0) 
Meloxicam 41 0.5 0.0 (0.0–0.1) 0.0 (0.0–0.0) 
Subtotal 6,809 76.8 — — 
Total supplied medications 8,869 100.0 9.1 (8.3–9.9) 5.9 (5.4–6.4) 
Note: CI – confidence interval; NEC – not elsewhere classified. Data are reported to one decimal place; a rate tabled as 0.0 means the rate was 
less than 0.05 per 100 encounters or per 100 problems. 
9.4 Medications advised for over-the-counter 
 purchase 
The GPs recorded 10,658 medications as recommended for OTC purchase, at rates of 10.9 per 100 
encounters and 7.1 per 100 problems managed. At least one OTC medication was advised at 9.3% of 
encounters, equivalent to an estimated 13.3 million encounters nationally where GPs recommended at 
least one OTC medication. At least one OTC medication was advised for 6.2% of problems 
(Table 8.2). Table 9.4 shows the 30 most frequent advised medications at the CAPS generic level 
(ATC level 5 equivalent). Advised medications covered a wide range, and the most common was 
paracetamol, which accounted for 27.5% of these medications. 
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Table 9.4: Most frequently advised over-the-counter medications  
Generic medication Number 
Per cent of 
OTC 
medications 
(n = 10,658) 
Rate per 100 
encounters 
 (95% CI) 
(n = 97,398) 
Rate per 100 
problems 
 (95% CI)  
(n = 150,279) 
Paracetamol [plain] 2,935 27.5 3.0 (2.7–3.4) 2.0 (1.7–2.2) 
Ibuprofen 785 7.4 0.8 (0.7–0.9) 0.5 (0.5–0.6) 
Sodium chloride topical nasal 293 2.7 0.3 (0.2–0.4) 0.2 (0.1–0.3) 
Mometasone nasal 217 2.0 0.2 (0.2–0.3) 0.1 (0.1–0.2) 
Sodium/potassium/citric acid/glucose 213 2.0 0.2 (0.2–0.3) 0.1 (0.1–0.2) 
Diclofenac topical 187 1.8 0.2 (0.1–0.2) 0.1 (0.1–0.2) 
Simple analgesics 184 1.7 0.2 (0.1–0.3) 0.1 (0.1–0.2) 
Loratadine 171 1.6 0.2 (0.1–0.2) 0.1 (0.1–0.1) 
Cetirizine 170 1.6 0.2 (0.1–0.2) 0.1 (0.1–0.1) 
Vitamin D3 (cholecalciferol) 160 1.5 0.2 (0.1–0.2) 0.1 (0.1–0.1) 
Cream/ointment/lotion NEC 144 1.4 0.1 (0.1–0.2) 0.1 (0.1–0.1) 
Hydrocortisone/clotrimazole 126 1.2 0.1 (0.1–0.2) 0.1 (0.1–0.1) 
Fexofenadine 124 1.2 0.1 (0.1–0.2) 0.1 (0.1–0.1) 
Saline bath/solution/gargle 117 1.1 0.1 (0.1–0.2) 0.1 (0.1–0.1) 
Clotrimazole topical 110 1.0 0.1 (0.1–0.1) 0.1 (0.1–0.1) 
Ferrous sulfate/sodium ascorbate 104 1.0 0.1 (0.1–0.1) 0.1 (0.1–0.1) 
Docusate otic 93 0.9 0.1 (0.1–0.1) 0.1 (0.0–0.1) 
Cold and flu medication NEC 85 0.8 0.1 (0.0–0.1) 0.1 (0.0–0.1) 
Aspirin cardiovascular 84 0.8 0.1 (0.1–0.1) 0.1 (0.0–0.1) 
Clotrimazole vaginal 80 0.8 0.1 (0.1–0.1) 0.1 (0.0–0.1) 
Vitamin D NEC 79 0.7 0.1 (0.1–0.1) 0.1 (0.0–0.1) 
Paracetamol/codeine 78 0.7 0.1 (0.1–0.1) 0.1 (0.0–0.1) 
Chloramphenicol eye 77 0.7 0.1 (0.1–0.1) 0.1 (0.0–0.1) 
Hyoscine butylbromide 74 0.7 0.1 (0.1–0.1) 0.0 (0.0–0.1) 
Povidone-iodine gargle 73 0.7 0.1 (0.0–0.1) 0.0 (0.0–0.1) 
Antihistamines 73 0.7 0.1 (0.0–0.1) 0.0 (0.0–0.1) 
Multivitamins with minerals 72 0.7 0.1 (0.1–0.1) 0.0 (0.0–0.1) 
Hydrocortisone topical 72 0.7 0.1 (0.0–0.1) 0.0 (0.0–0.1) 
Bromhexine 72 0.7 0.1 (0.0–0.1) 0.0 (0.0–0.1) 
Nasal drops/spray NEC 70 0.7 0.1 (0.0–0.1) 0.0 (0.0–0.1) 
Subtotal 7,120 66.8 — — 
Total advised medications 10,658 100.0 10.9 (10.1–11.8) 7.1 (6.6–7.6) 
Note: OTC – over-the-counter; CI – confidence interval; NEC – not elsewhere classified. Data are reported to one decimal place; a rate tabled as 
0.0 means the rate was less than 0.05 per 100 encounters or per 100 problems. 
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9.5 Changes in medications over the decade 
 2006–07 to 2015–16  
Data on medications are reported for each year from 2006–07 to 2015–16 in Chapter 9 of the 
companion report, A decade of Australian general practice activity 2006–07 to 2015–16.1 In that 
report, changes over time are measured as change in the management of problems (that is, as a rate 
per 100 problems). This reflects change in how GPs manage problems, and takes into account the 
significant increase in the number of problems managed per encounter over the decade to 2015–16. 
The rate at which medications were prescribed decreased significantly from 2006–07 (56.1 per 100 
problems, 95% CI: 54.7–57.4) to 2015–16 (53.1 per 100 problems, 95% CI: 51.9–54.4). Among the 
prescribed drug groups that decreased significantly were antibacterials for systemic use, agents acting 
on the renin-angiotensin system, drugs for obstructive airway disease, systemic anti-inflammatory 
medications and sex hormones. At the same time, prescribing rates of several drug groups increased 
significantly, including psychoanaleptics, digestive drugs for acid-related disorders, systemic 
corticosteroids and antiepileptic drugs. 
At the individual generic level, significant increases were found in the prescribing rates of a number of 
medications. Among them were esomeprazole, oxycodone, rosuvastatin, pantoprazole, oral 
prednisolone and pregabalin. On the other hand, amoxycillin, plain paracetamol and 
paracetamol/codeine combination products, temazepam and roxithromycin were among the 
medications for which significant decreases in prescribing rates occurred over time. 
Other changes that occurred over the 10-year period were significant increases in most vaccines 
supplied to children directly by the GP. Among medications advised for over-the-counter purchase, 
there was a significant rise in ibuprofen and vitamin D3. There was a significant increase in the 
proportion of prescriptions for which five repeats were recorded, and a corresponding decrease in 
those for which one, three or four repeats were recorded over the decade.  
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 10 Other treatments 
The BEACH survey form allows GPs to record up to two other (non-pharmacological) treatments for 
each problem managed at the encounter. Other treatments include all clinical and procedural 
treatments provided. These groups are defined in Appendix 4, Tables A4.3 and A4.4. 
Routine clinical measurements or observations, such as measurements of blood pressure and 
physical examinations, were not recorded if they were undertaken by the GP. However, GPs were 
instructed to record clinical measurements or observations if these were undertaken by a practice 
nurse (PN) or Aboriginal health worker (AHW) in conjunction with the GP at the encounter. 
In this chapter ‘other treatments’ have been counted irrespective of whether they were done by the GP 
or by the PN/AHW. That is, the non-pharmacological management provided at general practice patient 
encounters is described, rather than management provided specifically by the GP. In the analysis of 
procedural treatments, injections given in the provision of vaccines were removed, as this action has 
already been counted and reported in Section 9.3. 
Data on other treatments are reported for each year from 2006–07 to 2015–16 in the 10-year report,  
A decade of Australian general practice activity 2006–07 to 2015–16.1  
10.1 Number of other treatments 
In 2015–16, 54,744 other treatments were recorded, at least one being provided at 42.3% of 
encounters and for 35.6% of problems managed, at a rate of 56.2 per 100 encounters and 36.4 per 
100 problems managed. Extrapolation of the ‘at least one’ result to the 143.0 million Medicare claimed 
GP items of service in 2015–16, suggests that nationally there were about 60.5 million GP–patient 
encounters at which at least one other treatment was provided. 
Table 10.1: Summary of other treatments 
Variable Number 
 Rate per 100 
encounters 
(n = 97,398) 
95% 
LCL 
95% 
UCL 
Rate per 100 
problems 
(n = 150,279) 
95% 
LCL 
95% 
UCL 
At least one other treatment (%) 41,154 42.3 40.6 43.9 32.2 30.8 33.5 
Other treatments 54,744 56.2 53.4 59.0 36.4 34.8 38.1 
 Clinical treatments 37,563 38.6 36.1 41.0 25.0 23.5 26.5 
 Procedural treatments(a) 17,181 17.6 16.6 18.7 11.4 10.8 12.1 
(a) Excludes all local injection/infiltrations performed for immunisations/vaccinations (n = 3,850). 
Note: LCL – lower confidence limit; UCL – upper confidence limit. 
Table 10.2 shows the relationship between other treatments and pharmacological treatments given for 
problems managed. 
• For 61.8% of the problems that were managed with an ‘other treatment’, no medication was 
prescribed, supplied or advised for that problem at that encounter. 
• Around 1 in 5 problems (22.5%) were managed with at least one clinical treatment. For 61.0% of 
these problems, no concurrent pharmacological treatment was provided. 
• About 1 in 10 problems (10.7%) were managed with at least one procedural treatment, with no 
pharmacological management given for 62.6% of these problems. 
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Table 10.2: Relationship between other treatments and pharmacological treatments 
Co-management of problems with other treatments 
Number of 
problems  
Per cent  
within class 
Per cent of  
problems 
(n = 150,279) 
95%  
LCL 
95%  
UCL 
At least one other treatment  48,326 100.0 32.2 30.8 33.5 
 Without pharmacological treatment 29,859 61.8 19.9 19.1 20.7 
At least one clinical treatment  33,773 100.0 22.5 21.2 23.7 
 Without pharmacological treatment 20,618 61.0 13.7 13.0 14.5 
At least one procedural treatment 16,089 100.0 10.7 10.2 11.2 
 Without pharmacological treatment  10,070 62.6 6.7 6.4 7.0 
Note: LCL – lower confidence limit; UCL – upper confidence limit. 
10.2 Clinical treatments 
Clinical treatments include general and specific advice, counselling or education, and administrative 
processes. During 2015–16, there were 37,563 clinical treatments recorded, at a rate of 38.6 per 100 
encounters, and 25.0 per 100 problems managed. Clinical treatments accounted for more than 
two-thirds (68.6%) of all other treatments recorded (Table 10.1). 
Most frequent clinical treatments 
Table 10.3 lists the 20 most common clinical treatments provided. Each clinical treatment type is 
expressed as a percentage of all clinical treatments, and as a rate per 100 encounters and per 100 
problems managed with 95% confidence limits. 
At least one clinical treatment was recorded at 29.9% (95% CI: 28.3–31.5) of encounters. Using this to 
extrapolate to the 143.0 million GP items claimed from Medicare over the same period, we estimate 
that one or more clinical treatments were provided at 42.8 million Medicare claimed encounters. 
The top 10 clinical treatments most frequently provided accounted for 84.0% of all clinical treatments. 
General advice and education was the most frequently recorded (6.3 per 100 encounters), accounting 
for 16.3% of all clinical treatments, followed by counselling about the problem under management 
(4.9 per 100 encounters). 
Several groups of clinical treatments related to preventive activities. The most common was 
counselling/advice about nutrition and weight (3.8 per 100 encounters), followed by counselling/ 
advice about: lifestyle (1.3 per 100), exercise (1.1), health/body (0.6), smoking (0.6), alcohol (0.4), and 
prevention (0.4). Together, these preventive activities accounted for 21.2% of clinical treatments, 
provided at a rate of 8.2 per 100 encounters. 
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Table 10.3: Most frequent clinical treatments 
Clinical treatment Number 
Per cent of 
clinical 
treatments 
(n = 37,563) 
Rate per 100 
encounters 
(n = 97,398) 
95% 
LCL 
95% 
UCL 
Rate per 100 
problems 
(n = 150,279) 
95% 
LCL 
95% 
UCL 
Advice/education NEC* 6,132 16.3 6.3 5.3 7.3 4.1 3.4 4.7 
Counselling – problem* 4,798 12.8 4.9 4.2 5.6 3.2 2.8 3.6 
Advice/education – treatment* 4,243 11.3 4.4 3.9 4.8 2.8 2.5 3.1 
Counselling/advice – nutrition/weight* 3,685 9.8 3.8 3.3 4.3 2.5 2.1 2.8 
Counselling – psychological* 3,000 8.0 3.1 2.8 3.4 2.0 1.8 2.2 
Advice/education – medication* 2,976 7.9 3.1 2.8 3.3 2.0 1.8 2.2 
Other administrative procedure/ document 
(excluding sickness certificate)* 
2,487 6.6 2.6 2.4 2.8 1.7 1.5 1.8 
Sickness certificate* 1,568 4.2 1.6 1.4 1.8 1.0 0.9 1.2 
Reassurance, support* 1,421 3.8 1.5 1.3 1.7 0.9 0.8 1.1 
Counselling/advice – lifestyle* 1,242 3.3 1.3 1.0 1.5 0.8 0.7 1.0 
Counselling/advice – exercise* 1,093 2.9 1.1 0.9 1.3 0.7 0.6 0.9 
Counselling/advice – health/body* 594 1.6 0.6 0.5 0.8 0.4 0.3 0.5 
Counselling/advice – smoking* 555 1.5 0.6 0.5 0.7 0.4 0.3 0.4 
Counselling/advice – prevention* 406 1.1 0.4 0.3 0.5 0.3 0.2 0.3 
Counselling/advice – alcohol* 405 1.1 0.4 0.4 0.5 0.3 0.2 0.3 
Counselling/advice – other* 326 0.9 0.3 0.3 0.4 0.2 0.2 0.3 
Observe/wait* 301 0.8 0.3 0.2 0.4 0.2 0.2 0.2 
Family planning* 300 0.8 0.3 0.3 0.4 0.2 0.2 0.2 
Consultation with primary care provider* 291 0.8 0.3 0.2 0.4 0.2 0.2 0.2 
Counsel/advice – relaxation* 285 0.8 0.3 0.2 0.3 0.2 0.2 0.2 
Counselling/advice – pregnancy* 267 0.7 0.3 0.2 0.3 0.2 0.1 0.2 
Advice/education – sleep 249 0.7 0.3 0.2 0.3 0.2 0.1 0.2 
Subtotal  36,624 97.5 — — — — — — 
Total clinical treatments 37,563 68.6 38.6 36.1 41.0 25.0 23.5 26.5 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.3 <hdl.handle.net/2123/15514>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; NEC – not elsewhere classified. 
Problems managed with a clinical treatment 
Table 10.4 lists the top 10 problems managed with a clinical treatment. It also shows the extent to 
which clinical treatments were used for each problem, and the relationship between the use of a 
clinical treatment and the provision of medication for that problem at that encounter. 
• A total of 33,773 problems (22.5% of all problems) involved one or more clinical treatments in 
their management (Table 10.2). 
• While there was a very broad range of problems managed with clinical treatments, the 10 most 
common accounted for 29.5% of all problems for which clinical treatments were provided. 
• Upper respiratory tract infection (URTI) was the problem accounting for the most clinical 
treatments (5.6% of all problems managed with clinical treatment/s), followed by depression 
(4.8%), and diabetes (3.5%). 
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• URTI was managed with a clinical treatment at a rate of 1.9 per 100 encounters. Extrapolation of 
this result suggests that across Australia in 2015–16, there were 2.7 million occasions where 
URTI was managed with a clinical treatment. 
• A clinical treatment was provided at 35.3% of contacts with URTI, with no concurrent 
pharmacological treatment provided for 54.7% of these contacts where a clinical treatment was 
provided. 
• Of the top 10 problems managed with a clinical treatment, gastroenteritis was the problem most 
likely to be managed this way (at 51.5% of contacts) and no concurrent medication was 
prescribed, supplied or advised on more than half of these management occasions.  
Table 10.4: The 10 most common problems managed with a clinical treatment 
Problem managed Number(a) 
Per cent of 
problems with 
clinical treatment  
(n = 33,773) 
Rate per 100 
encounters(b) 
(n = 97,398) 
95% 
LCL 
95% 
UCL 
Per cent 
 of this 
problem(c) 
Per cent of 
treated 
 problems no 
medications(d) 
Upper respiratory tract infection 1,877 5.6 1.9 1.7 2.1 35.3 54.7 
Depression* 1,635 4.8 1.7 1.5 1.8 39.9 52.0 
Diabetes – all* 1,190 3.5 1.2 1.1 1.4 30.2 60.7 
Hypertension* 1,064 3.2 1.1 0.9 1.3 14.6 43.6 
Anxiety* 885 2.6 0.9 0.8 1.0 41.6 65.9 
Lipid disorder 817 2.4 0.8 0.7 0.9 27.6 69.3 
Gastroenteritis* 681 2.0 0.7 0.6 0.8 51.5 54.4 
Back complaint* 669 2.0 0.7 0.6 0.8 22.0 44.6 
Test results* 603 1.8 0.6 0.5 0.7 26.9 95.3 
Administrative procedure NOS 553 1.6 0.6 0.5 0.7 39.6 96.6 
Subtotal  9,974 29.5 — — — — — 
Total problems with clinical 
treatments 33,773 100.0 34.7 32.6 36.8 — — 
(a) Number of contacts with this problem that generated at least one clinical treatment. 
(b) Rate at which a selected problem was managed with one or more clinical treatments, per 100 encounters. 
(c) Percentage of contacts with this problem that generated at least one clinical treatment. 
(d) The numerator is the number of contacts with this problem that generated at least one clinical treatment but generated no medications.  
The denominator is the total number of contacts for this problem that generated at least one clinical treatment (with or without medications). 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1, <hdl.handle.net/2123/15514>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; NOS – not otherwise specified 
10.3 Procedural treatments 
Procedural treatments include therapeutic actions and diagnostic procedures undertaken at the 
encounter. Injections for immunisations/vaccinations (n = 3,850) are not counted here as these were 
already counted as a GP-supplied medication in Section 9.3. There were 17,181 procedures recorded 
at a rate of 17.6 per 100 encounters, and 11.4 per 100 problems managed (Table 10.2). 
At least one procedure was undertaken at 15.8% (95% CI: 15.0–16.5) of recorded encounters. 
Extrapolation of this result to the 143 million Medicare claimed GP consultations across the country in 
2015–16 suggests at least one procedure was undertaken at about 22.6 million of these. 
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Most frequent procedures 
Table 10.5 lists the most common procedural treatments recorded. Each procedural treatment is 
expressed as a percentage of all procedures, as a rate per 100 encounters and per 100 problems with 
95% confidence limits. Some of the procedures (for example, international normalised ratio [INR] 
tests, electrical tracings, physical function tests) are investigations undertaken at the encounter. 
Results presented in Table 10.5 do not include investigations that were ordered by the GP to be 
performed by an external provider. A summary of all investigations (both undertaken and ordered) is 
provided in Chapter 12 (Table 12.6). 
The top 10 most frequently performed procedural treatments accounted for 83.8% of all procedures. 
The most frequent group of procedures was excision/removal tissue/biopsy/destruction/debridement/ 
cauterisation (3.1 per 100 encounters), accounting for 17.4% of procedural treatments recorded. 
Table 10.5: Most frequent procedural treatments 
Procedural treatment Number 
Per cent of 
procedural 
treatments 
(n = 17,181) 
Rate per 100 
encounters 
(n = 97,398) 
95% 
LCL 
95% 
UCL 
Rate per 100 
problems 
(n = 150,279) 
95% 
LCL 
95% 
UCL 
Excision/removal tissue/biopsy/ 
destruction/debridement/cauterisation* 
2,996 17.4 3.1 2.8 3.3 2.0 1.8 2.2 
Local injection/infiltration*(a) 2,483 14.5 2.5 2.3 2.8 1.7 1.5 1.8 
Dressing/pressure/compression/ 
tamponade* 
2,474 14.4 2.5 2.4 2.7 1.6 1.5 1.8 
Physical medicine/rehabilitation – all* 1,385 8.1 1.4 1.2 1.6 0.9 0.8 1.1 
Incision/drainage/flushing/aspiration/ 
removal body fluid* 
991 5.8 1.0 0.9 1.1 0.7 0.6 0.7 
Check-up – PN/AHW* 935 5.4 1.0 0.3 1.6 0.6 0.2 1.1 
Pap smear* 844 4.9 0.9 0.8 1.0 0.6 0.5 0.6 
Repair/fixation-suture/cast/prosthetic 
device (apply/remove)* 
806 4.7 0.8 0.7 0.9 0.5 0.5 0.6 
Other preventive procedures/high-risk 
medication* 
774 4.5 0.8 0.7 0.9 0.5 0.4 0.6 
Other therapeutic procedures/minor 
surgery* 
717 4.2 0.7 0.6 0.9 0.5 0.4 0.6 
INR test 664 3.9 0.7 0.6 0.8 0.4 0.4 0.5 
Electrical tracings* 548 3.2 0.6 0.5 0.6 0.4 0.3 0.4 
Physical function test* 402 2.3 0.4 0.3 0.5 0.3 0.2 0.3 
Other diagnostic procedures* 386 2.2 0.4 0.3 0.5 0.3 0.2 0.3 
Urine test* 225 1.3 0.2 0.2 0.3 0.1 0.1 0.2 
Pregnancy test* 137 0.8 0.1 0.1 0.2 0.1 0.1 0.1 
Glucose test 128 0.7 0.1 0.1 0.2 0.1 0.1 0.1 
Hormone implant* 121 0.7 0.1 0.1 0.2 0.1 0.1 0.1 
Subtotal  17,017 99.0 — — — — — — 
Total procedural treatments  17,181 100.0 17.6 16.6 18.7 11.4 10.8 12.1 
(a) Excludes all local injection/infiltrations performed for immunisations/vaccinations (n = 2,573). 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Tables A4.4 and A4.5, <hdl.handle.net/2123/15514>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; INR – international normalised ratio; PN – practice nurse; AHW – Aboriginal 
health worker.  
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Problems managed with a procedural treatment 
Table 10.6 lists the top 10 problems managed with a procedural treatment. It also shows the 
proportion of contacts with each problem that were managed with a procedure, and the proportion of 
these contacts where medication was not given concurrently. 
• One or more procedural treatments were provided in the management of 16,089 problems 
(10.7% of all problems) (Table 10.2). 
• The top 10 problems accounted for more than one-third (34.6%) of all problems managed with a 
procedural treatment. 
• Laceration/cut accounted for the largest proportion of problems managed with a procedure 
(5.2%), followed by female genital check-up/Pap smear (4.7%), solar keratosis/sunburn (4.4%) 
and excessive ear wax (3.5%). 
• Two thirds (66.3%) of contacts with solar keratosis/sunburn were managed with a procedure at a 
rate of 0.7 per 100 encounters. Extrapolation of this result suggests that across Australia in  
2015–16, there were more than 1 million occasions where solar keratosis/sunburn was managed 
with a procedure by GPs. 
• Of the top 10 problems, warts was the most likely to be managed with a procedure, undertaken at 
4 out of 5 (82.4%) contacts with this problem. Of those contacts where warts were managed with 
a procedural treatment, no medication was prescribed, supplied or advised for that problem at 
95.4% of contacts. 
Table 10.6: The 10 most common problems managed with a procedural treatment 
Problem managed Number(a) 
Per cent of 
problems with 
procedure 
(n = 16,089)  
Rate per 100 
encounters(b) 
(n = 97,398) 
95% 
LCL 
95% 
UCL 
Per cent 
of this 
problem(c) 
Per cent of 
treated problems 
no medications(d) 
Laceration/cut 842 5.2 0.9 0.8 1.0 77.7 79.1 
Female genital check-up/ 
Pap smear* 
757 4.7 0.8 0.7 0.9 50.0 98.7 
Solar keratosis/sunburn 707 4.4 0.7 0.6 0.8 66.3 96.2 
Excessive ear wax 563 3.5 0.6 0.5 0.6 70.6 92.0 
Warts 556 3.5 0.6 0.5 0.6 82.4 95.4 
General check-up* 481 3.0 0.5 0.4 0.6 16.9 71.1 
Malignant neoplasm, skin 463 2.9 0.5 0.4 0.6 44.4 93.3 
Chronic ulcer skin 
(including varicose ulcer) 
438 2.7 0.4 0.4 0.5 74.1 79.2 
Vitamin/nutritional deficiency 387 2.4 0.4 0.3 0.5 27.3 0.8 
Atrial fibrillation/flutter 372 2.3 0.4 0.3 0.5 30.1 58.8 
Subtotal  5,566 34.6 — — — — — 
Total problems with 
procedural treatments 
16,089 100.0 16.5 15.6 17.4 — — 
(a) Number of contacts with this problem that generated at least one procedural treatment. 
(b) Rate at which a selected problem was managed with one or more procedural treatments, per 100 encounters. 
(c) Percentage of contacts with this problem that generated at least one procedural treatment. 
(d) The numerator is the number of contacts with this problem that generated at least one procedural treatment but generated no medications. 
The denominator is the total number of contacts for this problem that generated at least one procedural treatment (with or without 
medications). 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1, <hdl.handle.net/2123/15514>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit.  
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10.4 Changes in other treatments over the decade 
2006–07 to 2015–16 
An overview of changes in other treatments provided in general practice over the decade can be found 
in Chapter 10 of the companion report, A decade of Australian general practice activity 2006–07 to 
2015–16.1 A summary of the results is provided below. 
Clinical treatments 
From 2006–07 to 2015–16, there was a significant increase in the rate at which clinical treatments 
were provided at GP–patient encounters, from 19.9 per 100 problems managed to 25.0 per 100. 
However, this increase largely occurred between 2006–07 and 2007–08, and in the final BEACH year 
of 2015–16. We estimate that based on a 30% growth in clinical treatments per 100 encounters, 
24.6 million more clinical treatments were provided at GP–patient encounters nationally in 2015–16 
than in 2006–07. 
• General advice and education was the most frequently recorded clinical treatment throughout the 
decade and there was no significant change in its rate of use. The rates at which GPs provided 
psychological counselling and counselling about the problem also did not change. Provision of 
advice/education about treatment and about medication both significantly increased.  
• Counselling/advice about nutrition/weight remained steady at around 2 per 100 problems 
managed, but occasions of counselling about lifestyle almost tripled (from 0.3 per 100 problems 
managed to 0.8 per 100), as did counselling about health/body (0.1 to 0.4 per 100). However, 
there was no change in the rate of counselling/advice about smoking, over the decade. 
Procedural treatments 
There was a significant increase in the rate at which procedures were performed, from 10.2 per 
100 problems in 2006–07 to 11.4 per 100 in 2015–16. The extrapolated effect of this change suggests 
there were an estimated 9.6 million more procedures undertaken at GP–patient encounters in  
2015–16 than a decade earlier. 
For every 100 GP–patient encounters in 2006–07, one or more procedures were used in the 
management of 14.3 problems. This significantly increased over time, to reach 16.5 problems per 100 
encounters in 2015–16. This was reflected in a significant increase in procedures undertaken for the 
management of general check-up and a marginal increase in the procedures undertaken for atrial 
fibrillation/flutter. 
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 11 Referrals and admissions 
A referral is defined as the process by which the responsibility for part, or all, of the care of a patient is 
temporarily transferred to another health care provider. GPs were instructed only to record new 
referrals at the encounter (that is, to not record continuations). For each encounter, GPs could record 
up to two referrals, and each referral was linked by the GP to the problem(s) for which the patient was 
referred. Referrals included those to medical specialists, allied health services, hospitals for 
admission, emergency departments, and those to other services (including outpatient clinics and to 
other GPs). 
Data on referrals and admissions are reported for each of the most recent BEACH years from  
2006–07 to 2015–16, in the 10-year report, A decade of Australian general practice activity 2006–07 
to 2015–16.1  
11.1 Number of referrals and admissions 
Table 11.1 provides a summary of referrals and admissions, and the rates per 100 encounters and per 
100 problems managed. The patient was given at least one referral at 14.7% of all encounters, for 
10.3% of all problems managed. 
There were 15,671 referrals made at a rate of 16.1 per 100 encounters, most often to medical 
specialists (9.5 per 100 encounters, 6.2 per 100 problems managed), followed by referrals to allied 
health services (5.6 per 100 encounters, 3.6 per 100 problems). Relatively few patients were 
referred/admitted to hospital, or referred to the emergency department. 
Table 11.1: Summary of referrals and admissions 
Variable Number 
Rate per 100 
encounters 
(n = 97,398) 
95% 
LCL 
95% 
UCL 
Rate per 100 
problems 
(n = 150,279) 
95% 
LCL 
95% 
UCL 
At least one referral(a) 14,319 14.7 14.1 15.3 10.3 10.0 10.7 
Referrals 15,671 16.1 15.4 16.7 10.4 10.0 10.8 
 Medical specialist* 9,242 9.5 9.1 9.9 6.2 5.9 6.4 
 Allied health services* 5,452 5.6 5.2 6.0 3.6 3.4 3.9 
 Hospital* 305 0.3 0.3 0.4 0.2 0.2 0.2 
 Emergency department* 261 0.3 0.2 0.3 0.2 0.1 0.2 
 Other referrals* 410 0.4 0.3 0.5 0.3 0.2 0.3 
(a) At least one referral was given in the management of 15,531 problems at 14,319 encounters. 
* Includes multiple ICPC-2 and ICPC-2 PLUS codes (see Appendix 4, Table A4.6, <hdl.handle.net/2123/15514>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit. As elsewhere in this report, ‘number’ is weighted for GP activity and rounded.  
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11.2 Most frequent referrals 
Table 11.2 shows the medical specialists and allied health service groups to whom GPs most often 
referred patients. Referrals to medical specialists were most often to orthopaedic surgeons (9.1% of 
specialist referrals), dermatologists (8.3%) and surgeons (8.1%). The top 10 specialist types 
accounted for 63.7% of specialist referrals and for 40.0% of the 14,695 referrals to specialists and 
allied health services combined. 
Referrals to allied health services were most often to physiotherapists (28.9% of allied health services 
referrals), psychologists (22.4%), podiatrists/chiropodists (11.6%), dietitians/nutritionists (8.9%) and 
dentists (3.2%). The top 10 allied health services accounted for 84.3% of allied health referrals and 
31.3% of the 14,695 referrals to specialists and allied health services combined. 
Table 11.2: Most frequent referrals to medical specialists and allied health services 
Professional/organisation Number 
Per cent of 
referrals to 
spec/AHS  
Per cent 
of referral 
group 
Rate per 100 
encounters 
(n = 97,398) 
95% 
LCL 
95% 
UCL 
Rate per 100 
problems 
(n = 150,279) 
95% 
LCL 
95% 
UCL 
Medical specialist* 9,242 62.9 100.0 9.5 9.1 9.9 6.2 5.9 6.4 
 Orthopaedic surgeon 837 5.7 9.1 0.9 0.8 0.9 0.6 0.5 0.6 
 Dermatologist 766 5.2 8.3 0.8 0.7 0.9 0.5 0.5 0.6 
 Surgeon 753 5.1 8.1 0.8 0.7 0.8 0.5 0.5 0.5 
 Cardiologist 718 4.9 7.8 0.7 0.7 0.8 0.5 0.4 0.5 
 Ophthalmologist 600 4.1 6.5 0.6 0.6 0.7 0.4 0.4 0.4 
 Gastroenterologist 547 3.7 5.9 0.6 0.5 0.6 0.4 0.3 0.4 
 Ear, nose and throat 518 3.5 5.6 0.5 0.5 0.6 0.3 0.3 0.4 
 Gynaecologist  473 3.2 5.1 0.5 0.4 0.5 0.3 0.3 0.3 
 Urologist  337 2.3 3.6 0.3 0.3 0.4 0.2 0.2 0.3 
 Psychiatrist  337 2.3 3.6 0.3 0.3 0.4 0.2 0.2 0.3 
 Subtotal: top 10 medical  
 specialist referrals 
5,885 40.0 63.7 — — — — — — 
Allied health services* 5,452 37.1 100.0 5.6 5.2 6.0 3.6 3.4 3.9 
 Physiotherapist 1,574 10.7 28.9 1.6 1.5 1.8 1.0 1.0 1.1 
 Psychologist 1,222 8.3 22.4 1.3 1.1 1.4 0.8 0.7 0.9 
 Podiatrist/chiropodist 634 4.3 11.6 0.7 0.6 0.7 0.4 0.4 0.5 
 Dietitian/nutritionist 483 3.3 8.9 0.5 0.4 0.6 0.3 0.3 0.4 
 Dentist 172 1.2 3.2 0.2 0.1 0.2 0.1 0.1 0.1 
 Exercise physiologist 141 1.0 2.6 0.1 0.1 0.2 0.1 0.1 0.1 
 Audiologist 113 0.8 2.1 0.1 0.1 0.1 0.1 0.1 0.1 
 Optometrist 100 0.7 1.8 0.1 0.1 0.1 0.1 0.1 0.1 
 Diabetes educator 81 0.6 1.5 0.1 0.1 0.1 0.1 0.0Ŧ 0.1 
 Patient support group 75 0.5 1.4 0.1 0.1 0.1 0.0Ŧ 0.0Ŧ 0.1 
 Subtotal: top 10 allied  
 health referrals 
4,595 31.3 84.3 — — — — — — 
Total allied health and 
medical specialist referrals 14,695 100.0 — 15.1 14.5 15.7 9.8 9.4 10.2 
* Includes multiple ICPC-2 and ICPC-2 PLUS codes (see Appendix 4, Table A4.6, <hdl.handle.net/2123/15514>). 
Ŧ Rates are reported to one decimal place. This indicates that the rate is less than 0.05 per 100 encounters. 
Note: LCL – lower confidence limit; UCL – upper confidence limit; spec/AHS – specialists and allied health services combined. ‘Number’ is 
weighted for GP activity and rounded. Totals may differ slightly from summed components due to rounding.  
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11.3 Problems most frequently referred to a 
specialist 
The GP could link a single referral to one or more problems that were managed at the encounter. 
Therefore, there are more problem–referral links than referrals. Table 11.3 shows the most common 
problems referred to a medical specialist, in decreasing frequency of problem–referral links. 
The 9,242 referrals to a medical specialist were provided in the management of 9,459 problems. The 
10 problems most often referred to a specialist accounted for just 17.7% of all problem–referral links, 
reflecting the breadth of problems referred to specialists. Malignant skin neoplasm accounted for 2.4% 
of problem–referral links, followed by osteoarthritis (2.2%), sleep disturbance (2.2%) and diabetes 
(2.0%) (Table 11.3). The ranking of problems most often referred reflects not only the need for referral 
but how frequently that problem is managed at GP encounters. For example, osteoarthritis, commonly 
managed at GP encounters, is ranked highly, even though referrals were made (far right column) at 
only 8.1% of GP contacts with this problem. Malignant skin neoplasm resulted in a specialist referral at 
1 in 5 (21.9%) GP contacts with this problem. This was followed by ischaemic heart disease (14.0%) 
and pregnancy (13.9%). The likelihood of referral depends not only on the need for referral, but on 
other factors such as the acuity/chronicity of the condition. For example, at only 3.9% of GP contacts 
at which depression is managed is this problem referred, suggesting GPs undertake ongoing 
management of depression with or without the involvement of other health professionals. 
Table 11.3: The 10 problems most frequently referred to a medical specialist 
Problem managed 
Problem–referral links Rate per 100 
encounters 
(n = 97,398) 
95% 
LCL 
95% 
UCL 
Per cent of 
contacts with this 
problem(a) Number Per cent  
Malignant neoplasm, skin 228 2.4 0.2 0.2 0.3 21.9 
Osteoarthritis* 207 2.2 0.2 0.2 0.2 8.1 
Sleep disturbance 207 2.2 0.2 0.2 0.3 13.4 
Diabetes – all* 189 2.0 0.2 0.2 0.2 4.8 
Depression* 160 1.7 0.2 0.1 0.2 3.9 
Pregnancy* 156 1.6 0.2 0.1 0.2 13.9 
Back complaint* 146 1.5 0.2 0.1 0.2 4.8 
Abnormal test results* 143 1.5 0.1 0.1 0.2 10.6 
Ischaemic heart disease* 121 1.3 0.1 0.1 0.2 14.0 
Other referral NEC 115 1.2 0.1 0.1 0.2 57.5 
Subtotal: top 10 problems referred to a 
medical specialist 1,671 17.7 — — — — 
Total problems referred to medical 
specialist  9,459 100 9.7 9.3 10.1 — 
(a) The proportion of GP contacts with this problem that was referred to a medical specialist. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1 <hdl.handle.net/2123/15514>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; NEC – not elsewhere classified.  
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Table 11.4 shows the five problems accounting for the greatest proportion of referrals to each of the 
10 most common medical specialty types. The top five problems may represent a small or large 
proportion of all problems referred to a particular specialty. For example, the top five problems 
accounted for 24.0% of all referrals to general/unspecified surgeons (indicative of the broad range of 
conditions referred to them), but for 51.4% of all referrals to orthopaedic surgeons, consistent with a 
more defined range of clinical work. 
Orthopaedic surgeon: The two problems accounting for the most referrals were osteoarthritis (19.6% 
of referrals) and acute internal knee damage (12.2%). Of the five problems most frequently referred, 
those most likely to be referred were acute internal knee damage (referred at 28.8% of GP contacts) 
and musculoskeletal injury (not otherwise specified) (8.2%). 
Dermatologist: The two problems accounting for the most referrals were malignant skin neoplasm 
(13.8% of referrals) and other skin symptom/complaint (9.0%). Of the five problems most frequently 
referred to a dermatologist, those most likely to be referred were acne (referred at 13.8% of GP 
contacts) and other skin check-up (13.5%). 
Surgeon: The two problems accounting for the most referrals were other (not inguinal or 
diaphragmatic) abdominal hernia (6.2% of general/unspecified surgeon referrals) and inguinal hernia 
(5.6%). Of the five problems most frequently referred to a general/unspecified surgeon, those most 
likely to be referred at each GP contact with that problem were inguinal hernia (referred at 40.0% of 
contacts) and other (not inguinal or diaphragmatic) abdominal hernia (38.4%). 
Cardiologist: The two problems accounting for the most referrals were ischaemic heart disease 
(15.3% of referrals) and atrial fibrillation/flutter (12.9%). Of the five problems most frequently referred, 
those most likely to be referred were other (not ischaemic, arrhythmic or valvular) heart disease 
(referred at 23.4% of GP contacts) and chest pain (not otherwise specified) (17.0%). 
Ophthalmologist: The two problems accounting for the most referrals were cataract (14.8%) and 
diabetes (11.4%). Of the five problems most frequently referred to an ophthalmologist, those most 
likely to be referred were cataract (referred at 59.8% of GP contacts) and other (not blindness, 
cataract or refractive error) visual disturbance (49.1%). 
Gastroenterologist: The two problems accounting for the most referrals were gastro-oesophageal 
reflux disease (9.8% of referrals) and abdominal pain (8.7%). Of the five problems most frequently 
referred to a gastroenterologist, those most likely to be referred were rectal bleeding (referred at 
24.0% of GP contacts) and benign/uncertain digestive neoplasm (17.8%). 
Ear, nose and throat (ENT): The two problems accounting for the most referrals were tonsillitis (7.5% 
of referrals to an ENT specialist) and acute/chronic sinusitis (6.4%). Of the five problems most 
frequently referred to an ENT specialist, those most likely to be referred were hearing complaint 
(referred at 20.5% of GP contacts) and throat symptom/complaint (12.2%). 
Gynaecologist: The two problems accounting for the most referrals were menstrual problems (14.8% 
of referrals) and other (including cysts and dysplasia) female genital disease (14.5%). Of the five 
problems most frequently referred to a gynaecologist, those most likely to be referred were 
uterovaginal prolapse (referred at 48.3% of GP contacts) and other female genital disease (29.1%). 
Urologist: The two problems accounting for the most referrals were benign prostatic hypertrophy 
(13.0% of referrals) and abnormal test results (12.7%). Of the five problems most frequently referred, 
those most likely to be referred were urinary calculus (referred at 22.6% of GP contacts) and benign 
prostatic hypertrophy (18.1%). 
Psychiatrist: The two problems accounting for the most referrals were depression (40.2% of referrals) 
and anxiety (11.3%). Of the five problems most frequently referred to a psychiatrist, those most likely 
to be referred at each GP contact with that problem were hyperkinetic disorder (referred at 18.8% of 
GP contacts) and affective psychosis (9.3%) (Table 11.4). 
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Table 11.4: The top problems most frequently referred, by type of medical specialist 
Specialist Problem managed Number 
Per cent of problems 
referred to each 
specialist 
Per cent of  
contacts with  
this problem(a) 
Orthopaedic surgeon Total 847 100.0 — 
 Osteoarthritis* 166 19.6 6.5 
 Acute internal knee damage 104 12.2 28.8 
 Injury musculoskeletal NOS 66 7.8 8.2 
 Fracture* 53 6.3 6.3 
 Bursitis/tendonitis/synovitis NOS 46 5.4 3.6 
 Subtotal: top five problems 436 51.4  — 
Dermatologist Total 779 100.0 — 
 Malignant neoplasm, skin 108 13.8 10.4 
 Skin symptom/complaint, other 70 9.0 8.7 
 Contact dermatitis 66 8.5 3.8 
 Skin check-up* 64 8.3 13.5 
 Acne 60 7.7 13.8 
 Subtotal: top five problems 368 47.3  — 
Surgeon Total 760 100.0 — 
 Abdominal hernia, other 47 6.2 38.4 
 Inguinal hernia 42 5.6 40.0 
 Cholecystitis/cholelithiasis 33 4.3 22.3 
 Malignant neoplasm, skin 32 4.2 3.1 
 Haemorrhoids 28 3.6 9.9 
 Subtotal: top five problems 182 24.0  — 
Cardiologist Total 749 100.0 — 
 Ischaemic heart disease* 115 15.3 13.2 
 Atrial fibrillation/flutter 97 12.9 7.8 
 Hypertension* 65 8.7 0.9 
 Chest pain NOS 50 6.7 17.0 
 Heart disease, other 37 5.0 23.4 
 Subtotal: top five problems 364 48.6  — 
Ophthalmologist  Total 604 100.0 — 
 Cataract 90 14.8 59.8 
 Diabetes – all* 69 11.4 1.8 
 Glaucoma 49 8.1 30.4 
 Eye/adnexa disease, other 41 6.7 22.6 
 Visual disturbance, other 38 6.2 49.1 
 Subtotal: top five problems 286 47.4  — 
(continued) 
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Table 11.4 (continued): The top problems most frequently referred, by type of medical specialist 
Specialist Problem managed Number 
Per cent of 
problems referred 
to each specialist 
Per cent of 
contacts with 
this problem(a) 
Gastroenterologist Total 558 100.0 — 
 Gastro-oesophageal reflux disease* 55 9.8 2.2 
 Abdominal pain* 49 8.7 6.4 
 Rectal bleeding 46 8.2 24.0 
 Benign/uncertain neoplasm, digestive 31 5.6 17.8 
 Chronic enteritis/ulcerative colitis 28 5.0 15.6 
 Subtotal: top five problems 208 37.3  — 
Ear, nose and throat Total 527 100.0 — 
 Tonsillitis* 40 7.5 5.3 
 Sinusitis acute/chronic 34 6.4 2.8 
 Acute otitis media/myringitis 25 4.7 2.9 
 Hearing complaint 22 4.3 20.5 
 Throat symptom/complaint 21 3.9 12.2 
 Subtotal: top five problems 142 26.9  — 
Gynaecologist  Total 493 100.0 — 
 Menstrual problems* 73 14.8 11.1 
 Genital disease, other (female) 71 14.5 29.1 
 Uterovaginal prolapse 39 7.9 48.3 
 Abnormal test results* 28 5.8 2.1 
 Contraception, intrauterine 21 4.2 13.4 
 Subtotal: top five problems 233 47.2  — 
Urologist  Total 342 100.0 — 
 Benign prostatic hypertrophy 44 13.0 18.1 
 Abnormal test results* 43 12.7 3.2 
 Malignant neoplasm, prostate 27 7.9 9.0 
 Urinary tract infection * 25 7.5 1.5 
 Urinary calculus 21 6.2 22.6 
 Subtotal: top five problems 162 47.3  — 
Psychiatrist  Total 357 100.0 — 
 Depression* 143 40.2 3.5 
 Anxiety* 40 11.3 1.9 
 Affective psychosis 27 7.6 9.3 
 Hyperkinetic disorder 26 7.4 18.8 
 Schizophrenia 15 4.3 2.9 
 Subtotal: top five problems 252 70.7  — 
(a) The proportion of GP contacts with this problem that was referred to each type of medical specialist. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1 <hdl.handle.net/2123/15514>). 
Note: NOS – not otherwise specified. The unweighted totals in this table differ from the weighted totals in Tables 11.1 and 11.2. 
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11.4 Problems most frequently referred to allied 
health services and hospitals  
The 5,452 referrals to an allied health service were provided in the management of 5,742 problems. 
The 10 most commonly referred problems accounted for 48.8% of all problem–referral links. 
Depression was the problem accounting for the largest proportion of allied health referrals (10.8%), 
followed by diabetes (6.8%), back complaints (6.5%) and anxiety (5.6%). However, of the 10 most 
commonly referred problems, the most likely to be referred to an allied health service was obesity, 
referred at 25.0% of all GP contacts with this problem (Table 11.5). 
Table 11.5: The 10 problems most frequently referred to allied health services 
Problem managed 
Problem–referral links Rate per 100 
encounters 
(n = 97,398) 
95% 
LCL 
95% 
UCL 
Per cent of 
contacts with 
this problem(a) Number Per cent 
Depression* 623 10.8 0.6 0.6 0.7 15.2 
Diabetes – all* 392 6.8 0.4 0.3 0.5 10.0 
Back complaint* 370 6.5 0.4 0.3 0.4 12.2 
Anxiety* 323 5.6 0.3 0.3 0.4 15.2 
Osteoarthritis* 271 4.7 0.3 0.2 0.3 10.6 
Administrative procedure NOS 224 3.9 0.2 0.2 0.3 16.0 
Obesity (BMI > 30) 184 3.2 0.2 0.1 0.3 25.0 
Sprain/strain* 167 2.9 0.2 0.1 0.2 13.9 
Bursitis/tendonitis/synovitis NOS 129 2.3 0.1 0.1 0.2 10.1 
Acute stress reaction 117 2.0 0.1 0.1 0.1 15.7 
Subtotal: top 10 problems referred to AHS 2,800 48.8 — — — — 
Total problems referred to AHS 5,742 100.0 5.9 5.5 6.3 — 
(a) The proportion of GP contacts with this problem that was referred to allied health services. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1, <hdl.handle.net/2123/15514>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; NOS – not otherwise specified; BMI – body mass index; AHS – allied health 
service. 
 
The 305 referrals to a hospital were provided in the management of 320 problems. The 10 problems 
most frequently referred to a hospital are shown in Table 11.6. Fracture accounted for the highest 
proportion (4.0%) of these referrals, but appendicitis was the problem most likely to be referred 
(35.5% of GP contacts). 
The 261 referrals to an emergency department were associated with the management of 
271 problems. The 10 problems most frequently referred to an emergency department are shown in 
Table 11.7. Pneumonia accounted for the highest proportion (4.5%) of these referrals, but appendicitis 
was the problem most likely to be referred (25.9% of GP contacts). 
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Table 11.6: The 10 problems most frequently referred to hospital 
Problem managed 
Problem–referral links Rate per 100 
encounters 
(n = 97,398) 
95% 
LCL 
95% 
UCL 
Per cent of 
contacts with 
this problem(a) Number Per cent 
Fracture* 13 4.0 0.01 0.00 0.02 1.5 
Appendicitis 12 3.7 0.01 0.00 0.02 35.5 
Atrial fibrillation/flutter 10 3.2 0.01 0.00 0.02 0.8 
Heart failure 10 3.0 0.01 0.00 0.02 1.8 
Pregnancy* 9 2.8 0.01 0.00 0.02 0.8 
Abdominal pain* 8 2.5 0.01 0.00 0.01 1.1 
Acute myocardial infarction 8 2.4 0.01 0.00 0.02 11.2 
Viral hepatitis 6 1.9 0.01 0.00 0.01 3.9 
Pneumonia 6 1.8 0.01 0.00 0.01 2.1 
Skin infection, other 6 1.8 0.01 0.00 0.01 1.2 
Subtotal: top 10 problems referred for 
admission 86 26.9 — — — — 
Total problems referred to hospital 320 100.0 0.33 0.27 0.39 — 
(a) The proportion of GP contacts with this problem that was referred to hospital. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1, <hdl.handle.net/2123/15514>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit. Rates in this table are reported to two decimal places; rates tabled as 0.00 
indicate the rate is less than 0.005 per 100 encounters. 
 
Table 11.7: The 10 problems most frequently referred to an emergency department 
Problem managed 
Problem–referral links Rate per 100 
encounters 
(n = 97,398) 
95% 
LCL 
95% 
UCL 
Per cent of 
contacts with 
this problem(a) Number Per cent 
Pneumonia 12 4.5 0.01 0.00 0.02 4.4 
Abdominal pain* 11 4.2 0.01 0.00 0.02 1.5 
Cerebrovascular disease (all)* 11 4.2 0.01 0.00 0.02 3.4 
Fracture* 10 3.9 0.01 0.00 0.02 1.2 
Skin infection, other 10 3.8 0.01 0.00 0.02 2.1 
Acute bronchitis/bronchiolitis 9 3.3 0.01 0.00 0.02 0.5 
Appendicitis 9 3.2 0.01 0.00 0.02 25.9 
Headache* 7 2.6 0.01 0.00 0.01 0.6 
Chest pain NOS 7 2.5 0.01 0.00 0.01 2.3 
Digestive system disease, other 7 2.5 0.01 0.00 0.01 2.2 
Subtotal: top 10 problems referred to 
emergency department 93 34.5 — — — — 
Total problems referred to emergency 
department 271 100.0 0.28 0.23 0.33 — 
(a) The proportion of GP contacts with this problem that was referred to an emergency department. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1, <hdl.handle.net/2123/15514>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; NOS – not otherwise specified. Rates in this table are reported to two decimal 
places; rates tabled as 0.00 indicate the rate is less than 0.005 per 100 encounters. 
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11.5 Changes in referrals over the decade 2006–07 
to 2015–16 
An overview of changes in referrals over the decade can be found in Chapter 11 of the companion 
report, A decade of Australian general practice activity 2006–07 to 2015–16.1 In that report, changes 
over time are discussed in terms of change in the management of problems (that is, as a rate per 100 
problems managed). This reflects change in how GPs manage problems, and accounts for the 
significant increase in the number of problems managed per encounter over the decade. 
In summary, over the 10 years there was a significant increase in the proportion of problems that were 
referred: in 2006–07 at least one referral was made in the management of 8.3% of problems and this 
increased to 10.3% of problems managed by 2015–16. 
The overall rate of referral per 100 problems managed increased from 8.2 in 2006–07 to 10.4 in  
2015–16, and per 100 encounters from 12.2 to 16.1. This suggests that there were 10.4 million more 
referrals made by GPs nationally in 2015–16 than a decade earlier. 
Referrals to medical specialists increased from 5.4 per 100 problems managed in 2006–07 to 6.2 in 
2015–16. There was a significant decrease in the rate of referrals to ophthalmologists, and marginally 
significant increases in referrals to dermatologists, cardiologists and psychiatrists. 
Referrals to allied health services increased from 2.1 per 100 problems managed in 2006–07 to 3.6 in 
2015–16. This was reflected in significant increases in referral rates per 100 problems to 
physiotherapists, psychologists, podiatrists/chiropodists and dietitians/nutritionists. 
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 12 Investigations 
The GP participants were asked to record (in free text) any pathology, imaging or other tests ordered 
or undertaken at the encounter, and to nominate the patient problem(s) associated with each test 
order placed. This allows the linkage of a test order to a single problem or multiple problems. Up to 
five orders for pathology, and two for imaging and other tests could be recorded at each encounter. A 
single test may have been ordered for the management of multiple problems, and multiple tests may 
have been ordered in the management of a single problem. 
A pathology test order may be for a single test (for example, Pap smear, HbA1c) or for a battery of 
tests (for example, lipids, full blood count). Where a battery of tests was ordered, the battery name 
was recorded rather than each individual test within the battery. GPs also recorded the body site for 
any imaging ordered (for example, x-ray chest, CT head). 
Data on investigations are reported for each year from 2006–07 to 2015–16 in the 10-year report,  
A decade of Australian general practice activity 2006–07 to 2015–16.1 
12.1 Number of investigations 
Table 12.1 shows the number of encounters and problems at which a pathology or imaging test was 
ordered. There were no pathology or imaging tests recorded at three-quarters (74.8%) of encounters. 
At least one pathology test order was recorded at 18.4% of encounters (and for 13.7% of problems 
managed), and at least one imaging test was ordered at 9.4% of encounters (and for 6.4% of 
problems managed). 
Table 12.1: Number of encounters and problems for which pathology or imaging was ordered 
Pathology/imaging test 
ordered 
Number of 
encounters  
Per cent of 
encounters 
(n = 97,398) 
95% 
LCL 
95% 
UCL 
Number of 
problems 
Per cent of 
problems 
(n = 150,279) 
95% 
LCL 
95% 
UCL 
Pathology and imaging ordered 2,532 2.6 2.4 2.8 1,811 1.2 1.1 1.3 
Pathology only ordered 15,406 15.8 15.3 16.3 18,740 12.5 12.1 12.9 
Imaging only ordered 6,634 6.8 6.5 7.1 7,738 5.1 4.9 5.4 
No pathology or imaging tests 
ordered 
72,827 74.8 74.1 75.5 121,991 81.2 80.7 81.7 
At least one pathology ordered 17,938 18.4 17.8 19.0 20,550 13.7 13.2 14.1 
At least one imaging ordered 9,166 9.4 9.1 9.8 9,549 6.4 6.1 6.6 
At least one other investigation 
ordered 
799 0.8 0.7 0.9 818 0.5 0.5 0.6 
At least one other investigation 
performed in the practice 
1,262 1.3 1.1 1.5 1,277 0.8 0.7 1.0 
At least one other investigation 
ordered or performed 
2,014 2.1 1.9 2.2 2,051 1.4 1.2 1.5 
Note: LCL – lower confidence limit; UCL – upper confidence limit. 
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12.2 Pathology ordering 
A report on changes in pathology ordering by GPs from 1998 to 2001 was produced in 2003.68 A 
review of GP pathology orders in the National Health Priority Areas and other selected problems 
between 2000 and 2008 was reported in General practice in Australia, health priorities and policies 
1998 to 2008.14 A report, Evidence-practice gap in pathology test ordering: a comparison of BEACH 
pathology data and recommended testing, was produced by the FMRC for the Australian Government 
Quality Use of Pathology Program in June 2009.17 A PhD thesis, Evaluation of pathology ordering by 
general practitioners in Australia, was completed in 2013.15 Readers may wish to consider those 
publications in conjunction with the information presented below. 
Nature of pathology orders at encounter 
The GPs recorded 46,315 orders for pathology tests (or batteries of tests), at a rate of 47.6 per 
100 encounters or 30.8 per 100 problems managed (Table 12.2). The pathology tests recorded were 
grouped according to the categories set out in Appendix 4, Table A4.7. The main pathology groups 
reflect those used in the Medicare Benefits Schedule (MBS).69 
The distribution of pathology tests by MBS group, and the most common tests within each group are 
presented in Table 12.2. Each group and individual test is expressed as a proportion of all pathology 
tests, as a proportion of the group, and as a rate per 100 encounters and per 100 problems managed 
with 95% confidence limits. 
Tests classed as chemistry accounted for more than half (58.7%) of the pathology test orders, the 
most common being: lipid tests, for which there were 3.7 orders per 100 encounters and 2.4 per 100 
problems managed, electrolytes, urea and creatinine (3.2 per 100 encounters and 2.1 per 100 
problems), thyroid function tests (3.1 and 2.0), and multi-biochemical analysis (3.1 and 2.0). 
Haematology tests accounted for 17.2% of all pathology, including the most frequently ordered 
individual pathology test, full blood count (FBC). FBC tests accounted for 14.0% of all pathology, there 
being 6.7 FBC orders per 100 encounters and 4.3 per 100 problems managed. Microbiology 
accounted for 13.7% of pathology orders, with urine microscopy, culture and sensitivity being the most 
frequent test type in the group at 2.0 orders per 100 encounters and 1.3 per 100 problems managed. 
Table 12.2: Most frequent pathology tests ordered within each MBS pathology group  
Pathology test ordered Number 
Per cent  
of all 
pathology  
Per cent  
of group 
Rate per 100 
encounters 
(n = 97,398) 
95% 
LCL 
95% 
UCL 
Rate per 100 
problems 
(n = 150,279) 
95% 
LCL 
95% 
UCL 
Chemistry*  27,197 58.7 100.0 27.9 26.4 29.4 18.1 17.2 19.0 
 Lipids* 3,602 7.8 13.2 3.7 3.4 4.0 2.4 2.2 2.6 
 Electrolytes, urea and creatinine* 3,091 6.7 11.4 3.2 2.9 3.5 2.1 1.9 2.2 
 Thyroid function* 3,043 6.6 11.2 3.1 2.9 3.4 2.0 1.9 2.2 
 Multi-biochemical analysis* 3,018 6.5 11.1 3.1 2.8 3.4 2.0 1.8 2.2 
 Liver function* 2,464 5.3 9.1 2.5 2.3 2.8 1.6 1.5 1.8 
 Glucose/glucose tolerance* 2,394 5.2 8.8 2.5 2.2 2.7 1.6 1.5 1.7 
 Ferritin* 1,821 3.9 6.7 1.9 1.7 2.0 1.2 1.1 1.3 
 HbA1c* 1,429 3.1 5.3 1.5 1.3 1.6 1.0 0.9 1.0 
 Chemistry, other*  1,075 2.3 4.0 1.1 0.9 1.3 0.7 0.6 0.8 
 C reactive protein 1,068 2.3 3.9 1.1 1.0 1.2 0.7 0.6 0.8 
 Hormone assay* 792 1.7 2.9 0.8 0.7 0.9 0.5 0.5 0.6 
(continued) 
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Table 12.2 (continued): Most frequent pathology tests ordered within each MBS pathology group  
Pathology test ordered Number 
Per cent  
of all 
pathology  
Per cent  
of group 
Rate per 100 
encounters 
(n = 97,398) 
95% 
LCL 
95% 
UCL 
Rate per 100 
problems 
(n = 150,279) 
95% 
LCL 
95% 
UCL 
 Prostate specific antigen*  692 1.5 2.5 0.7 0.6 0.8 0.5 0.4 0.5 
 Vitamin B12 606 1.3 2.2 0.6 0.5 0.7 0.4 0.3 0.5 
 Albumin/creatinine, urine* 550 1.2 2.0 0.6 0.5 0.6 0.4 0.3 0.4 
 Vitamin D 422 0.9 1.6 0.4 0.4 0.5 0.3 0.2 0.3 
 Calcium/phosphate/magnesium* 327 0.7 1.2 0.3 0.3 0.4 0.2 0.2 0.3 
 Urate/uric acid 211 0.5 0.8 0.2 0.2 0.3 0.1 0.1 0.2 
Haematology*  7,945 17.2 100.0 8.2 7.7 8.6 5.3 5.0 5.6 
 Full blood count 6,478 14.0 81.5 6.7 6.3 7.0 4.3 4.1 4.5 
 ESR 788 1.7 9.9 0.8 0.7 0.9 0.5 0.5 0.6 
 Coagulation*  530 1.1 6.7 0.5 0.5 0.6 0.4 0.3 0.4 
Microbiology*  6,354 13.7 100.0 6.5 6.1 6.9 4.2 4.0 4.5 
 Urine M,C&S* 1,912 4.1 30.1 2.0 1.8 2.1 1.3 1.2 1.4 
 Microbiology, other* 778 1.7 12.2 0.8 0.7 0.9 0.5 0.5 0.6 
 Faeces M,C&S* 630 1.4 9.9 0.6 0.5 0.8 0.4 0.3 0.5 
 Venereal disease* 526 1.1 8.3 0.5 0.5 0.6 0.3 0.3 0.4 
 Hepatitis serology* 420 0.9 6.6 0.4 0.4 0.5 0.3 0.2 0.3 
 Vaginal swab M,C&S* 320 0.7 5.0 0.3 0.3 0.4 0.2 0.2 0.2 
 Chlamydia* 314 0.7 4.9 0.3 0.3 0.4 0.2 0.2 0.2 
 Skin swab M,C&S* 224 0.5 3.5 0.2 0.2 0.3 0.1 0.1 0.2 
 H pylori* 217 0.5 3.4 0.2 0.2 0.3 0.1 0.1 0.2 
Cytopathology*  1,465 3.2 100.0 1.5 1.3 1.7 1.0 0.9 1.1 
 Pap smear*  1,425 3.1 97.3 1.5 1.3 1.6 0.9 0.8 1.0 
Other NEC*  1,020 2.2 100.0 1.0 0.8 1.3 0.7 0.5 0.8 
 Blood test  581 1.3 56.9 0.6 0.4 0.8 0.4 0.3 0.5 
 Other test NEC* 220 0.5 21.6 0.2 0.2 0.3 0.1 0.1 0.2 
Tissue pathology*  931 2.0 100.0 1.0 0.8 1.1 0.6 0.5 0.7 
 Histology, skin 884 1.9 94.9 0.9 0.8 1.0 0.6 0.5 0.7 
Immunology*  920 2.0 100.0 0.9 0.8 1.1 0.6 0.5 0.7 
 Immunology, other* 521 1.1 56.6 0.5 0.5 0.6 0.3 0.3 0.4 
Simple tests*  247 0.5 100.0 0.3 0.2 0.3 0.2 0.1 0.2 
Infertility/pregnancy* 236 0.5 100.0 0.2 0.2 0.3 0.2 0.1 0.2 
Total pathology tests  46,315 100.0 — 47.6 45.5 49.6 30.8 29.7 32.0 
* Includes multiple ICPC-2 and ICPC-2 PLUS codes (see Appendix 4, Table A4.7, <hdl.handle.net/2123/15514>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; ESR – erythrocyte sedimentation rate; M,C&S – microscopy, culture and 
sensitivity; H Pylori – test for Helicobacter pylori infection; NEC – not elsewhere classified. 
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Problems for which pathology tests were ordered 
Table 12.3 describes the problems for which pathology was commonly ordered, in decreasing 
frequency order of problem–pathology combinations. Diabetes (accounting for 7.1% of all  
problem–pathology combinations), hypertension, general check-up, and weakness/tiredness were the 
most common problems for which pathology tests were ordered. 
The two columns on the far right show the proportion of each problem that resulted in a pathology 
order, and the rate of pathology tests/batteries of tests per 100 specified problems when at least one 
test was ordered. For example, 69.7% of contacts with weakness/tiredness resulted in pathology 
orders, and when pathology was ordered for weakness/tiredness, the GPs ordered an average of 
395 tests/batteries of tests per 100 ‘tested’ weakness/tiredness contacts. In contrast, only 12.7% of 
contacts with hypertension problems resulted in a pathology test, but the resulting test orders 
accounted for more tests (5.7%) than those ordered for weakness/tiredness (4.2%). This is because in 
general practice, hypertension is managed far more frequently (7.5 per 100 encounters) than 
weakness/tiredness (0.8 per 100 encounters) (see Section 7.3). 
Table 12.3: The 10 problems for which pathology was most frequently ordered 
Problem managed 
Number of 
problems 
Number of 
problem–
pathology 
combinations(a) 
Per cent of 
problem–
pathology 
combinations(a) 
Per cent of 
problems  
with test(b) 
Rate of pathology 
orders per 100 
problems with 
pathology(c) 
Diabetes – all* 3,939 3,452 7.1 30.4 288.0 
Hypertension* 7,289 2,768 5.7 12.7 298.6 
General check-up* 2,852 2,494 5.2 25.1 347.6 
Weakness/tiredness 739 2,033 4.2 69.7 394.7 
Lipid disorder 2,956 1,681 3.5 24.6 230.7 
Female genital check-up/ 
Pap smear*  
1,515 1,445 3.0 78.8 121.0 
Abnormal test results* 1,348 1,304 2.7 51.1 189.5 
Blood test NOS 415 1,199 2.5 83.6 345.6 
Urinary tract infection* 1,754 1,160 2.4 55.2 119.8 
Pregnancy* 1,118 892 1.8 38.3 208.4 
Subtotal 23,926 18,428 38.1 — — 
Total problems 150,279 48,319 100.0 13.7 235.1 
(a) A test was counted more than once if it was ordered for the management of more than one problem at an encounter. There were 49,501 
pathology test orders and 48,319 problem–pathology combinations. 
(b) The percentage of total contacts with the problem that generated at least one order for pathology. 
(c) The rate of pathology orders placed per 100 problem contacts with at least one order for pathology. 
* Includes multiple ICPC-2 and ICPC-2 PLUS codes (see Appendix 4, Table A4.1, <hdl.handle.net/2123/15514>). 
Note: NOS – not otherwise specified. 
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12.3 Imaging ordering 
Readers wanting a more detailed study of imaging orders should consult the comprehensive report on 
imaging orders by GPs in Australia in 1999–00, by the FMRC using BEACH data, and published by 
the Australian Institute of Health and Welfare and the University of Sydney in 2001.70 A 2014 report, 
Evaluation of imaging ordering by general practitioners in Australia 2002–03 to 2011–12, described 
changes in GPs’ imaging ordering over time and evaluated the alignment between guidelines and GP 
test ordering for selected problems.18 This recent report was funded by a grant from the Diagnostic 
Imaging Quality Program, through the Australian Government Department of Health. Readers may 
wish to consider those reports in conjunction with the information presented below. 
Nature of imaging orders at encounter 
There were 10,733 imaging test orders recorded, at a rate of 11.0 per 100 encounters and 7.1 per 100 
problems managed. The distribution of imaging tests by MBS group and the most common tests within 
each group are presented in Table 12.4. Each group and individual test is expressed as a percentage 
of all imaging tests, as a percentage of the group, and as a rate per 100 encounters and per 100 
problems with 95% confidence limits. Ultrasound accounted for 44.4% of all imaging test orders, the 
most common being pelvis (ordered at a rate of 0.7 per 100 encounters) and shoulder ultrasounds 
(0.6). Diagnostic radiology accounted for 39.1% of all tests, and included the most commonly ordered 
individual imaging test, chest x-ray (0.9 per 100 encounters). 
Table 12.4: Most frequent imaging tests ordered within each MBS imaging group 
Imaging test ordered Number 
Per cent of 
all imaging  
 Per cent 
of group 
Rate per 100 
encounters 
(n = 97,398) 
95% 
LCL 
95% 
UCL 
Rate per 100 
problems 
(n = 150,279) 
95% 
LCL 
95% 
UCL 
Ultrasound* 4,770 44.4 100.0 4.9 4.7 5.1 3.2 3.0 3.3 
 Ultrasound; pelvis 656 6.1 13.8 0.7 0.6 0.7 0.4 0.4 0.5 
 Ultrasound; shoulder  569 5.3 11.9 0.6 0.5 0.6 0.4 0.3 0.4 
 Ultrasound; abdomen 390 3.6 8.2 0.4 0.4 0.4 0.3 0.2 0.3 
 Ultrasound; breast; female 378 3.5 7.9 0.4 0.3 0.4 0.3 0.2 0.3 
 Ultrasound; obstetric 269 2.5 5.6 0.3 0.2 0.3 0.2 0.1 0.2 
 Ultrasound; hip  191 1.8 4.0 0.2 0.2 0.2 0.1 0.1 0.1 
 Test; Doppler 166 1.5 3.5 0.2 0.1 0.2 0.1 0.1 0.1 
 Echocardiography 163 1.5 3.4 0.2 0.1 0.2 0.1 0.1 0.1 
 Ultrasound; foot/toe(s)  150 1.4 3.1 0.2 0.1 0.2 0.1 0.1 0.1 
 Ultrasound; knee 134 1.2 2.8 0.1 0.1 0.2 0.1 0.1 0.1 
 Ultrasound; kidney 132 1.2 2.8 0.1 0.1 0.2 0.1 0.1 0.1 
 Ultrasound; leg  131 1.2 2.7 0.1 0.1 0.2 0.1 0.1 0.1 
 Ultrasound; thyroid 128 1.2 2.7 0.1 0.1 0.2 0.1 0.1 0.1 
 Ultrasound; kidney/ureter/bladder 123 1.2 2.6 0.1 0.1 0.2 0.1 0.1 0.1 
 Ultrasound; elbow 106 1.0 2.2 0.1 0.1 0.1 0.1 0.1 0.1 
 Ultrasound; hand/finger(s) 96 0.9 2.0 0.1 0.1 0.1 0.1 0.0 0.1 
 Ultrasound; wrist 94 0.9 2.0 0.1 0.1 0.1 0.1 0.0 0.1 
 Ultrasound; ankle 89 0.8 1.9 0.1 0.1 0.1 0.1 0.0 0.1 
 Ultrasound; scrotum 86 0.8 1.8 0.1 0.1 0.1 0.1 0.0 0.1 
(continued) 
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Table 12.4 (continued): Most frequent imaging tests ordered within each MBS imaging group 
Imaging test ordered Number 
Per cent of 
all imaging  
 Per cent 
of group 
Rate per 100 
encounters 
(n = 97,398) 
95% 
LCL 
95% 
UCL 
Rate per 100 
problems 
(n = 150,279) 
95% 
LCL 
95% 
UCL 
 Ultrasound; neck 75 0.7 1.6 0.1 0.1 0.1 0.0 0.0 0.1 
 Echocardiography; stress 66 0.6 1.4 0.1 0.0 0.1 0.0 0.0 0.1 
 Ultrasound; abdomen upper 62 0.6 1.3 0.1 0.0 0.1 0.0 0.0 0.1 
 Test; doppler carotid 59 0.6 1.2 0.1 0.0 0.1 0.0 0.0 0.1 
 Ultrasound; nuchal translucency 57 0.5 1.2 0.1 0.0 0.1 0.0 0.0 0.1 
 Ultrasound; liver 50 0.5 1.0 0.1 0.0 0.1 0.0 0.0 0.0 
Diagnostic radiology* 4,201 39.1 100.0 4.3 4.1 4.5 2.8 2.7 2.9 
 X-ray; chest 856 8.0 20.4 0.9 0.8 1.0 0.6 0.5 0.6 
 X-ray; knee 466 4.3 11.1 0.5 0.4 0.5 0.3 0.3 0.3 
 Test; densitometry  334 3.1 8.0 0.3 0.3 0.4 0.2 0.2 0.3 
 Mammography; female 324 3.0 7.7 0.3 0.3 0.4 0.2 0.2 0.2 
 X-ray; foot/feet 259 2.4 6.2 0.3 0.2 0.3 0.2 0.1 0.2 
 X-ray; shoulder 258 2.4 6.1 0.3 0.2 0.3 0.2 0.1 0.2 
 X-ray; hip  237 2.2 5.6 0.2 0.2 0.3 0.2 0.1 0.2 
 X-ray; ankle 198 1.8 4.7 0.2 0.2 0.2 0.1 0.1 0.2 
 X-ray; hand 157 1.5 3.7 0.2 0.1 0.2 0.1 0.1 0.1 
 X-ray; wrist  132 1.2 3.1 0.1 0.1 0.2 0.1 0.1 0.1 
 X-ray; finger(s)/thumb 101 0.9 2.4 0.1 0.1 0.1 0.1 0.1 0.1 
 X-ray; abdomen  90 0.8 2.1 0.1 0.1 0.1 0.1 0.0 0.1 
 X-ray; spine; cervical 77 0.7 1.8 0.1 0.1 0.1 0.1 0.0 0.1 
 X-ray; spine; lumbar  77 0.7 1.8 0.1 0.1 0.1 0.1 0.0 0.1 
 X-ray; spine; lumbosacral 65 0.6 1.5 0.1 0.0 0.1 0.0 0.0 0.1 
 X-ray; elbow  52 0.5 1.2 0.1 0.0 0.1 0.0 0.0 0.0 
Computerised tomography* 1,242 11.6 100.0 1.3 1.2 1.4 0.8 0.8 0.9 
 CT scan; spine; lumbar 179 1.7 14.4 0.2 0.1 0.2 0.1 0.1 0.1 
 CT scan; abdomen  158 1.5 12.7 0.2 0.1 0.2 0.1 0.1 0.1 
 CT scan; brain 147 1.4 11.8 0.2 0.1 0.2 0.1 0.1 0.1 
 CT scan; chest  136 1.3 11.0 0.1 0.1 0.2 0.1 0.1 0.1 
 CT scan; sinus  82 0.8 6.6 0.1 0.1 0.1 0.1 0.0 0.1 
 CT scan; spine; lumbosacral  74 0.7 6.0 0.1 0.1 0.1 0.0 0.0 0.1 
 CT scan; head  71 0.7 5.7 0.1 0.1 0.1 0.0 0.0 0.1 
 CT scan; spine; cervical 52 0.5 4.2 0.1 0.0 0.1 0.0 0.0 0.0 
Magnetic resonance imaging* 464 4.3 100.0 0.5 0.4 0.5 0.3 0.3 0.4 
 MRI; knee 173 1.6 37.3 0.2 0.1 0.2 0.1 0.1 0.1 
 MRI; brain 80 0.7 17.2 0.1 0.1 0.1 0.1 0.0 0.1 
Nuclear medicine* 56 0.5 100.0 0.1 0.0 0.1 0.0 0.0 0.0 
Total imaging tests 10,733 100.0 — 11.0 10.6 11.5 7.1 6.9 7.4 
* Includes multiple ICPC-2 and ICPC-2 PLUS codes (see Appendix 4, Table A4.8 <hdl.handle.net/2123/15514>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; CT – computerised tomography; MRI – magnetic resonance imaging. Rates are 
reported to one decimal place, a rate tabled as 0.0 indicates the rate is less than 0.05 per 100 encounters or per 100 problems. 
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Problems for which imaging tests were ordered 
Table 12.5 lists the problems for which imaging was commonly ordered, in decreasing frequency order 
of problem–imaging combinations. Bursitis/tendonitis/synovitis accounted for 5.1% of all orders, 
followed by back complaint (4.3%), osteoarthritis (4.2%) and shoulder syndrome (3.4%). 
The two columns on the far right show the proportion of each problem that resulted in an imaging test, 
and the rate of imaging tests per 100 specified problems when at least one test was ordered. For 
example, 13.2% of contacts with back complaints resulted in an imaging test, and 114.8 tests were 
ordered per 100 back complaint contacts that involved a test order. Note that breast lump/mass 
(female) and shoulder syndrome were the problems most likely to be tested (78.4% and 45.5% 
respectively). 
Table 12.5: The 10 problems for which an imaging test was most frequently ordered 
Problem managed 
Number of 
problems 
Number of  
problem–imaging 
 combinations(a) 
Per cent of 
problem–imaging 
combinations(a) 
Per cent  
of problems 
with test(b) 
Rate of imaging 
orders per 100 
problems with 
imaging(c) 
Bursitis/tendonitis/synovitis NOS 1,277 552 5.1 35.1 123.3 
Back complaint* 3,045 461 4.3 13.2 114.8 
Osteoarthritis* 2,548 460 4.2 15.8 114.3 
Shoulder syndrome 659 371 3.4 45.5 123.6 
Sprain/strain* 1,205 361 3.3 25.4 118.1 
Injury musculoskeletal NOS  805 357 3.3 37.6 118.1 
Pregnancy* 1,118 340 3.1 30.1 100.8 
Abdominal pain* 756 312 2.9 36.4 113.3 
Fracture* 843 300 2.8 32.4 110.0 
Breast lump/mass (female)  170 190 1.8 78.4 142.3 
Subtotal 12,426 3,705 34.2 — — 
Total problems 150,279 10,824 100.0 6.4 113.3 
(a) A test was counted more than once if it was ordered for the management of more than one problem at an encounter. There were 10,733 
imaging test orders and 10,824 problem–imaging combinations. 
(b) The percentage of total contacts with the problem that generated at least one order for imaging. 
(c) The rate of imaging orders placed per 100 tested problem contacts with at least one order for imaging. 
* Includes multiple ICPC-2 and ICPC-2 PLUS codes (see Appendix 4, Table A4.1 <hdl.handle.net/2123/15514>). 
Note: NOS – not otherwise specified. 
12.4 Other investigations 
Other investigations include diagnostic procedures ordered by the GP, or undertaken by the GP or 
practice staff at the encounter. GPs ordered 829 other investigations during the study year, and GPs 
or practice staff undertook a further 1,313. There were, in total, 2,142 other investigations either 
ordered or undertaken (Table 12.6). 
The first section of Table 12.6 lists the other investigations ordered by GPs. The second lists the other 
investigations undertaken in the practice by GPs or practice staff. The third section lists the total other 
investigations (either ordered or undertaken in the practice). Each investigation is expressed as a 
percentage of total other investigations ordered or undertaken and as a rate per 100 encounters and 
per 100 problems with 95% confidence limits. Electrical tracings were the most common group of 
other investigations ordered or undertaken, making up 45.0% of other investigations, followed by 
physical function test (27.6%). 
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The results also demonstrate that the majority of electrical tracings were undertaken in the practice 
(56.9%). In contrast, the majority (96.9%) of diagnostic endoscopies were ordered to be done by 
external providers (Table 12.6). 
Table 12.6: Other investigations ordered by GPs or performed in the practice 
 Investigations ordered by the GP 
Investigation  Number Per cent 
Rate per 100 
encounters (95% CI) 
(n = 97,398) 
Rate per 100 
problems (95% CI) 
(n = 150,279) 
Investigations ordered by the GP 829 100.0 0.9 (0.8–0.9) 0.6 (0.5–0.6) 
 Electrical tracings* 415 50.0 0.4 (0.4–0.5) 0.3 (0.2–0.3) 
 Diagnostic endoscopy* 217 26.2 0.2 (0.2–0.3) 0.1 (0.1–0.2) 
 Physical function test*  189 22.8 0.2 (0.2–0.2) 0.1 (0.1–0.1) 
 Other diagnostic procedures* 9 1.0 0.0 (0.0–0.0) 0.0 (0.0–0.0) 
Investigations undertaken in the practice 1,313 100.0 1.3 (1.2–1.5) 0.9 (0.8–1.0) 
 Electrical tracings* 548 41.8 0.6 (0.5–0.6) 0.4 (0.3–0.4) 
 Diagnostic endoscopy* 8 0.6 0.0 (0.0–0.0) 0.0 (0.0–0.0) 
 Physical function test* 402 30.6 0.4 (0.3–0.5) 0.3 (0.2–0.3) 
 Other diagnostic procedures* 355 27.1 0.4 (0.2–0.5) 0.2 (0.2–0.3) 
All investigations (ordered or undertaken) 2,142 100.0 2.2 (2.0–2.4) 1.4 (1.3–1.5) 
 Electrical tracings* 963 45.0 1.0 (0.9–1.1) 0.6 (0.6–0.7) 
 Diagnostic endoscopy* 224 10.5 0.2 (0.2–0.3) 0.1 (0.1–0.2) 
 Physical function test* 591 27.6 0.6 (0.5–0.7) 0.4 (0.3–0.4) 
 Other diagnostic procedures* 364 17.0 0.4 (0.3–0.5) 0.2 (0.2–0.3) 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.5 <hdl.handle.net/2123/15514>). 
Note: CI – confidence interval. 
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12.5 Changes in investigations over the decade 
2006–07 to 2015–16 
Data on investigations are reported for each year from 2006–07 to 2015–16 in Chapter 12 of the 
companion report, A decade of Australian general practice activity 2006–07 to 2015–16.1 In that 
report, changes over time are measured as change in the management of problems (that is, as a rate 
per 100 problems). This reflects change in how GPs manage problems, and adjusts for the significant 
increase in the number of problems managed per encounter over the decade. The major changes are 
highlighted below. 
• There was no change in the proportion of problems where at least one pathology test was ordered 
(13.4% of problems managed in 2006–07 and 13.7% in 2015–16). However, the number of 
pathology tests ordered increased over the decade from 28.6 tests (or batteries of tests) per 100 
problems managed in 2006–07 to 30.8 in 2015–16. This increased rate of ordering (per 100 
problems) was due to GPs ordering more tests per problem once the decision to order pathology 
had been made, not to any change in the likelihood of pathology being ordered in the 
management of problems. Rates of chemistry, immunology and ‘simple’ tests increased 
marginally over the decade. Order rates for all other pathology groups did not change. 
• There was no change in the proportion of encounters involving at least one pathology test (17.4% 
of encounters in 2006–07 to 18.4% in 2015–16. However, the rate of tests ordered per 100 
encounters increased from 42.4 to 47.6 over the decade, equating to approximately 24.2 million 
more pathology tests ordered nationally in 2015–16 than 10 years earlier. This national increase 
was driven by a rise in the number of problems managed at encounter (increasing from 148.5 to 
154.3 per 100 encounters over the decade, see Chapter 5) and the increased GP attendance rate 
in Australia.3,4 
• At least one imaging test was ordered for 5.5% of all problems managed in 2006–07, rising to 
6.4% of all problems in 2015–16. The proportion of encounters generating imaging orders 
increased from 7.9% in 2006–07 to 9.4% in 2015–16. This resulted in an estimated 5.3 million 
more encounters nationally at which imaging was ordered by GPs in 2015–16 than in 2006–07. 
• The number of imaging tests ordered increased from 6.0 tests per 100 problems managed in 
2006–07 to 7.1 per 100 problems in 2015–16. Total imaging orders per 100 encounters increased 
significantly from 9.0 per 100 encounters in 2006–07 to 11.0 in 2015–16, suggesting that 
nationally there were 6.4 million more imaging tests ordered by GPs in 2015–16 than in 2006–07. 
• There were changes in the types of imaging tests ordered, with a move away from diagnostic 
radiology toward ultrasound imaging. Ultrasounds were the most commonly ordered imaging test, 
and GPs’ ordering increased from 3.2 to 4.9 per 100 encounters, a national increase of about 
3.7 million ultrasound orders over the decade period. The rate of computerised tomography 
orders increased marginally and magnetic resonance imaging increased significantly over the 
decade, but these tests accounted for a smaller proportion of total imaging orders.  
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 13 Patient risk factors 
General practice is a useful intervention point for health promotion because the majority of the 
population visit a GP at least once per year. In 2015–16, 86.8% of Australians visited a GP at least 
once (personal communication, DoH, May 2016). GPs have substantial knowledge of population 
health, screening programs and other interventions. They are therefore in an ideal position to advise 
patients about the benefits of health screening, and to counsel individuals about their lifestyle choices. 
Since the BEACH program began in 1998, a section at the bottom of each encounter form has been 
used to investigate aspects of patient health or healthcare delivery not covered by general practice 
consultation-based information. These additional substudies are referred to as SAND (Supplementary 
Analysis of Nominated Data). The SAND methods are described in Section 2.6. 
The patient risk factors collected in BEACH include body mass index (BMI) (calculated using 
self-reported height and weight), self-reported alcohol consumption and self-reported smoking status. 
These patient risk factors are recorded for a subsample of 40 of the 100 patient encounters recorded 
by each GP. An example of the encounter form with the patient risk factor SAND questions is included 
as Appendix 1. The methods used in the risk factor substudies reported in this chapter are described 
in each section below. 
Unweighted (sample) data on patient risk factors measured in SAND are reported for each of the 
10 most recent years, and risk factor prevalence after adjustment for general practice attendance 
patterns by age–sex for each of the 9 most recent years are reported in the companion report,  
A decade of Australian general practice activity 2006–07 to 2015–16.1 
Abstracts of results and the research tools used in other SAND substudies from April 1998 to March 
2016 have been published. Those conducted: 
• from April 1998 to March 1999 were published in Measures of health and health care delivery in 
general practice in Australia26 
• from April 1999 to July 2006 were published in Patient-based substudies from BEACH: abstracts 
and research tools 1999–200627 
• since August 2006 have been published in each of the general practice annual reports28-36 
• in the 2015–16 BEACH year are provided in Chapter 15 of this publication. 
13.1 Body mass index 
From the most recent publicly available Australian data, high body mass index (BMI) was the third 
highest contributor to the total burden of disease in Australia in 2003, accounting for 7.5% of the total 
burden,71 an increase from 4.3% of the total burden and sixth rank in 1996.72  
More recently, Australasian (comprising Australia and New Zealand) disease burdens have been 
estimated by the Global Burden of Disease 2010 study. It describes and compares the burden of 
disease and injury attributable to 67 risk factors in 21 regions. In Australasia, ‘dietary risks’ accounted 
for 11% of the total disease burden, followed by ‘high body mass index’ (9% of burden) and smoking 
(8%).73,74 
In 2016, the Organisation for Economic Co-operation and Development (OECD) reported that 
Australia’s adult obesity rates (based on measured data) in 1989, 1995, 2007, 2011 and 2014 were 
among the highest in the world (10.8%, 19.8%, 24.6%, 28.3% and 27.9% of adults respectively), with 
Australia’s adult obesity rate fifth globally, behind the United States, Mexico, Hungary and New 
Zealand.75 
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In 2007 (or nearest year), Australia was fourth, with obesity rates two percentage points below that of 
New Zealand, and in 2014 (or nearest year), Australia was fifth with obesity rates still around two 
percentage points below New Zealand. Over this period, the obesity rates of both nations increased by 
about three percentage points (from 24.6% to 27.9% and 26.5% to 29.9% respectively). In a similar 
7-year period, obesity rates in the United States increased by about four percentage points to 38.2%, 
and those in Mexico increased by two percentage points to 32.4%.75 
Australia’s obesity rate of 27.9% in 2014 is much higher than the average for the 19 OECD countries 
most recent measured data (22.8%). The OECD suggest that the rise in adult obesity in Australia 
should be treated as a public health priority.76 They indicate that preventable conditions such as type 2 
diabetes and other chronic conditions are associated with obesity, resulting in avoidable escalating 
health care costs in the future. They make five suggestions regarding what can be done to tackle the 
obesity problem, one of which is to “Encourage primary care physicians to counsel at-risk patients 
about making healthy lifestyle choices”.76 
The Australian Bureau of Statistics’ National Health Survey (2014–15), using trained interviewer 
measured data, estimated that 35.5% of Australians aged 18 years and over were overweight (BMI 
25–< 30) and 27.9% were obese (BMI 30 or more); 63.4% were overweight or obese. Men were more 
likely to be overweight or obese (70.8%) than women (56.3%).77 
The National Health Survey also reported that about one in four (27.4%) of children aged 5–17 years 
were classified as overweight or obese (20.2% overweight, 7.4% obese).77 
The Australian government has recognised the epidemic of overweight and obesity, and the likely 
impact on future health costs and negative health outcomes. New guidelines about the clinical 
management of overweight and obesity were released by the National Health and Medical Research 
Council (NHMRC) in May 2013.78 
Method 
Patient BMI was investigated for a subsample of 40 of each GP’s 100 patient encounters. Each GP 
was instructed to ask the patient (or their carer in the case of children): 
• What is your height in centimetres (without shoes)? 
• What is your weight in kilograms (unclothed)? 
Metric conversion tables (from feet and inches; from stones and pounds) were provided to the GP. 
The BMI for an individual was calculated by dividing weight (kilograms) by height (metres) squared. 
The WHO recommendations79 for BMI groups were used. They specify that an adult (18 years and 
over) with a BMI: 
• less than 18.5 is underweight 
• greater than or equal to 18.5 and less than 25 is normal weight 
• greater than or equal to 25 and less than 30 is overweight 
• of 30 or more is obese. 
The reported height for adult patients was checked against sex-appropriate upper and lower height 
limits from the ABS.80 Adults whose self-reported height was outside the sex-appropriate limits were 
excluded from the analysis. 
The standard BMI cut-offs described above are not appropriate in the case of children. Cole et al. 
(2000 & 2007) developed a method to calculate the age–sex-specific BMI cut-off levels for 
underweight, overweight and obesity specific to children aged 2–17 years.81,82 There are four 
categories defined for childhood BMI: underweight, normal weight, overweight and obese. This 
method, based on international data from developed Western cultures, is applicable in the Australian 
setting. 
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The reported height of children was checked against age–sex-appropriate upper and lower height 
limits from the ABS and Centres for Disease Control.80,83 Children whose self-reported height was 
outside the age–sex-appropriate limits were excluded from the analysis. 
The BEACH data on BMI are presented separately for adults (aged 18 years and over) and children 
(aged 2–17 years). 
Results 
Body mass index of adults 
The sample size was 31,662 patients aged 18 years and over at encounters with 964 GPs. 
• Almost two-thirds (63.2%) of these adults were overweight (34.5%) or obese (28.8%)  
(Table 13.1). 
• Just over one-third (34.6%) of adult patients had a BMI in the normal range, and 2.2% of were 
underweight. Underweight was more prevalent among females than males. 
• Males were more likely to be overweight or obese (70.2%, 95% CI: 69.2–71.3) than females 
(58.6%, 95% CI: 57.5–59.6) (results not tabled). 
• Overweight/obesity was most prevalent among male patients aged 65–74 years (77.2%) and  
45–64 years (77.0%) (Figure 13.1). 
• In female patients, overweight/obesity was most prevalent in those aged 65–74 years (70.1%) 
and 45–64 years (64.9%) (Figure 13.1). 
• Underweight was most prevalent among patients aged 18–24 years (5.7%, 95% CI: 4.7–6.7) 
(results not tabled). 
• Of young adults (aged 18–24 years), 7.1% of females and 3.2% of males were underweight, and 
among those aged 75 years and over, 4.0% of females and 1.5% of males were underweight 
(Figure 13.2). 
Our overall and sex-specific prevalence estimates of overweight/obesity among patients at general 
practice encounters (63% of adults, 70% of males and 59% of females) are consistent with the ABS 
2014–15 figures from the National Health Survey (based on measured BMI data), which reported that 
63% of adults aged 18 years and over (71% of males and 56% of females) were overweight or 
obese.77 
Readers interested in the prevalence of the three WHO-defined levels of obesity will find more 
information and discussion in Chapter 7 of General practice in Australia, health priorities and policies 
1998 to 2008.84  
Estimation of body mass index for the adult general practice patient population 
The BEACH study provides data about patient BMI from a sample of the patients attending general 
practice. As older people attend a GP more often than young adults, and females attend more often 
than males, they have a greater chance of being selected in the subsample. This leads to a greater 
proportion of older and female patients in the BEACH sample than in the total population who attend a 
GP at least once in a year. The 2015–16 BEACH sample was weighted to estimate the BMI of the 
GP–patient attending population (that is, the 16.2 million adult patients who attended a GP at least 
once in 2015–16 (personal communication, DoH, May 2016), using the method described by Knox 
et al. (2008).21 This statistical adjustment had little effect on the resulting proportions. 
The estimates for the adult population who attended general practice at least once (after adjusting for 
age–sex general practice attendance patterns) suggest that 27.9% of the adult patient population were 
obese, 34.0% were overweight, 35.8% were normal weight and 2.2% were underweight (Table 13.1). 
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Table 13.1: Patient body mass index (aged 18 years and over) 
 Male(a)  Female(a)  Total respondents 
BMI class 
Per cent in 
BEACH sample 
(95% CI) 
(n = 12,499) 
Per cent  
in patient 
population 
(95% CI)(b)  
Per cent in 
BEACH sample 
(95% CI) 
(n = 18,932) 
Per cent  
in patient 
population 
(95% CI)(b)  
Per cent in 
BEACH sample 
(95% CI) 
(n = 31,662) 
Per cent  
in patient 
population 
(95% CI)(b) 
Obese 28.5 
(27.5–29.6) 
27.7 
(26.6–28.8)  
28.9 
(28.0–29.8) 
28.2 
(27.2–29.1)  
28.8 
(28.0–29.6) 
27.9 
(27.1–28.8) 
Overweight 41.7 
(40.7–42.7) 
40.5 
(39.4–41.5)  
29.7 
(29.0–30.4) 
28.5 
(27.7–29.2)  
34.5 
(33.9–35.1) 
34.0 
(33.4–34.7) 
Normal 28.7 
(27.6–29.7) 
30.7 
(29.5–31.9)  
38.5 
(37.5–39.5) 
40.4 
(39.3–41.4)  
34.6 
(33.7–35.4) 
35.8 
(34.9–36.7) 
Underweight 1.1 
(0.9–1.3) 
1.2 
(1.0–1.4  
3.0 
(2.7–3.2) 
3.0 
(2.7–3.3)  
2.2 
(2.0–2.4) 
2.2 
(2.0–2.4) 
(a) Patient sex was not recorded for 231 respondents, missing data removed. 
(b) Estimation of BMI among the total adult general practice patient population (that is, patients aged 18 years and over who attended a GP at 
least once in 2015–16). 
Note: BMI – body mass index; CI – confidence interval. 
 
 
 
 Figure 13.1: Age–sex-specific rates of overweight/obesity among sampled male (n = 12,499) and 
female (n = 18,932) adults, 2015–16 (95% confidence intervals) 
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 Figure 13.2: Age–sex-specific rates of underweight among sampled male (n = 12,499) and female 
(n = 18,932) adults, 2015–16 (95% confidence intervals) 
 
Body mass index of children 
BMI was calculated for 3,077 patients aged 2–17 years at encounters with 800 GPs. 
• More than one in four children (28.0%, 95% CI: 26.2–29.8) were classed as overweight or obese, 
including 9.9% (95% CI: 8.7–11.1) obese and 18.1% (95% CI: 16.7–19.5) overweight (results not 
tabled). 
• There was no difference in the prevalence of overweight/obesity among male (28.4%, 95% CI: 
26.1–30.8) and female children (27.5%, 95% CI: 25.0–30.0) (results not tabled). 
• The age-specific rates of obesity followed similar patterns for both sexes (Figures 13.3 and 13.4). 
Readers interested in further detail and discussion about overweight and obesity in children attending 
general practice will find more information in Cretikos et al. (2008) General practice management of 
overweight and obesity in children and adolescents in Australia.85 
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Figure 13.3: Age-specific rates of obesity, overweight, normal weight and underweight among  
sampled male children (n = 1,541), 2015–16 
 
 
 
 
 Figure 13.4: Age-specific rates of obesity, overweight, normal weight and underweight among  
sampled female children (n = 1,536), 2015–16 
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13.2 Smoking (patients aged 18 years and over) 
Tobacco smoking is the leading cause of ill health, drug-related death and hospital separations in 
Australia.86 It is a major risk factor for coronary heart disease, stroke, peripheral vascular disease, 
several cancers, respiratory disorders and other diseases.87 The most recent publicly available 
Australian data identified smoking as the risk factor associated with the greatest disease burden, 
accounting for 7.8% of the total burden of disease in Australia in 2003,71 a decrease from 9.7% of the 
total burden in 1996.72  
The Global Burden of Disease 2010 study has compared burden of disease and injury attributable to 
67 risk factors in 21 regions. In Australasia (which includes Australia), ‘tobacco smoking, including 
second-hand smoke’ was ranked as the second most important risk factor for disease burden. These 
Australasian rankings are on par with the global risk factor rankings, with ‘tobacco smoking, including 
second-hand smoke’ also second globally.73  
In 2016, the OECD reported that Australia has been successful in reducing tobacco consumption by 
more than half, from 30.6% of adults in 1986 to 13.0% in 2013.75 Their 2015 Health Policy in Australia 
overview suggested that through a range of public health and policy initiatives, “Australia has achieved 
one of the lowest smoking rates in the world.” They attribute this remarkable reduction to policies and 
programs including the world’s first plain packaging legislation, smoking bans in public places and 
continually increasing prices through taxation.76 
According to the 2010 National Drug Strategy Household Survey (NDSHS), 15.1% of Australians aged 
14 years and over smoked daily: 16.4% of males and 13.9% of females.88 The 2014–15 National 
Health Survey reported that 14.5% of Australians aged 18 years and over were daily smokers: 16.9% 
of males and 12.1% of females.77 
Method 
GPs were instructed to ask adult patients (18 years and over): 
• What best describes your smoking status?   Smoke daily 
       Smoke occasionally 
       Previous smoker 
       Never smoked 
Results 
The smoking status of 32,664 adult patients was established at encounters with 965 GPs. Table 13.2 
shows that: 
• 13.3% of sampled adult patients were daily smokers 
• significantly more male (16.1%) than female patients (11.5%) were daily smokers (Table 13.2) 
• only 2.1% of sampled adult patients were occasional smokers 
• more than one-quarter of sampled adults (27.7%) were previous smokers. 
Estimation of smoking in the adult general practice patient population 
The BEACH study provides data about patient smoking habits from a sample of the patients attending 
general practice. As older people attend a GP more often than young adults, and females attend more 
often than males, they have a greater chance of being selected in the subsample. This leads to a 
greater proportion of older and female patients in the BEACH sample than in the total population who 
attend a GP at least once in a year. The 2015–16 BEACH sample was weighted to estimate the 
smoking status of the GP–patient attending population (that is, the 16.2 million adult patients who 
109
  
attended a GP at least once in 2015–16 [personal communication, DoH, May 2016]), using the 
method described by Knox et al. (2008).21  
After adjusting for age–sex general practice attendance patterns, we estimated that 15.8% of the 
patient population aged 18 or more were daily smokers, 2.8% were occasional smokers, 25.0% were 
previous smokers and 56.4% had never smoked. Male patients in the total general practice population 
were significantly more likely to be daily (19.3%), occasional (3.5%) and previous smokers (29.5%), 
than female patients (12.8%, 2.1% and 21.2%, respectively) (Table 13.2). 
Table 13.2: Patient smoking status (aged 18 years and over) 
 Male(a)  Female(a)  Total respondents 
Smoking 
status 
Per cent in 
BEACH sample 
(95% CI) 
(n = 12,881) 
Per cent in 
patient 
population 
(95% CI)(b)  
Per cent in 
BEACH sample 
(95% CI) 
(n = 19,546) 
Per cent in 
patient 
population 
(95% CI)(b)  
Per cent in 
BEACH sample 
(95% CI) 
(n = 32,664) 
Per cent in 
patient 
population 
(95% CI)(b) 
Daily 16.1 
(15.2–17.0) 
19.3 
(18.2–20.3)  
11.5 
(10.9–12.2) 
12.8 
(12.1–13.5)  
13.3 
(12.7–14.0) 
15.8 
(15.1–16.6) 
Occasional 2.7 
(2.3–3.1) 
3.5 
(3.0–4.0)  
1.8 
(1.5–2.0) 
2.1 
(1.8–2.4)  
2.1 
(1.9–2.4) 
2.8 
(2.4–3.1) 
Previous 35.8 
(34.6–37.0) 
29.5 
(28.3–30.6)  
22.4 
(21.5–23.2) 
21.2 
(20.3–22.0)  
27.7 
(26.9–28.5) 
25.0 
(24.3–25.8) 
Never 45.4 
(44.2–46.6) 
47.8 
(46.4–49.1)  
64.3 
(63.3–65.4) 
63.9 
(62.8–65.0)  
56.8 
(55.8–57.7) 
56.4 
(55.4–57.4) 
(a) Patient sex was not recorded for 237 respondents, missing data removed. 
(b) Estimation of smoking status among the total adult general practice patient population (that is, patients aged 18 years and over who 
attended a GP at least once in 2015–16). 
Note: CI – confidence interval. 
 
Daily smoking was least prevalent among older adults aged 65–74 and 75 years or more (7.7% and 
3.8% respectively), and most prevalent among adult patients aged 25–44 years (18.5%) (results not 
tabled). Over half (54.8%) of the male and 24.0% of the female patients aged 75 years and over were 
previous smokers, but only 4.1% of males and 3.5% of females in this age group were daily smokers 
(Figures 13.5 and 13.6). 
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 Figure 13.5: Smoking status – male age-specific rates among sampled patients (n = 12,881), 2015–16  
 
 
 
Figure 13.6: Smoking status – female age-specific rates among sampled patients (n = 19,546), 
2015–16 
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13.3 Alcohol consumption (patients aged 18 years 
and over) 
Among people aged 65 years and over, low to moderate consumption of alcohol has been found to 
have a preventive effect against selected causes of morbidity.89 Following a review of the evidence, 
the NHMRC stated that at low levels of consumption, alcohol has some cardiovascular health benefits 
in certain age groups (middle-aged and older males, and women after menopause). Low levels of 
alcohol consumption raise high-density lipoprotein cholesterol and reduce plaque accumulations in 
arteries. Alcohol can also have a mild anti-coagulating effect. However, the authors of the review 
noted that the extent of cardiovascular risk reduction is uncertain, and the potential cardiovascular 
benefits can be gained from other means, such as exercise or diet modification.90 From the most 
recent publicly available Australian data, in 2003, alcohol consumption accounted for 3.3% of the total 
burden of disease in Australia; however, after taking into account the benefit derived from low to 
moderate alcohol consumption, this fell to 2.3%.71 
The Global Burden of Disease 2010 study compared burden of disease and injury attributable to 
67 risk factors in 21 regions. In Australasia (which includes Australia) ‘alcohol use’ was ranked as the 
ninth risk factor for disease burden, a lower ranking than in the global risk factor rankings, where 
‘alcohol use’ ranked fifth.73 
The 2014–15 National Health Survey uses the lifetime risk of harm from alcohol-related disease or 
injury described by the National Health and Medical Research Council 2009 guidelines. They 
effectively define ‘at-risk’ drinking as ‘drinking more than two standard drinks on any day’.77 They 
report 17.4% of Australian adults consumed at ‘risky levels’, down from 19.5% in 2011–12.77 
The Australian Health Survey classified alcohol use for those aged 18 years or more based on the 
estimated average daily consumption of alcohol during the previous week. The results indicated that 
11.7% drank at levels considered to be risky (13.4% of males and 10.1% of females), based on the 
2001 NHMRC guidelines.19 Based on the NHMRC 2009 guidelines, 19.5% of adults drank at levels 
exceeding the guidelines (29.1% of males and 10.1% of females).19 
The 2010 National Drug Strategy Household Survey (NDSHS) found that 20.1% of people aged 
14 years and over (29.0% of males and 11.3% of females) drank at levels considered to put them at 
risk of harm from alcohol-related disease or injury over their lifetime. The study also found that 28.4% 
of people aged 14 years or more (38.2% of males and 18.9% of females) drank (at least once in the 
previous month) in a pattern that placed them at risk of an alcohol-related injury from a single drinking 
occasion.88 These alcohol consumption risk levels were based on the NHMRC 2009 guidelines.90 
For consistency over time, this report uses the definitions of alcohol-related risk developed by WHO 
(see ‘Method’ below).91 This differs from the definition in the NHMRC guidelines. 
Method 
To measure alcohol consumption, BEACH uses AUDIT-C,92 which is the first three items from the 
WHO Alcohol Use Disorders Identification Test (AUDIT),91 with scoring for an Australian setting.93 The 
AUDIT-C tool has demonstrated validity and internal consistency and performs as well as the full 
AUDIT tool.94 The three AUDIT-C questions are practical and valid in a primary care setting to assess 
‘at-risk’ alcohol consumption (heavy drinking and/or active alcohol dependence).92 The scores for each 
question range from zero to four. A total (sum of all three questions) score of five or more for males, or 
four or more for females, suggests that the person’s drinking level is placing him or her at risk.93 
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GPs were instructed to ask adult patients (18 years and over): 
• How often do you have a drink containing alcohol?  Never 
        Monthly or less 
        Once a week/fortnight 
        2–3 times a week 
        4 times a week or more 
• How many standard drinks do you have on a typical day when you are drinking?   
 
        _______________ 
• How often do you have six or more standard drinks on one occasion?  
        Never 
        Less than monthly 
        Monthly 
        Weekly 
        Daily or almost daily 
A standard drinks chart was provided to each GP to help the patient identify the number of standard 
drinks consumed. 
Results 
Patient self-reported alcohol consumption was recorded for 31,720 adult patients (18 years and over) 
at encounters with 965 GPs. 
• Just under one-quarter of sampled adults reported drinking alcohol at at-risk levels (22.7%) 
(Table 13.3). 
• At-risk drinking was more prevalent among male (26.5%) than female patients (20.3%) 
(Table 13.3). 
• At-risk drinking was most prevalent in those aged 18–24 years, particularly among males. In this 
age group, over a third of males (39.5%) and over a quarter of females (30.9%) reported at-risk 
alcohol consumption (Figure 13.7). 
• The proportion of patients who were at-risk drinkers decreased with age among both males and 
females (Figure 13.7). 
Estimation of alcohol consumption levels in the adult general practice patient 
population 
The BEACH study provides data about patient alcohol consumption from a sample of the patients 
attending general practice. As older people attend a GP more often than young adults, and females 
attend more often than males, they have a greater chance of being selected in the subsample. This 
leads to a greater proportion of older and female patients in the BEACH sample than in the total 
population who attend a GP at least once in a year. The 2015–16 BEACH sample was weighted to 
estimate the prevalence of at-risk alcohol consumption among the GP–patient attending population 
(that is, the 16.2 million adult patients who attended a GP at least once in 2015–16 (personal 
communication, DoH, May 2016), using the method described by Knox et al. (2008).21  
After adjusting for age–sex general practice attendance patterns, we estimated that 25.3% of the 
patient population were at-risk drinkers, 44.0% were responsible drinkers and 30.7% were 
non-drinkers. Males in the general practice attending population were significantly more likely to be 
at-risk drinkers (29.6%) than females (21.7%) (Table 13.3). 
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Table 13.3: Patient alcohol consumption (aged 18 years and over) 
 Male  Female  Total respondents 
Alcohol 
consumption 
Per cent in 
BEACH sample 
(95% CI) 
(n = 12,588) 
Per cent in 
patient 
population 
(95% CI)(a)  
Per cent in 
BEACH sample 
(95% CI) 
(n = 19,132) 
Per cent in 
patient 
population 
(95% CI)(a)  
Per cent in 
BEACH sample 
(95% CI) 
(n = 31,720) 
Per cent in 
patient 
population 
(95% CI)(a) 
At-risk drinker 26.5 
(25.3–27.7) 
29.6 
(28.2–30.9)  
20.3 
(19.3–21.2) 
21.7 
(20.7–22.6)  
22.7 
(21.9–23.6) 
25.3 
(24.4–26.3) 
Responsible 
drinker 
48.4 
(47.2–49.7) 
46.6 
(45.3–47.9)  
41.0 
(39.9–42.1) 
41.8 
(40.6–42.9)  
43.9 
(43.0–44.9) 
44.0 
(43.0–45.0) 
Non-drinker 25.1 
(23.9–26.3) 
23.8 
(22.5–25.1)  
38.7 
(37.4–40.1) 
36.6 
(35.2–38.0)  
33.3 
(32.2–34.5) 
30.7 
(29.5–31.8) 
(a) Estimation of alcohol consumption among the total adult general practice patient population (that is, patients aged 18 years and over who 
attended a GP at least once in 2015–16). 
Note: CI – confidence interval. 
 
These estimates are not directly comparable with the results from the 2014–15 National Health 
Survey77, 2011–12 Australian Health Survey19 or the 2010 NDSHS.88 They all use different definitions 
for risky levels of alcohol consumption, and different adult populations (patients aged 18 years or more 
for BEACH study and National Health Survey, persons aged 15 or 18 years or more for the Australian 
Health Survey, and persons aged 14 years or more for the NDSHS). 
Readers interested in the relationship between morbidities managed and alcohol consumption will find 
more information in Proude et al. (2006) The relationship between self-reported alcohol intake and the 
morbidities managed by GPs in Australia.95 
 
 
 
 Figure 13.7: Age–sex-specific rates of at-risk alcohol consumption in sampled patients, 2015–16  
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13.4 Risk factor profile of adult patients 
All patient risk factor questions (BMI, smoking and alcohol consumption) were asked of the same 
subsample of patients. This allows us to build a risk profile of this sample. For the purposes of this 
analysis, being overweight or obese, a daily smoker or an at-risk drinker was considered a risk factor. 
A risk factor profile was prepared for the 30,672 adult patients from 964 GPs, for whom data were 
available in all three elements (Table 13.4). 
• About half (53.7%) the sampled adult respondents had one risk factor. The most common was 
overweight (23.7% of adults) followed by obesity (20.3%). 
• Almost 1 in 5 patients (18.5%) had two risk factors. The most common combinations were: 
– overweight and at-risk alcohol consumption – 6.6% of patients 
– obesity and at-risk alcohol consumption – 4.7% of patients 
– overweight and daily smoking – 2.5% of patients 
– obesity and daily smoking – 2.5% of patients. 
• A small group of patients (2.9%) had all three risk factors. 
Table 13.5 shows the number of risk factors by patient sex. 
• Sampled females were significantly more likely to have no risk factors (28.7%) than sampled 
males (19.0%). 
• Sampled females were significantly less likely to have two or three risk factors (15.0% and 2.1% 
respectively) than sampled males 23.9% and 4.1%). 
Estimation of the risk profile of the adult general practice patient population 
The 2015–16 BEACH sample was weighted to estimate the risk profile of the GP–patient attending 
population, that is, the 16.2 million adult patients who attended a GP at least once in 2015–16. 
After adjusting for age–sex general practice attendance patterns we estimated that:  
• one-quarter of all attending adult patients had no risk factors (24.3%) 
• half of the adult patients had one risk factor (51.7%), with the most common being overweight 
(22.0% of adults) followed by obesity (18.7%) 
• 1 in 5 patients had two risk factors (20.4%), with the most common combinations being 
overweight and at-risk alcohol consumption (7.0%), followed by obesity and at-risk alcohol 
consumption (4.8%)  
• 3.6% of patients who attended general practice had three risk factors (Table 13.4) 
• significantly more female than male patients had no risk factors (29.3% and 18.6% respectively). 
Male patients were also more likely to have two and three risk factors (25.9% and 4.9%) than 
females (15.6% and 2.4%) (Table 13.5). 
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Table 13.4: Risk factor profile of patients (aged 18 years and over) 
Number of risk factors  Number 
Per cent in 
BEACH sample  
(n = 30,672) 
95% 
LCL 
95% 
UCL 
Per cent in 
patient 
population(a) 
95% 
LCL 
95% 
UCL 
No risk factors 7,628 24.9 24.1 25.6 24.3 23.5 25.1 
One risk factor 16,481 53.7 53.0 54.5 51.7 50.9 52.5 
 Overweight only 7,261 23.7 23.1 24.3 22.0 21.4 22.6 
 Obese only 6,235 20.3 19.7 21.0 18.7 18.1 19.4 
 At-risk alcohol level only 2,020 6.6 6.1 7.0 7.4 6.9 7.9 
 Current daily smoker only 965 3.1 2.9 3.4 3.6 3.3 3.9 
Two risk factors 5,684 18.5 17.9 19.2 20.4 19.7 21.1 
 Overweight and at-risk alcohol level 2,026 6.6 6.2 7.0 7.0 6.6 7.4 
 Obese and at-risk alcohol level 1,433 4.7 4.4 5.0 4.8 4.5 5.2 
 Overweight and current daily smoker 771 2.5 2.3 2.7 2.9 2.7 3.2 
 Obese and current daily smoker 774 2.5 2.3 2.7 2.8 2.6 3.1 
 Daily smoker and at-risk alcohol level 680 2.2 2.0 2.4 2.8 2.5 3.0 
Three risk factors 879 2.9 2.6 3.1 3.6 3.3 3.9 
Overweight and current daily smoker 
and at-risk alcohol level 
513 1.7 1.5 1.8 2.1 1.9 2.3 
Obese and current daily smoker and 
at-risk alcohol level 
366 1.2 1.1 1.3 1.5 1.3 1.6 
(a) Estimation of risk factor profile among the total adult general practice patient population (that is, patients aged 18 years and over who 
attended a GP at least once in 2015–16). 
Note: LCL – lower confidence limit; UCL – upper confidence limit. 
 
Table 13.5: Number of risk factors by patient sex 
 Male  Female 
Number of risk factors 
Per cent in BEACH 
sample (95% CI) 
(n = 12,194) 
Per cent in patient 
population 
(95% CI)(a)  
Per cent in BEACH 
sample (95% CI) 
(n = 18,478) 
Per cent in patient 
population 
(95% CI)(a) 
No risk factors 19.0 
(18.1–20.0) 
18.6 
(17.6–19.6)  
28.7 
(27.8–29.6) 
29.3 
(28.3–30.3) 
One risk factor 53.0 
(51.9–54.1) 
50.6 
(49.4–51.7)  
54.2 
(53.4–55.1) 
52.7 
(51.8–53.5) 
Two risk factors 23.9 
(23.0–24.9) 
25.9 
(24.8–27.0)  
15.0 
(14.3–15.6) 
15.6 
(14.9–16.3) 
Three risk factors 4.1 
(3.7–4.5) 
4.9 
(4.5–5.4)  
2.1 
(1.8–2.3) 
2.4 
(2.1–2.6) 
(a) Estimation of risk factor profile among the total adult general practice patient population (that is, patients aged 18 years and over who 
attended a GP at least once in 2015–16).  
Note: CI – confidence interval. 
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13.5 Changes in patient risk factors over the decade 
2006–07 to 2015–16 
To investigate changes over time in prevalence of patient risk factors (overweight and obesity, 
smoking and at-risk alcohol consumption), results are reported from the BEACH sample data for 
each year from 2006–07 to 2015–16 in Chapter 13 of the companion report, A decade of Australian 
general practice activity 2006–07 to 2015–16.1 
The major changes between 2006–07 and 2015–16 are summarised below. 
• The prevalence of obesity in sampled adults attending general practice increased significantly, 
from 23.5% to 28.8%, an increase apparent in both male and female patients. In parallel, the 
prevalence of normal weight in adults attending general practice decreased significantly, from 
39.0% to 34.6%. 
• The prevalence of overweight and obesity among sampled children aged 2–17 years effectively 
remained static for the 10-year period from 2006–07 to 2015–16 (around 18% and 10% 
respectively). Similar patterns were noted for both male and female children.  
• There was a significant decrease in the prevalence of current daily smoking and occasional 
smoking among sampled adults aged 18 years and over, from 16.1% and 3.2% respectively in 
2006–07, to 13.3% and 2.1% in 2015–16. These decreases were apparent among both male and 
female patients. 
• Prevalence of at-risk levels of alcohol consumption among sampled adults declined from about 
27% in 2006–07 to 23% in 2015–16. A corresponding increase in non-drinkers from about 28% in 
2006–07 to 33% in 2015–16 was apparent. The significant decrease in at-risk levels of alcohol 
consumption and increase in non-drinkers applied among both male and female patients. 
• There was a significant increase in the proportion of sampled adults with one risk factor from 
49.8% in 2006–07, to 53.7% in 2015–16, and the increase applied to both male and female 
patients. There was a significant decrease in the proportion of patients with two (20.4% to 18.5%) 
or three (3.7% to 2.9%) risk factors — corresponding with the increase in the proportion with one 
risk factor. This pattern was reflected among both male and female patients. 
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 14 Care of middle-aged people in general 
practice 
14.1 Introduction 
In last year’s BEACH annual report, we wrote a special feature on the care of older Australians (aged 
65 years or more [65+]) in general practice36 with main results summarised below. This year we 
examine ‘middle-aged’ patients (aged 45 to 64 years) as these patients would be prime targets for 
interventions to improve their future health. 
The 65+ study highlighted some of the challenges facing general practice as a result of the ageing of 
the population. We showed that since 2000–01, patients aged 65+ consistently used a greater share 
of GP service resources than the proportion they accounted for in the population. Further, over the 15 
years studied, this share had increased by more than their relative increase as a proportion of the 
population. 
Patients aged 65+ used more health resources than the average Australian (1.9 times as many GP 
encounters and 2.4 times as many medications). When they visited a GP in 2014–15, they were about 
50% more likely to be referred and about 45% more likely to have tests ordered than in 2000–01. 
Nearly all patients aged 65+ at a GP consultation had one or more diagnosed chronic condition(s). In 
the Australian population, 90% of this older group had at least one chronic condition, the majority 
(57%) had three or more (multimorbidity) and almost 10% had seven or more diagnosed chronic 
conditions. For example, both hypertension and osteoarthritis had already been diagnosed in more 
than 50% of older patients sitting in front of a GP.  
Our results demonstrated the level of complexity in the management of these patients. When GPs 
manage a single chronic condition in an older patient, they usually have to consider the implications of 
the presence of multiple other diagnosed chronic morbidities and the average 5.6 medications being 
taken for these conditions. 
Considered collectively, our findings suggested that though we have some challenges ahead of us, 
these are mostly a by-product of the success of our health system. For example, the ageing 
population is partly a product of our increased longevity. We are better able to keep people alive, with 
increased years without disability than in the past. This allows people to extend their years as 
productive members of the workforce or the community. Medical advances have changed many once 
life-threatening health events (for example, acute coronary syndrome) into ones for which intervention 
(for example, stents) can solve (but not cure) the problem, though the patient may require ongoing (for 
example, cardiovascular) management for the rest of their lives. 
The overall effect is that there are more people being diagnosed with more conditions, where each 
condition will be managed for a longer period of time. The resulting exponential increase in chronic 
condition management generates a similar growth in the number of GP visits and the number of 
management actions, such as prescriptions and test orders. The increased use of GP services has no 
doubt contributed to our increased life expectancy, and is provided at a per-person cost in line with, or 
less than, that of other countries. 
The current feature examines the care of ‘middle-aged’ Australians in general practice—those aged 
45–64 years. It is likely that this group of patients would be prime targets of interventions as they 
should be less likely to have the complex morbidity we found in older Australians. By examining this 
group of patients, we may identify areas of potential improvement that could enhance patients’ long 
term health. 
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14.2 Results 
The share of general practice use by patients aged 45–64 years 
Figure 14.1 provides an overview of change in the population and use of GP services. 
• People aged 45–64 years increased from 22.8% of the population in June 2000 to 25.1% in June 
2011. By June 2015, the proportion of people aged 45–64 years had decreased to 24.6%. The 
initial increase was likely due to the wave of younger ‘baby boomers’ entering this age group. The 
decrease from 2011 was likely to be the reverse, when a wave of older ‘baby boomers’ moved 
into the 65+ range without being replaced in the same volume by younger generations. 
• GP encounters with patients aged 45–64 years increased from 25.9% of all BEACH encounters in 
2000–01 to a peak of 28.9% in 2008–09. By 2015–16, it had decreased to 26.9%. The proportion 
of GP encounters used by 45–64 year olds follows a pattern similar to the change in the age 
distribution of the Australian population. 
• GP face-to-face clinical consulting time spent managing patients aged 45–64 years increased 
from 27.4% of all clinical time in 2000–01 to 30.3% in 2008–09 and then decreased to 28.1% in 
2015–16. 
• Problems managed at GP encounters with patients aged 45–64 years increased from 28.1% in 
2000–01 to 30.6% in 2008–09 and then decreased to 28.6% in 2015–16. 
• All medications that were GP-prescribed, supplied or advised for over-the-counter (OTC) 
purchase for patients aged 45–64 increased from 27.6% in 2000–01 to 29.8% in 2008–09, then 
decreased to 28.5% in 2015–16. 
• Pathology and imaging tests ordered for patients aged 45–64 increased from 33.5% of all tests in 
2000–01 to 35.8% in 2008–09, then decreased to 32.2% in 2015–16. 
• Referrals made by GPs that were for patients aged 45–64 years increased from 29.4% of all 
referrals in 2000–01 to 32.3% in 2007–08, then decreased to 29.6% in 2015–16. 
In summary, as the proportion of GP encounters used by patients aged 45–64 years followed change 
in the age distribution of the Australian population, so too did the proportion of problems managed by 
GPs for this age group, and therefore the proportions of medications, tests and referrals accounted for 
by these middle-aged patients. 
The previous feature36 found that in 2000–01, patients aged 45–64 years accounted for more GP 
encounters, GP clinical time, problems managed and referrals than patients aged 65+. By 2014–15, 
patients aged 65+ accounted for more of all these services than patients aged 45–64 years. The 
exceptions were: medications, for which patients aged 65+ accounted for more across all the years 
studied; and tests, for which patients aged 45–64 years accounted for more across all years studied. 
Figure 14.1 facilitates relative comparisons between the proportion of management actions accounted 
for by patients aged 45–64 years and the proportion they account for in the population. For example, 
in 2015–16, patients aged 45–64 years accounted for 32.2% of all tests ordered by GPs while 
accounting for just 24.6% of the population. By dividing the 32.2% by 24.6%, we find that people aged 
45–64 on average used 31% more tests than the average Australian. Using the same approach, in 
2015–16, compared with the average Australian, people aged 45–64 years had: 
• 9% more GP encounters 
• 14% more clinical face-to-face time with GPs 
• 16% more problems managed 
• 16% more medications prescribed/advised or supplied 
• 31% more tests ordered 
• 20% more referrals made. 
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While patients aged 45–64 years used more health resources than the average Australian, patients 
aged 65 years or older used more again. In 2015–16, compared with an average person aged 45–64 
years, people aged 65+ had an average: 
• 88% more GP encounters 
• 102% more problems managed 
• 108% more medications prescribed/advised or supplied 
• 56% more tests ordered 
• 76% more referrals made (results not shown). 
Figure 14.2 gives an idea of the content of GP encounters with patients aged 45–64 years, from 
2000–01 to 2015–16. On average, for every 100 encounters with these patients: 
• the number of problems managed increased by 5% 
• the number of tests ordered increased by 46% 
• the number of referrals (to specialists, allied health professionals, emergency departments or 
hospitals) increased by 53% 
• the number of medications prescribed, supplied to the patient or advised for over-the-counter 
purchase decreased by 5%. This decrease may be due to the increasing number of combination 
medication products available (which now require a single prescription, when previously GPs had 
to prescribe the two products separately) and to the increasing numbers of medications that were 
previously prescription-only, but are now available for over-the-counter purchase, without the 
need to see a GP. 
Figure 14.3 examines the age-specific rate of problems managed and management actions used per 
100 encounters in 2015–16.  
• The number of problems managed per 100 encounters increased significantly with age, with 
patients aged 65+ having 9% more problems managed than patients aged 45–64 years.  
• Medications per 100 encounters also increased significantly with age; patients aged 65+ had 12% 
more medications prescribed/advised/supplied than patients aged 45–64 years.  
• Patients aged 45–64 years had a significantly higher rate of tests ordered per 100 encounters 
than both younger (34% higher) and older patients (19% higher).  
• Patients aged 45–64 had a significantly higher rate of referrals per 100 encounters than younger 
patients (18%), however there was no significant difference found between patients aged 45–64 
years and older patients. 
Figure 14.4 shows that patients aged 45–64 years had significantly longer average measured 
consultations than patients at all GP encounters across all the years studied. It also shows that the 
average length of consultations with patients aged 45–64 years significantly increased from 14.7 
minutes in 2000–01 to 15.5 minutes in 2015–16. 
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Figure 14.3 Age-specific rate of problems managed, medications, tests and referrals per 100 
encounters, 2015–16 (95% confidence intervals) 
 
Problems managed Medications Tests Referrals
Less than 45 years 132.9 85.6 51.7 14.8
45–64 years 162.5 107.3 69.5 17.5
65 years or more 176.6 120.4 58.4 16.7
0
20
40
60
80
100
120
140
160
180
200
Rate per 100 age-specific encounters 
123
  
  
 
F
ig
u
re
 1
4
.4
: 
A
v
e
ra
g
e
 l
e
n
g
th
 o
f 
G
P
 c
o
n
s
u
lt
a
ti
o
n
s
 w
it
h
 p
a
ti
e
n
ts
 a
g
e
d
 4
5
–
6
4
 y
e
a
rs
 c
o
m
p
a
re
d
 w
it
h
 a
ll
 p
a
ti
e
n
ts
 (
2
0
0
0
–
0
1
 t
o
 2
0
1
5
–
1
6
) 
20
00
–0
1
20
01
–0
2
20
02
–0
3
20
03
–0
4
20
04
–0
5
20
05
–0
6
20
06
–0
7
20
07
–0
8
20
08
–0
9
20
09
–1
0
20
10
–1
1
20
11
–1
2
20
12
–1
3
20
13
–1
4
20
14
–1
5
20
15
–1
6
45
–6
4 
ye
ar
s
14
.7
14
.8
14
.3
14
.6
14
.8
14
.7
14
.8
14
.5
14
.4
14
.8
14
.4
14
.7
14
.9
15
.5
15
.4
15
.5
A
ll 
pa
tie
nt
s
13
.9
14
.0
13
.7
14
.0
14
.0
13
.8
14
.0
13
.8
13
.8
14
.0
13
.7
14
.0
14
.3
14
.7
14
.6
14
.9
024681012141618
B
E
A
C
H
 d
a
ta
 y
e
a
rs
 
A
v
e
ra
g
e
 l
e
n
g
th
 o
f 
c
o
n
s
u
lt
a
ti
o
n
s
 i
n
 m
in
u
te
s
 
124
  
Number of chronic conditions in people aged 45–64 years 
Between December 2012 and March 2016, we conducted a series of SAND substudies (see 
Section 2.6 for SAND methods) that examined the prevalence of diagnosed chronic conditions and 
multimorbidity among patients at general practice encounters. In total, information was collected from 
43,531 patients, making it one of the largest nationally representative multimorbidity studies in the 
world. There were 11,747 patients in the sample aged 45–64 years. The study is described in more 
detail in SAND abstract 246 (Chapter 15). 
Figure 14.5 shows that among those aged 45–64 years: 
• the majority had one or more chronic conditions (80.3% of patients at GP encounters and 59.7% 
of people in the population). This means that only 19.7% of patients at encounters and 40.3% of 
people in the population aged 45–64 years had no diagnosed chronic conditions  
• over one-third (38.5%) of patients at encounters and one in five (21.2%) people in the population 
had three or more diagnosed chronic conditions  
• 9.0% of patients at encounters and 3.4% of people in the population had six or more diagnosed 
chronic conditions 
• 1.0% of patients at encounters and 0.3% of people in the population had 10 or more diagnosed 
chronic conditions. Although this appears to be a very small proportion it does suggest about 
19,000 middle-aged people have 10 or more diagnosed chronic conditions.  
Extrapolating the proportion in the population with at least one diagnosed chronic condition (59.7%) to 
the number of people aged 45–64 in the population as of June 2015 (5,858,207) gives an estimated 
3.5 million people aged 45–64 years with at least one chronic condition. Extrapolating last year’s 
estimate of 89.7% of people aged 65+ having at least one diagnosed chronic condition to the number 
of people aged 65+ in the population in 2015 (3,569,020), gives an estimate of about 3.2 million 
people aged 65+ who have at least one diagnosed chronic condition. This is 300,000 less than the 
number of people aged 45–64 years with at least one diagnosed chronic condition. 
Repeating the extrapolation for people with three or more diagnosed chronic conditions, we estimate 
there were about 1.2 million people aged 45–64 and 2.0 million people aged 65+ with three or more 
chronic conditions. 
  
 
Figure 14.5 Proportion of people aged 45–64 years with a minimum number of chronic conditions, 
2012–16 
1+ 2+ 3+ 4+ 5+ 6+ 7+ 8+ 9+ 10+
Patients at encounters 80.3 58.0 38.5 24.8 14.8 9.0 5.3 3.1 1.8 1.0
People in population 59.7 37.0 21.2 12.0 6.4 3.4 1.9 1.1 0.6 0.3
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Prevalence and management of chronic conditions 
Table 14.1 shows the prevalence and management rates of common chronic conditions among 
patients aged 45–64 years. The pattern differs markedly for individual chronic conditions. 
Example 1: diagnosed hypertension 
• was present in 26.4% of patients aged 45–64 years at GP–patient encounters 
• was managed at 9.7% of encounters with patients aged 45–64 years, and therefore was managed 
at 36.6% of encounters with patients with diagnosed hypertension. 
Patients aged 45–64 years with diagnosed hypertension visited a GP an average 7.9 times a year. 
Therefore, we can conclude that among patients with diagnosed hypertension, this condition was 
managed at 2.9 of their 7.9 visits a year on average. 
The prevalence of diagnosed hypertension among people aged 45–64 years in the population was 
17.5%. Of those people with hypertension, 70.5% had two or more other chronic conditions (that is, 
they had three or more diagnosed chronic conditions in total). 
Example 2: diagnosed type 2 diabetes 
• was present in 10.6% of patients aged 45–64 years at encounters 
• was managed at 5.1% of encounters with patients aged 45–64 years 
• was managed at 48.0% of GP encounters with a patient with diagnosed type 2 diabetes. 
Patients aged 45–64 years with diagnosed type 2 diabetes visited 8.6 times a year on average (a little 
more often than patients with hypertension). This means that for these patients, their type 2 diabetes 
was managed 4.1 times a year on average. 
The prevalence of type 2 diabetes among people aged 45–64 years in the population was 6.0%, and 
78.6% of these people had two or more other diagnosed chronic conditions. 
Example 3: diagnosed congestive heart failure (CHF) 
• was present in 0.9% of patients aged 45–64 years at encounters 
• was managed at only 0.2% of encounters with patients aged 45–64 years 
• was therefore managed at 21.8% of GP visits made by a patient with diagnosed CHF. 
Patients aged 45–64 years with CHF visited 12.4 times a year on average (over 50% more often than 
patients with hypertension). We conclude that in these patients, CHF was managed 2.7 times a year 
on average. 
The prevalence of CHF among people aged 45–64 years in the population was 0.4% and nearly all of 
these people (94.5%) had two or more other chronic conditions. 
Patterns of multimorbidity 
We examined specific patterns of multimorbidity, and found the most common ‘pair’ of chronic 
conditions diagnosed among patients aged 45–64 years was hypertension and hyperlipidaemia: 
• 10.3% (95% CI: 9.6–11.0) of patients surveyed at GP encounters have both  
• 6.4% (95% CI: 5.9–7.0) of people in the population have both.  
Of patients with both these conditions who were surveyed at encounter, 51.6% (95% CI: 49.3–53.9) 
had three or more other chronic conditions (i.e. five or more in total).  
Hypertension and osteoarthritis was the second most prevalent pair, and both conditions were 
diagnosed in:  
• 8.2% (95% CI: 7.6–8.8) of patients surveyed at encounter  
• 4.1% (95% CI: 3.6–4.5) of people in the population.  
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Hyperlipidaemia and osteoarthritis was the third most common pair: 
• 6.1% (95% CI: 5.5–6.6) of patients at encounters have both 
• 3.2% (95% CI: 2.8–3.6) of people in the population have both. 
It is therefore not surprising, that the most prevalent ‘trio’ of diagnosed chronic conditions was 
hypertension, hyperlipidaemia and osteoarthritis; all three conditions were diagnosed in: 
• 3.8% (95% CI: 3.4–4.3) of patients at encounters  
• 1.8% (95% CI: 1.5–2.0) of people in the population in this age group. 
Of those patients at encounters with these three conditions, 77.4% (95% CI: 74.9–79.9) had at least 
two or more other conditions (5 or more diagnosed chronic conditions in total). 
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Lifestyle risk factors in patients aged 45–64 years 
While age is an important contributing factor for many chronic conditions, lifestyle risk factors are also 
contributors. Patient weight, smoking status and level of alcohol consumption were all studied in 
SAND subsamples in each BEACH year. The SAND methods are described in Section 2.6, and 
Chapter 13 examines the prevalence of risk factors among all adult patients at GP encounters. 
Body Mass Index 
For samples from each year 2000–01 to 2015–16, the number of patients aged 45–64 years for whom 
BMI could be calculated ranged from 9,858 to 10,995. 
Using the WHO definitions of BMI79, Figure 14.6 shows that between 2000–01 and 2015–16, the 
proportion of sampled patients aged 45–64 years who were: 
• underweight stayed relatively constant at around 1.4% 
• classed as ‘normal’ weight decreased from 33.1% to 27.4% 
• considered ‘overweight’ decreased from 39.3% to 35.4% 
• classed as ‘obese’ increased by 37% from 26.1% to 35.8% 
– classed as ‘Class III obesity’ or ‘morbidly obese’ more than doubled from 2.7% to 5.7%. 
This increase in the proportion of patients considered to be obese is a concern as it is expected to 
increase the prevalence of related health problems (such as diabetes and cardiovascular disease) and 
escalate health care costs in future.97 
Smoking status & alcohol consumption 
As discussed in Chapter 13, tobacco smoking is the leading cause of ill health, drug-related death and 
hospital separations in Australia.98 
Figure 14.7 shows that between 2000–01 and 2015–16, there was no significant change in the 
proportion of patients aged 45–64 years who were daily smokers, staying steady at around 18% of 
patients. 
Figure 14.7 also shows there was no significant change in the proportion of patients aged 45–64 years 
at GP encounters who were ‘hazardous drinkers’ of alcohol (defined as ‘at risk’ drinkers in 
Chapter 13), around one-quarter of 45–64 year olds. 
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14.3 Discussion 
This study has highlighted areas in which the health of people aged 45–64 years differs significantly 
from that of people in other age groups. However, like their older counterparts(those aged 65+), 
middle-aged patients use more health resources than average, have high rates of morbidity and have 
shown no improvement in their lifestyle risk factor profile over the 16 years of this study.  
Patients aged 45–64 years, account for a significant proportion of GP resources. In 2000–01, they 
accounted for more GP encounters, GP clinical time, problems managed and referrals than older 
patients aged 65+. However, by 2014–15, patients aged 65+ accounted for more of all these services 
than those aged 45–64 years. Our results suggest that this change in proportional GP resource use by 
45–64 year olds reflected their changed proportion of the population. This trend is likely to continue as 
more baby boomers progress into the 65+ cohort.  
In November 2006, a new item number (item 717) was added to the MBS for a ‘well person’s health 
check’ (one check per person) for people aged 45–49 years attending general practice99 who have 
one or more identifiable risk factors for chronic disease. In theory, the health assessment at this age 
could help patients make lifestyle changes to prevent or delay the onset of chronic disease. Risk 
factors for consideration included lifestyle factors (smoking, physical activity, poor nutrition and alcohol 
consumption), biomedical factors (high cholesterol, high blood pressure, impaired glucose metabolism 
or excess weight), and family history of chronic disease.99 In 2008 an additional item number was 
added to the MBS, covering a check once every 3 years for patients aged 40–49 years, with diabetes 
health risk factors.100 
The rate of test ordering at encounters with 45–64 year olds was higher than average among all 
patients, and higher than that for those 65+, but was relatively consistent over the study period. Some 
of this may be due to screening of ‘well persons’ but considering the age of these patients and the 
number of already diagnosed chronic conditions, much of this testing may well be associated with 
monitoring, with the aim of secondary prevention. In fact, the growth in test ordering for the 45–64 year 
olds was less (46%) than it was for patients at all encounters (57%). Further, compared with the 8% 
growth of the population aged 45–64 years, the proportion of tests they accounted for actually 
decreased by 4%.  
Earlier diagnosis of chronic conditions and their subsequent ongoing management is likely to mean 
more encounters in general practice, because chronic conditions usually require lifelong management. 
However, the extra associated costs should improve patients’ overall health and potentially reduce the 
number of avoidable hospitalisations which generally incur far greater costs than the extra care 
provided in general practice. 
Almost 60% of the population in this age group have one or more diagnosed chronic problems. Given 
the focus of the 45–49 health check was to prevent or delay the onset of chronic disease, and the 
focus of the diabetes check was prevention and/or early diagnosis, it is highly possible that some of 
these chronic conditions were diagnosed as a result of these checks.  
Our results suggest there are about 300,000 more people aged 45–64 years (3.5 million) than aged 
65+ years (3.2 million) with at least one diagnosed chronic condition. While people aged 65+ are far 
more likely than middle-aged patients to have multiple diagnosed chronic conditions, we estimate that 
about 1.2 million 45–64 year olds have three or more. Counting those in each age group with three or 
more chronic conditions results in 4.2 million Australians aged 45 years or older with at least three 
diagnosed chronic health problems. Since these conditions will generally continue to be treated over 
the patient’s lifetime, and people with multiple diagnosed chronic conditions visit the GP more often 
than average, this has implications for future visit rates in general practice, and for the costs 
associated with the care of these patients as they age. 
One in five 45–64 year olds, already had three or more diagnosed chronic conditions, the most 
common combination being hypertension + hyperlipidaemia + osteoarthritis. The most common ‘pair’ 
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of diagnosed chronic conditions in this age group was hypertension + hyperlipidaemia: 1 in 10 
surveyed patients and 1 in 15 of the population have both. 
By 2015–16, over 70% of surveyed 45–64 year old patients were either overweight or obese, with the 
proportion who were morbidly obese more than doubling over the study period. Our results indicate 
that over the 16 year study period, there was a steady pattern of people moving ‘up the obesity scale’. 
This does not augur well for their future health as they move into the 65+ cohort. Further, if the sharp 
decrease observed in the proportion of normal weight patients since 2000–01 continues, in another 16 
years we will have very few normal weight 45–64 year old patients at general practice encounters in 
Australia. Obesity is a problem being faced by most OECD countries and, as yet, none have found a 
solution to this ever-growing ‘epidemic’.97 
While the proportions of patients who were daily smokers and hazardous drinkers decreased 
significantly among all adult patients at encounters (Chapter 13), there was no change in these risk 
behaviours for patients in the 45–64 year age group. Around 1 in 5 were daily smokers and 1 in 4 
drank alcohol at hazardous levels. Despite interventions to address lifestyle risk factors, this age group 
is increasingly more likely to be overweight or obese, and there has been no measurable change in 
smoking and hazardous alcohol consumption for patients at GP encounters. 
The Federal Government’s ‘Health Care Homes’ initiative currently proposes to target people with 
multiple chronic conditions,101 to improve the coordination of care of these people. However, our study 
suggests there will be middle-aged patients who do not have multiple chronic conditions, but who do 
have potentially modifiable lifestyle risk factors who would benefit from a ‘Health Care Home’ 
environment that enables greater access to allied health professionals. 
We have reported on the 45–64 age group of patients because this is the group where early diagnosis 
of chronic conditions and the institution of secondary prevention measures could have a large long-
term impact on both longevity and the number of quality-adjusted life years that will be enjoyed by 
future elder Australians. These early primary care interventions could significantly reduce the need for 
secondary and tertiary services (and associated costs) as the population continues to age. The study 
demonstrates that GPs are rising to the challenge of early diagnosis and management in middle-aged 
people. 
 
This chapter contains unpublished methods that form part of Christopher Harrison’s thesis for his 
candidature for Doctor of Philosophy in Medicine. 
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 15 SAND abstracts and research tools 
Since BEACH began in April 1998, a section on the bottom of each encounter form has been used to 
investigate aspects of patient health or healthcare delivery not covered by general practice 
consultation-based information. These additional substudies are referred to as SAND (Supplementary 
Analysis of Nominated Data). The SAND methods are described in Section 2.6. All substudies were 
approved by the Human Ethics Committee of the University of Sydney. 
The Family Medicine Research Centre (FMRC) and most of the organisations supporting the BEACH 
program select topics for investigation in the SAND studies. In each BEACH year, up to 20 substudies 
can be conducted in addition to the study of patient risk behaviours (see Chapter 13). Topics can be 
repeated to increase the sample size and its statistical power. 
This chapter includes the abstracts and research tools for SAND substudies, most of which were 
conducted from April 2015 to March 2016. The subjects covered in the abstracts in this chapter are 
listed in Table 15.1, with the sample size for each topic. 
Table 15.1: SAND abstracts for 2015–16 and sample size for each 
Abstract 
number Subject 
Number of 
respondents  
Number  
of GPs 
236 Prevalence, severity and management of heart failure 2,922 99 
237 Influenza risk factors and vaccination in general practice patients 2,885 99 
238 
Diabetes prevalence and management (including insulin use) in general practice 
patients 2,403 81 
239 Continuity of care and health service utilisation in general practice 4,927 168 
240 Management of asthma and COPD in general practice patients – 2015 2,547 86 
241 Proton pump inhibitor use among general practice patients 2,642 89 
242 Cardiovascular disease risk and use of lipid-lowering medication(a) 3,182 184 
243 Rhinitis management among Australian general practice patients 2,723 93 
244 Continual medication and adverse drug events in general practice patients 10,667 363 
245 Health care utilisation by general practice patients 2,688 91 
246 Prevalence of chronic conditions and multimorbidity 43,531 1,450 
247 COPD prevalence, severity and management in general practice patients – 2016 2,437 87 
248 Influenza risk factors and vaccination in general practice patients – 2016 2,826 95 
(a) Substudy limited to patients aged 45 years and over. 
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SAND abstract number 236: Prevalence, severity and management 
of heart failure 
Organisation collaborating for this study: Novartis Pharmaceuticals Australia Pty Ltd.  
Issues: Prevalence of heart failure (HF) in general practice. For those with HF: stage of HF; condition 
testing; current medication use, initiator of medication; complementary medications taken; 
hospitalisation for acute HF episode; discharge to community-based management program. 
Sample: 2,922 patients from 99 GPs; data collection period: 31/03/2015 – 04/05/2015. 
Method: Detailed in the paper entitled SAND Method 2015–16 on this website: 
<sydney.edu.au/medicine/fmrc/publications/sand-abstracts>. 
Methods for this substudy: The stages of HF were based on the New York Heart Association’s 
(NYHA) functional classification system of symptoms, see <https://heartfoundation.org.au/images/ 
uploads/publications/Chronic_Heart_Failure_Guidelines_2011.pdf>. 
Summary of results  
The sex distribution of the 2,922 respondents did not differ from patients at all 2014–15 BEACH 
encounters. 
Of 2,922 respondents, 103 (3.5%, 95% Cl: 2.6–4.5) reported they had diagnosed HF; prevalence did 
not differ among males (3.4%) and females (3.6%). Prevalence was higher in the 75+ age group 
(13.8%, 95% Cl: 10.3–7.3) than in the 65–74 age group (3.8%) and the 45–64 age group (1.6%). The 
prevalence of HF among patients who attended general practice at least once in the year was 
estimated to be 1.8% (95% Cl: 1.3–2.3), and among the Australian population 1.5% (95% Cl: 1.1–2.0).  
Of the 95 patients for whom stage of HF was recorded, 20 (21.1%) were asymptomatic, 36 (37.9%) 
had mild HF, and 12 (12.6%) had severe HF. Of the 96 respondents to the question on brain 
natriuretic peptide testing, 16 had been tested (5.2% at diagnosis and 11.5% since diagnosis), half 
(51%) had not been tested and 32.3% did not know.  
At least one medication for HF was being taken by the majority (98.0%) of 99 respondents: 69.7% 
were taking 1+ diuretic(s), 49.5% 1+ beta blocker(s), 24.2% 1+ angiotensin-converting enzyme (ACE) 
inhibitor(s), 20.2% 1+ angina medication(s) and 19.2% 1+ angiotensin II receptor antagonist(s) 
(ATRA). Two patients (2.0%) were not taking any medication for HF. Among the 99 respondents 222 
medications were recorded. Of these medications, 27.9% were high ceiling diuretics and 22.1% were 
beta blockers. Overwhelmingly, the most common individual medication used was diuretic furosemide 
(27.9%), followed by the potassium-sparing agent spironolactone (5.9%). 
Of the 222 medications recorded, 72.6% were initiated by specialists and 27.4% by GPs. However, 
ATRA + diuretic had been initiated by GPs for 3 of the 4 patients on this medication. 
Of 92 respondents, 25 (27.2%) were taking at least one complementary product; vitamin D was the 
most common (19.0%) of the 42 products recorded.  
Of 94 respondents, 24 (25.5%) had been hospitalised for an acute HF episode in the previous 12 
months. Only 1 in 5 HF patients had been discharged under a community-based management 
program. 
The following page contains the recording form and instructions with which the data in this substudy were 
collected. 
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SAND abstract number 237: Influenza risk factors and vaccination 
in general practice patients 
Organisation collaborating for this study: Seqirus (Australia) Pty Ltd. 
Issues: Proportion of general practice patients with influenza (flu) infection risk factors. For those at 
risk: types of risk factors, awareness of eligibility for free flu vaccination. For all respondents: 
vaccination status for 2015 and for 2014; reasons for not vaccinating. Proportion diagnosed with 
influenza in prior 12 months. 
Sample: 2,885 patients from 99 GPs; data collection period: 31/03/2015 – 04/05/2015.  
Method: Detailed in the paper entitled SAND Method 2015–16 on this website: 
<sydney.edu.au/medicine/fmrc/publications/sand-abstracts>.  
Summary of results  
The age and sex distributions of patients did not differ from that of all BEACH encounters in 2014–15. 
Of the 2,885 respondents, 51.9% (95% CI: 47.6–56.3) (n = 1,498) had at least one risk factor for 
influenza (35.7% had one, 11.8% two, and 3.5% three risk factors). There was no significant 
difference between risk factor status of males (53.5%) and females (50.9%).  
The most common risk factors were older age (34.4% were aged 65+ years), chronic respiratory 
condition (10.4%), diabetes (7.9%), chronic heart disease (7.7%), chronic neurological condition 
(3.2%) and Indigenous patients aged 15 years or more (1.4%). For patients aged 15–64 years 
(n = 1,610), 29.9% (95% CI: 25.8–34.1) had at least one risk factor, and for patients aged 65+ years 
(n = 992), 42.1% had at least one risk factor in addition to their age. Risk factor status increased 
significantly with patient age, risk(s) being present in 6.7% of patients aged 0–14 years, increasing to 
100.0% of patients aged 65+.  
Of 1,453 respondents with one or more risk factor(s), 91.2% were aware of the availability of free flu 
vaccinations through the National Immunisation Program. Awareness was significantly higher in older 
patients (97.5% of patients aged 65+ were aware) than among others (79.2% of patients aged <65). 
Of 2,712 respondents for whom vaccination status was recorded, 60.9% were either already 
vaccinated, or planned to be vaccinated, for the 2015 flu season. Of 2,706 respondents, 51.2% had 
been vaccinated for the 2014 flu season. Reported vaccination/ intention to vaccinate in 2015 is 
reported as a percentage of each risk subgroup, with the percentage reported vaccinated in 2014 in 
parentheses: 84.9% (74.9%) of those with at least one risk factor; 87.6% (84.0%) of those aged 65+ 
years; 76.0% (76.0%) of those who were pregnant; 90.0% (78.0%) of Indigenous patients aged 15+; 
90.9% (87.3%) of those with chronic heart disease; 89.8% (78.0%) of those with diabetes; 76.9% 
(68.8%) of those with a chronic metabolic disorder; 85.0% (73.7%) of patients with a chronic 
respiratory condition; 85.5% (83.9%) of patients with chronic renal failure; 69.1% (60.0%) of patients 
with impaired immunity; 81.7% (76.1%) of those with a chronic neurological condition; and 84.6% 
(70.8%) of those with a haematological disorder. 
Of the 1,162 patients who were not vaccinated for the 2014 flu season, 1,102 gave a total of 1,126 
reasons for non-vaccination. Of these, 57.4% reported they considered themselves at low risk and 
14.4% reported patient objections. For 9.5%, the GP did not consider the patient to be at risk.  
Of 2,709 respondents, 83 (3.1%, 95% CI: 1.9–4.3) had been diagnosed with influenza in the prior 
12 months. Flu vaccination status in 2014 was known for 2,529 of these respondents; 54.4% were 
vaccinated. Of those vaccinated, 36 (2.6%) had been diagnosed with influenza in the prior 12 months, 
and this did not significantly differ from the 47 (4.1%) of those not vaccinated.  
The following page contains the recording form and instructions with which the data in this substudy were 
collected. 
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SAND abstract number 238: Diabetes prevalence and management 
(including insulin use) in general practice patients 
Organisation collaborating for this study: AstraZeneca Pty Ltd (Australia). 
Issues: Prevalence of Type 1 and Type 2 diabetes in general practice patients. For all those with 
diabetes: HBA1c and estimated glomerular filtration rate (eGFR) levels; BMI; current medication use; 
initiator of mediation; patient home glucose monitoring; current insulin management.  
Sample: 2,403 patients from 81 GPs; data collection period: 05/05/2015 – 08/06/2015.  
Method: Detailed in the paper entitled SAND Method 2015–16 on this website: 
<sydney.edu.au/medicine/fmrc/publications/sand-abstracts>.  
Summary of results  
The age and sex distributions of the 2,403 respondents were similar to those of all patients at 2015–16 
BEACH encounters. Of 2,403 respondents, 9.1% (95% CI: 7.5–10.7) had diagnosed diabetes: 0.7% 
had Type 1 and 8.4% had Type 2. Prevalence was estimated among the Australian population to be 
6.0% (95% CI: 4.8–7.2): 0.6% Type 1 and 5.4% Type 2. Prevalence of Type 2 diabetes increased with 
age: 1.7% in the 25–44 age group, 10.5% in the 45–64 age group, 20.7% in the 65–74 age group and 
16.7% in the 75+ age group. Type 1 diabetes was most prevalent in the 75+ age group (1.4%). 
Of 197 patients with HbA1c level reported, 30.5% had a high HbA1c when using a > 58 mmol/mol cut-
off and 41.1% had high levels when using a > 53 mmol/mol cut-off. Of 200 patients with eGFR level 
reported, 74.5% had abnormal eGFR with cut-off of < 90 mL/min/1.732 and 27.0% abnormal with cut-
off of < 60 mL/min/1.732. Body mass index (BMI) was calculated for 196 diabetic adult patients. Half 
were obese (51.0%), 33.7% overweight and 15.3% normal weight. 
Of 211 respondents, 84.8% were currently taking medication for diabetes. Metformin was most 
common (59.2%), followed by gliclazide (25.6%). At group level the most common medications used 
were metformin (59.2%), sulphonamides (27.0%) and basal insulin (13.3%). The number of therapy 
groups used showed 9.5% (n = 211) were taking triple therapy, 37.9% dual, 37.4% mono, and 15.2% 
no therapy. 
For more than two-thirds of patients with diabetes (70.1%) (n = 184), the GP alone made decisions 
about hypoglycaemic initiation/titration, for 23.4% the GP was in consultation with a specialist and for 
6.5% the specialist alone made the decisions. For diabetic patients taking insulin (n = 50), GP + 
specialist was more common (48.0%, 95% CI: 31.6–64.4) than for all patients with diabetes. Of the 
206 respondents to home glucose monitoring frequency, 38.3% monitored daily (median 2.5 
tests/day), 38.8% less than daily (median 2.5 tests/week) and 22.8% did not home monitor. 
For the 50 patients taking insulin, the GP regarded postprandial glucose levels as important for 94.0%. 
Of the 50 patients, 56.0% were taking basal, 42.0% rapid acting insulin, 34.0% premix insulin, 30.0% 
basal and rapid acting insulin, 30.0% premix insulin and 24% basal insulin alone. The mean duration 
of insulin use was 6.0 years and median 5.0 years. 
For 60 insulin medications with a recorded dosage, the mean daily dose for insulin aspart (n = 25) was 
48.2 mg, and for insulin glargine (n = 25) 49.6 mg. For 46 patients on insulin whose HBA1c level was 
recorded, the mean level was 62.5 mmol/mol. eGFR was known for 46: 73.9% had abnormal eGFR 
with cut-off of < 90 mL/min/1.732 and 39.1% abnormal for cut-off of < 60 mL/min/1.732. For the 47 
patients on insulin with a recorded BMI, 57.4% were obese, 25.5% were overweight and 17.0% were 
of normal weight. 
The following page contains the recording form and instructions with which the data in this substudy were 
collected. 
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SAND abstract number 239: Continuity of care and health service 
utilisation in general practice 
Organisation collaborating for this study: Family Medicine Research Centre.  
Issues: Whether patients had a regular practice they usually visited. Health service utilisation in 
previous 12 months including: number of GP visits, regular GP and practice; allied health 
professionals, medical/surgical specialists, emergency departments visited and hospital admissions; 
prevalence of chronic conditions.  
Sample: 4,972 patients from 168 GPs; data collection period: 05/05/2015 – 13/07/2015. 
Method: Detailed in the paper entitled SAND Method 2015–16 on this website: 
<sydney.edu.au/medicine/fmrc/publications/sand-abstracts>.  
Methods for this substudy: Each patient’s data were weighted by the number of times they saw a 
GP in the previous year to account for varying attendance rates. This provided a prevalence estimate 
for the ‘active patient population’, i.e. patients who visited a GP at least once in the previous year. 
Summary of results  
The age and sex distributions of the 4,972 respondents did not differ from patients at all 2015–16 
BEACH encounters. Males were significantly more likely to record just 1–3 GP visits (28.3%, 95% CI: 
25.3–31.3) than females (22.3%, 95% CI: 19.7–24.9). Visit rate increased with age, with 9.6% of 
patients aged 0–14 frequent or very frequent attendees, compared with 51.5% of those aged 75+.  
Of the 4,972 patients, 95.1% (95% CI: 93.6–96.7) had a regular general practice they usually visited. 
After adjustment for attendance rates, we estimate 91.3% (95% CI: 88.9–93.7) of people who 
attended a GP at least once in the year (active patients) have a regular practice.  
The average number of GP visits in the previous 12 months was 8.9 for 4,927 respondents, and for 
active patients it was 4.3. The average number of different GPs seen by respondents was 2.5, and for 
active patients 2.0. The majority of respondents (75.6%) visited only one practice in the previous 12 
months, and 19.3% visited two. Of active patients, 78.7% visited one practice and 17.0% two. 
The average number of allied health professionals visited in the previous 12 months was 0.8: 62.4% of 
respondents visited none, 21.1% one and 16.5% two or more. In the total active patient population, we 
estimate the mean number visited to be 0.4: 74.8% visited none, and 16.3% one. The average number 
of medical specialists seen was 0.8: 54.7% none, 24.6% one, and 20.7% two or more. For the active 
patient population, the adjusted average was 0.5: 20.1% one, and 10.8% two or more.  
Of 4,927 respondents, 19.3% had at least one emergency department visit. We estimate that 13.5% of 
the active patient population had at least one visit to an emergency department in the previous 12 
months. At least one hospital admission in the previous 12 months was reported for 18.2% of the 
sample, two-thirds of whom (12.8% of the respondents) were admitted only once. Of active patients, 
we estimate 12.0% had been admitted to hospital at least once, with the majority (9.2%) admitted only 
once in the previous 12 months. 
Of the respondents, 32.1% had no diagnosed chronic conditions, 67.9% at least one: 22.0% one, 
15.6% two, 10.1% three and the remaining 20.2% four or more. For the total active patient population 
we estimate: 48.5% had no diagnosed chronic conditions, 22.4% had one, 12.7% two, 7.2% three and 
9.2% four or more. Hypertension was the most prevalent chronic condition (23.0% of respondents and 
15.3% of the active patient population) followed by osteoarthritis (15.2% and 8.7%), hyperlipidaemia, 
depression and anxiety. 
The following page contains the recording form and instructions with which the data in this substudy were 
collected.  
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SAND abstract number 240: Management of asthma and COPD in 
general practice patients – 2015 
Organisation collaborating for this study: AstraZeneca Pty Ltd (Australia). 
Issues: Prevalence of diagnosed asthma and chronic obstructive pulmonary disease (COPD) in 
general practice patients. For patients with asthma and/or COPD: their age when diagnosed; current 
medication; exacerbation management action in previous 12 months.  
Sample: 2,547 patients from 86 GPs; data collection period: 09/06/2015 – 13/07/2015. 
Method: Detailed in the paper entitled SAND Method 2015–16 on this website: 
<sydney.edu.au/medicine/fmrc/publications/sand-abstracts>. Note: SABA – short-acting beta agonist;  
ICS – inhaled corticosteroid; LABA – long-acting beta agonist; LAMA – long-acting muscarinic agent. 
Summary of results  
The age and sex distribution of the 2,547 respondents did not significantly differ from that of patients 
at all 2014–15 BEACH encounters. Of the 2,547 respondents, 280 (11.0%) had asthma only, 28 
(1.1%) both asthma and COPD, and 68 (2.7%) had COPD only. In total, 12.1% had asthma and 3.8% 
had COPD. 
Among 278 of the 280 patients with asthma only, most (58.5%) were diagnosed by the age of 18 
years (n = 265): 16.6% by age 5, 27.5% 5–11 years, and 14.3% 12–18 years. Patients had been 
diagnosed for an average of 24.4 years. Of 274 respondents with asthma only, 82.1% were taking at 
least one asthma medication, most commonly SABA (56.9%), ICS/LABA (46.0%) and ICS (10.6%). 
Salbutamol was the most commonly used medication (46.9%), followed by salbutamol/fluticasone 
(24.7%). At least one asthma exacerbation management action was required in the previous 
12 months for 40.4% of 265 respondents. Actions included: corticosteroids (21.1%), antibiotics 
(34.7%), emergency department attendance (5.3%), and hospital admission (3.0%). 
Among the 28 patients with asthma and COPD, prevalence increased with age, from 0.2% of patients 
aged 30–44 to 3.1% of patients aged 75+. Of 23 respondents, the majority were diagnosed with 
asthma before COPD (n = 16), 5 at the same time and 2 with COPD before asthma. The average 
number of years since diagnosis was 41.3 for asthma and 17.7 years for COPD. For 23 patients for 
whom severity of COPD was known, 4 were mild, 15 moderate and 4 severe. The most commonly 
used medication types were ICS/LABA (n = 23), SABA (n = 18) and LAMA (n = 14). Salmeterol/ 
fluticasone was most commonly used (n = 19), followed by salbutamol (n = 17). Of 27 respondents, 
92.6% required at least one exacerbation management action including: corticosteroids (51.9%), 
antibiotics (88.9%), emergency department attendance (25.9%), and hospital admission (22.2%). 
Among 66 of the 68 patients with COPD only, prevalence increased with age, from 0.5% of those 
aged 30–44 to 7.0% of patients aged 75+. Of 63 respondents, 55.6% were diagnosed between  
45 and 64 years of age. The average time since diagnosis was 11.7 years. Of 62 patients for whom 
severity was known, 48.4% were mild, 40.3% moderate and 11.3% severe. Of 66 respondents, 81.8% 
took at least one medication. LAMA was the most common type (45.5%), followed by ICS/LABA 
(43.9%) and SABA (30.3%). Tiotropium bromide was the most common medication (30.1%) followed 
by salbutamol (21.5%) and salmeterol/fluticasone (18.3%). The majority (57.8%) of patients required 
at least one exacerbation management action including: corticosteroids (40.6%), antibiotics (56.3%), 
emergency department attendance (14.1%), and hospital admission (10.9%). 
Of 107 respondents aged 12–18 years, 22.4% had asthma and none had COPD. Of 23 with asthma, 
13 were taking at least one medication. SABA was the most common medication type and salbutamol 
was the most common medication taken by this age group. 
The following page contains the recording form and instructions with which the data in this substudy were 
collected. 
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SAND abstract number 241: Proton pump inhibitor use among 
general practice patients 
Organisation collaborating for this study: Family Medicine Research Centre. 
Issues: The proportion of general practice patients taking proton pump inhibitors (PPIs) and the 
conditions for which they were prescribed; proportion prescribed for initial or maintenance treatment; 
how long patients have been taking PPIs and the PPI they are taking; proportion of patients who had 
attempted to stop PPI or reduce dose and their level of success. 
Sample: 2,642 patients from 89 GPs; data collection period: 14/07/2015 – 17/08/2015. 
Method: Detailed in the paper entitled SAND Method 2015–16 on this website: 
<sydney.edu.au/medicine/fmrc/publications/sand-abstracts>.  
Summary of results  
The age and sex distributions of the respondents in this sample did not differ from the age and sex 
distributions of patients at all 2014–15 BEACH encounters. 
Of 2,642 patients who responded to the SAND questions about PPI use, a total of 474 (17.9%) were 
either currently taking (n = 375, 14.2%) or had previously taken (n = 99, 3.7%) PPIs in the past 
12 months. When these results are extrapolated to all patients who attended general practice at least 
once in 2014–15, we estimate that 14.4% of the attending population, and 12.4% of the Australian 
population are currently taking/have taken PPIs in the previous 12 months. 
Of 471 respondents currently taking/who had taken PPIs in the past 12 months, 67.9% were taking it 
for oesophageal reflux, 15.3% for oesophagitis, 9.1% for gastrointestinal risk reduction and 8.1% for 
peptic ulcer disease (multiple responses allowed). Other indications for PPI use included gastritis 
(1.9%), hiatus hernia (1.3%) and Helicobacter pylori infection (0.8%). 
Of 461 respondents, a PPI was prescribed for the initial treatment/healing phase for 18.9% of patients 
and the maintenance phase for 76.8%. 
Of 427 respondents currently taking/who had taken a PPI in the past 12 months, the average duration 
of PPI use at any dose was 3.8 years. The 396 patients who responded to the question on duration 
had been taking the specified PPI at the current/most recent dose for an average of 3 years. 
Of the most recent PPI prescribed for 463 respondents currently taking/who had taken PPI in the past 
12 months, 44.1% were taking/had taken esomeprazole, 24.6% pantoprazole, 17.3% rabeprazole, 
11.4% omeprazole and 2.2% lansoprazole.  
Of 356 respondents currently taking a PPI, 14.9% had attempted to cease PPI use and 22.5% had 
attempted to reduce the dose in the previous 12 months. Of 127 patients who had attempted to cease 
or reduce the dose of PPI, the majority (64.6%) indicated that the attempt had been unsuccessful. 
Of 209 patients currently taking PPI, for whom PPI cessation or dose reduction had not been 
attempted in the previous 12 months, reasons were recorded for 205 patients. For 80.0% of patients, 
PPI cessation/dose reduction was considered by the GP to be not clinically indicated, for 10.7% no 
attempt was made due to patient refusal, 2.0% were planning to reduce PPI soon and 7.8% gave 
other reasons. 
The following page contains the recording form and instructions with which the data in this substudy were 
collected.  
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SAND abstract number 242: Cardiovascular disease risk and use of 
lipid-lowering medication 
Organisation collaborating for this study: Sanofi-Aventis Australia Pty Ltd. 
Issues: Prevalence of cardiovascular disease (CVD) risk factors; blood pressure level; low–density 
lipoprotein level (LDL); lipid medication management; changes in lipid medication use.  
Sample: 3,182 patients aged 45+ from 184 GPs; data collection period: 18/08/2015 – 26/10/2015. 
Method: Detailed in the paper entitled SAND Method 2015–16 on this website: 
<sydney.edu.au/medicine/fmrc/publications/sand-abstracts>. 
Methods for this substudy: Patient cardiovascular risk status was calculated using a three-step 
process involving CVD risk guidelines from the National Vascular Disease Prevention Alliance, the 
Framingham equation, and other factors for consideration in CVD risk (family history of premature 
heart disease; obesity calculated from reported BMI). 
 <www.cvdcheck.org.au/index.php?option=com_content&view=article&id=47Itemid=27>. 
Summary of results 
There were 3,182 respondents aged 45+ years. The age and sex distributions of these respondents 
did not differ from patients in this age group at all BEACH encounters in 2015–16.  
Hypertension (54.1%) was the most common CVD risk factor reported in these patients, followed by 
dyslipidaemia (35.5%) and BMI of 30 or more (21.7%). Diabetes was reported for 14.9% of patients, 
13.3% had a family history of coronary artery disease, and 10.7% were current smokers. For 745 
(23.4%) respondents, CVD risk factors placed them in the known very high risk category. Sufficient 
information was given to estimate overall CVD risk via the Framingham equation for 2,962 
respondents. Of these, 34.1% had high risk, 12.2% moderate risk and 53.7% low CVD risk. 
Based on National Heart Foundation categories, 15.6% of 2,932 respondents had normal blood 
pressure, 48.2% high-normal and 36.3% high. Of 2,380 respondents, the average LDL was 
2.8 mmol/L. Women had significantly higher average LDL (2.9 mmol/L, 95% CI: 2.85–2.96) than men 
(2.7 mmol/L, 95% CI: 2.63–2.77). Average LDL decreased significantly with age, from 3.1 mmol/L 
(95% CI: 3.0–3.1) in patients aged 45–64 years to 2.5 mmol/L (95% CI: 2.4–2.6) in patients 75 years 
and older. Average LDL for patients with very high CVD risk (2.3 mmol/L, 95% CI: 2.2–2.4) was 
significantly lower than for all other groups. 
Of 2,578 patients for whom triglyceride level was known, the average was 1.5 mmol/L (95% CI:  
1.5–1.6). There were no significant differences in average triglyceride levels between males and 
females, or among different patient age groups. Average triglyceride level was significantly lower for 
patients at low CVD risk than for patients in moderate, high or very high risk groups, although none of 
the latter groups differed from each other. 
Of 3,088 respondents, 37.3% were currently taking at least one lipid medication, predominantly statin 
(34.0%), ezetimibe (2.0%), statin + ezetimibe combination (1.7%) or a fibrate (0.8%). There were 
1,189 current lipid medications recorded, with the most common being atorvastatin (39.0%) and 
rosuvastatin (33.2%). The majority (71.9%) of the very high CVD risk group were taking at least one 
lipid medication, a significantly higher proportion than all other risk groups.  
The following page contains the recording form and instructions with which the data in this substudy were 
collected. 
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SAND abstract number 243: Rhinitis management among Australian 
general practice patients 
Organisation collaborating for this study: Seqirus (Australia) Pty Ltd. 
Issues: Prevalence of allergic and non-allergic rhinitis and asthma in general practice patients. For 
patients with allergic and non-allergic rhinitis (separately analysed): proportion with asthma; suspected 
causes; confirmatory diagnostic tests; duration; specialist referral; and number of GP and specialist 
visits in previous 12 months.  
Sample: 2,723 patients from 93 GPs; data collection period: 22/09/2015 – 26/10/2015. 
Method: Detailed in the paper entitled SAND Method 2015–16 on this website: 
<sydney.edu.au/medicine/fmrc/publications/sand-abstracts>.  
Summary of results  
Of 2,723 patients who responded to the SAND questions about rhinitis, a total of 536 (19.7%) had 
either allergic (n = 446, 16.4%) or non-allergic (n = 91, 3.3%) rhinitis.  
There were no significant differences in the sex-specific rates of rhinitis, 21.1% of females and 17.6% 
of males having some type of rhinitis. Rhinitis was significantly more prevalent among surveyed 
patients aged 45–64 years (23.2%) than among patients aged less than 15 years (12.2%), but there 
were no significant differences between other patient age groups.  
Of 445 patients with allergic rhinitis, 319 responded to the co-existence of diagnosed asthma. Of 
these, 39.5% (95% CI: 34.0–45.0) also had diagnosed asthma. 
Of 445 patients with allergic rhinitis, 434 advised causal agents. Grasses/pollens were the most 
commonly reported (67.5%), followed by indoor allergens (25.8%), animal dander (16.6%); infections 
(6.5%), and 6.7% advised ‘other’ causes, the most frequent of which was perfume (n = 8). The cause 
was reported as ‘unknown’ for 21.0%.  
Of 445 patients with allergic rhinitis, 430 patients responded about diagnostic tests. Of these, 109 
reported 148 tests: no tests had been undertaken for 321 respondents (74.7%), a skin prick test was 
used for 16.3%, allergen-specific immunoglobulin E (IgE) test for 8.8%, and total IgE test for 7.7%. 
The majority of skin prick tests (63.8%) were ordered by specialists, and 34.5% were ordered by GPs. 
Of total IgE tests, 53.1% were ordered by a GP and 46.9% by a specialist. Two-thirds (68.6%) of 
allergen-specific IgE tests had been ordered by GPs and 31.4% by specialists.  
Of 431 respondents with allergic rhinitis, the majority (68.4%) had been diagnosed more than 5 years 
earlier than the recorded encounter. A further 11.8% were diagnosed between 3 and 5 years earlier, 
12.8% 1–3 years earlier, and 7.0% less than 12 months ago. 
Of 433 respondents with allergic rhinitis, 18.2% had been referred to a specialist for its management. 
The highest proportions of referrals were to ENT specialists (7.9% of respondents), followed by 
allergists (6.5%), immunologists (2.5%), respiratory physicians (1.2%), and dermatologists (0.7%). 
Of 415 respondents with allergic rhinitis, the majority (58.8%) had not required GP management of 
their rhinitis in the previous 12 months, 17.6% had had one GP visit for allergic rhinitis, 11.3% two 
visits, and 12.3% three or more visits. 
Only 257 patients with allergic rhinitis responded about the number of specialist visits. Of these, 89.9% 
had required none in the previous 12 months, 6.6% one visit, and 3.5% two or more visits. 
Of 90 patients with non-allergic rhinitis: 8 (13.8%, 95% CI: 5.2–22.3) of 58 respondents also had 
asthma, the most common known cause was infection (20/87, 23.0%), the majority (74/86, 86.0%) 
reported no diagnostic tests and 41/84 (48.8%) had been diagnosed more than 5 years earlier. 
The following page contains the recording form and instructions with which the data in this substudy were 
collected.
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SAND abstract number 244: Continual medication and adverse drug 
events in general practice patients 
Organisation collaborating for this study: Family Medicine Research Centre. 
Issues: The proportion of general practice patients on continual medications, the number of 
medications and the number of prescribers; the proportion who had a medication review; the 
proportion who had an adverse drug event; the severity and rate of hospitalisation for adverse drug 
events.  
Sample: 10,667 patients from 363 GPs; data collection periods: 14/07/2015 – 21/09/2015, and 
27/10/2015 – 18/01/2016.  
Method: Detailed in the paper entitled SAND Method 2015–16 on this website: 
<sydney.edu.au/medicine/fmrc/publications/sand-abstracts>.  
Summary of results  
A significantly greater proportion of this sample was female, but there was no significant difference in 
age distribution, when compared with patients at all 2014–15 encounters. 
Of the 10,667 patients in this sample, two-thirds (68.5%, 95% CI: 66.2–70.8) had been prescribed or 
advised at least one medication for continual use in the previous 6 months. On average, patients took 
3.2 continual medications. Polypharmacy (defined as a patient taking five or more continual 
medications) was present in 27.2% of the patients. 
Of 7,138 respondents who were taking at least one continual medication, 21.4% reported that no 
doctor had prescribed or advised any new medication in the previous 6 months, 47.9% reported that 
one doctor had prescribed or advised a new medication, and 30.7% reported that two doctors had 
done so. For those on continual medications, on average, 1.2 doctors had prescribed or advised new 
medications. 
Medication reviews had been performed for 69.1% of the 6,955 respondents taking continual 
medication for which medication review status was known. GPs were involved (either alone or in 
conjunction with a pharmacist or nurse) in 92.5% of medication reviews. Patients with polypharmacy 
were significantly more likely to have a medication review (77.7%, 95% CI: 74.3–81.0) than those 
without (63.3%, 95% CI: 59.9–67.0).  
Of 7,253 respondents taking at least one continual medication, 11.2% (n = 813) had experienced an 
adverse drug event in the previous 6 months. Significantly more patients with polypharmacy had an 
adverse drug event in the previous 6 months (16.1%, 95% CI: 14.2–18.0) than those who were taking 
less than five continual medications (5.4%, 95% CI: 4.8–6.0). 
For 870 patients who had experienced an adverse drug event and for whom information was provided 
about the severity of the most recent event: 60.9% had experienced an adverse drug event regarded 
as ‘mild’ in the GP’s clinical opinion, 32.3% had experienced a ‘moderate’ adverse drug event, and 
6.8% had experienced a ‘severe’ event. 
Of 842 patients who had an adverse drug event and for whom information was provided about 
hospitalisation, 5.0% reported a hospital admission as a result of their most recent adverse drug event 
and 2.3% reported attendance at an emergency department without admission to hospital. 
The following page contains the recording form and instructions with which the data in this substudy were 
collected.
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SAND abstract number 245: Health care utilisation by general 
practice patients 
Organisation collaborating for this study: Family Medicine Research Centre. 
Issues: Proportion of patients with a regular practice; health resources used in the previous year, 
specifically, frequency of visits to GPs, to practices, to specialists, to emergency departments, and 
hospital admissions; prevalence and number of chronic problems.  
Sample: 2,688 patients from 91 GPs; data collection period: 27/10/2015 – 30/11/2015. 
Method: Detailed in the paper entitled SAND Method 2015–16 on this website: 
<sydney.edu.au/medicine/fmrc/publications/sand-abstracts>. A general practice was defined as ‘a solo 
GP or a group of GPs who share medical records’. 
Summary of results  
The age and sex distributions of respondents did not differ from those of patients at all BEACH 
encounters in 2014–15. Of 2,688 respondents, 90.2% said the practice they were visiting that day was 
their regular one, 6.4% said another practice was their regular one, and 3.4% did not have a regular 
practice. In total, 2,596 patients (96.6%, 95% CI: 94.8–98.3) had a regular practice. 
The average number of GP visits per patient was 9.6. Of 2,650 respondents, 10.2% had visited a GP 
more than 20 times in the previous 12 months. GP visits rose with patient age: patients aged 25–44 
years had a significantly higher average number of visits than younger patients, and patients aged 75+ 
had significantly more visits than those aged less than 65 years. The average number of individual 
GPs visited in the previous 12 months was 2.4 per patient. Of 2,629 respondents: 31.2% had seen 
only one GP, 32.0% had seen two, one in five patients (19.3%) had visited three GPs, and 17.4% had 
visited four or more. 
The mean number of different general practices attended in the previous 12 months was 1.3 and the 
median was 1.0 per patient. Of 2,598 respondents, 78.7% had attended only one practice, and 19.1% 
had attended two. Only 2.2% had attended three or more practices. 
The average number of individual specialists seen in the previous 12 months was 1.1 per patient. Of 
2,662 respondents, 47.9% had not seen a specialist, 24.0% had seen one, and 13.9% had seen two. 
Significantly higher numbers of specialists were seen by older age groups. 
The average number of emergency department visits per patient in the previous 12 months was 0.34. 
Of 2,628 respondents, 79.3% had not visited an emergency department, 13.3% had been once, and 
4.6% had been twice. Emergency department visit numbers were similar across all age groups except 
for patients aged 75+ years, for whom a significantly higher average number of visits were recorded.  
The average number of hospital admissions per patient in the previous 12 months was 0.36. Of 2,512 
respondents, 77.7% had not been admitted to hospital, 15.5% had been admitted once, and 4.3% had 
been admitted twice. Hospital admissions were significantly higher among patients aged 65–74 years 
(0.40) compared with younger age groups and significantly higher again for patients aged 75+ years.  
Of 2,661 respondents, 28.5% had no chronic conditions, 24.5% had one, 15.1% had two, and 31.8% 
had three or more. The proportion with three or more chronic conditions rose significantly through 
each age group to 75.4% of those aged 75+ years. 
Factors predicting higher health care utilisation varied: higher number of GP visits and chronic 
conditions increase the number of specialists seen; having a regular practice, higher number of 
different GPs and more chronic conditions increase emergency department visits; and having a higher 
number of different GPs and chronic problems increase the number of hospital admissions. 
The following page contains the recording form and instructions with which the data in this substudy were 
collected. 
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SAND abstract number 246: Prevalence of chronic conditions and 
multimorbidity 
Organisation collaborating for this study: Family Medicine Research Centre and the National 
Health Performance Authority. 
Issues: The prevalence of chronic conditions and multimorbidity among: patients at GP encounters; 
active patients (those who see a GP at least once in a year); people in the general Australian 
population. The number of times patients had seen a GP in the previous 12 months. 
Sample: 43,531 patients from 1,450 GPs; data collection period: 27/11/2012 – 28/03/2016.  
Method: Detailed in the paper entitled SAND Method 2015–16 on this website: 
<sydney.edu.au/medicine/fmrc/publications/sand-abstracts>.  
Summary of results  
There were 43,531 patients in the total sample. The age of the patient was recorded at 43,200 
encounters. There was no significant difference between the age distribution of respondents in this 
sample and that of patients at all 2014–15 BEACH encounters. Sex was also known for 43,186 
patients. There was no significant difference between the sex distribution of respondents in this 
sample (40.4% male) and that of patients at all 2014–15 BEACH encounters (40.7% male).  
On average, patients at GP encounters saw a GP 9.6 times in the previous year. On average, active 
patients saw a GP 4.6 times in the previous year. This is lower than the average 6.8 GP Medicare 
items claimed per person who claimed at least one item in 2014–15. 
The most prevalent condition was hypertension – an estimated 26.5% of patients at encounters, 
15.5% of patients who attended general practice at least once in the previous year and 12.4% of the 
Australian population have diagnosed hypertension. The second most prevalent condition was 
osteoarthritis – an estimated 22.7% of patients at encounters, 12.1% of active patients and 9.5% of 
the Australian population have osteoarthritis. The third was hyperlipidaemia, prevalent in an estimated 
16.5% of patients at encounters, 10.1% of active patients and 8.2% of the population. 
The body system (ICPC-2 chapter) most likely to be affected by a chronic condition was the circulatory 
system – 32.4% of patients at encounters, 18.7% of patients who attended general practice in the past 
year and 15.0% of the general population have a chronic circulatory condition. The second most 
common was musculoskeletal conditions – 32.0% of patients at encounters, 18.0% of active patients 
and 14.4% of people in the population have at least one. 
Prevalence estimates range widely depending on the type of multimorbidity considered and the group 
of interest.  
For multimorbidity defined as 2+ diagnosed chronic conditions, about half of patients at encounters 
(51.6%), 31.5% of active patients and 25.7% of people in the population have two or more diagnosed 
chronic conditions. 
For multimorbidity defined as 3+ diagnosed chronic conditions, over one-third (37.4%) of patients at 
encounters, 19.7% of active patients and 15.8% of people in the population had three or more 
diagnosed chronic conditions. 
For multimorbidity defined as 2+ ICPC-2 chapters affected, nearly half (47.8%) of patients at 
encounters, 28.3% of active patients and 23.0% of people in the population had diagnosed chronic 
conditions from two or more ICPC 2 chapters. 
For complex multimorbidity, defined as 3+ ICPC-2 chapters affected, 30.4% of patients at encounters, 
15.2% of active patients and 12.1% of people in the population had been diagnosed with chronic 
conditions from three or more ICPC-2 chapters. 
The following page contains the recording form and instructions with which the data in this substudy were 
collected. 
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SAND abstract number 247: COPD prevalence, severity and 
management in general practice patients – 2016 
Organisation collaborating for this study: Novartis Pharmaceuticals Australia Pty Ltd. 
Issues: The surveyed prevalence of patients with diagnosed chronic obstructive pulmonary disease 
(COPD) with/without asthma; severity of COPD; exacerbations; management of COPD. 
Sample: 2,437 patients from 87 GPs; data collection period: 19/01/2016 – 22/02/2016. 
Method: Detailed in the paper entitled SAND Method 2015–16 on this website: 
<sydney.edu.au/medicine/fmrc/publications/sand-abstracts>. 
Methods for this substudy: COPD severity was defined using the COPD-X guideline (see 
<copdx.org.au/copd-x-plan/confirm-diagnosis/c3-assessing-the-severity-of-copd/>).  
Post-bronchodilator forced expiratory volume in one second (FEV1) > 80 was defined as normal, FEV1 
60–80 mild, FEV1 40–59 moderate, and FEV1 < 40 severe. Note: LABA – long-acting beta agonist; 
SABA – short-acting beta agonist; LAMA – long-acting muscarinic agent; SAMA – short-acting 
muscarinic agent; ICS – inhaled corticosteroid. 
Summary of results 
The age and sex distributions of the 2,437 respondents did not differ from the age and sex 
distributions of patients at all 2014–15 BEACH encounters.  
Of 2,437 patients who responded to questions about COPD, 122 (5.0%; 95% CI: 3.9–6.1) had 
diagnosed COPD. Of these, one-third (n = 42) had COPD with asthma and two-thirds (n = 80) had 
COPD without asthma. A further 199 (8.2%) had asthma without COPD. 
Extrapolating to the population (assuming people who did not attend general practice at least once in 
a year did not have COPD), it was estimated that 2.6% (95% CI: 1.9–3.2) of the Australian population 
have diagnosed COPD with or without asthma. 
There was no significant difference between the proportions of male and female patients with 
diagnosed COPD (6.5% males and 3.9% females). Age-specific rates showed that COPD increased 
with patient age. Only 6 patients aged <45 years had COPD, while 3.0% of those aged 45–64, 9.8% of 
those aged 65–74 and 12.7% of patients aged 75 years or older had been diagnosed with COPD. 
FEV1 responses were recorded for 115 of the 122 patients with COPD. For nearly half (47.8%) the 
response was ‘Don’t know’. Of those with a known FEV1 (n = 60), GPs reported that 5.0% had normal 
lung function, 60.0% had mild COPD, 25.0% moderate COPD, and 10.0% severe COPD. 
More than half (72/121, 59.5%) of patients with COPD had experienced at least one exacerbation in 
the previous 12 months. Of those with exacerbations, (26/71), 36.6% had experienced three or more 
exacerbations in the previous 12 months. 
COPD medication information was reported for 121 patients, 9 of whom (7.4%) were not taking any 
COPD medications, and 33 (27.3%) who were taking one type of medication. Two different types of 
COPD medication were taken by 43.8% of patients and 21.5% were taking three or more. The most 
common medication combination was LABA/ICS in fixed dose combination with a LAMA taken by 
19.8% of patients (24/121), followed by SABA/SAMA (19/121, 15.7%). 
For patients taking a LABA+LAMA, 44.4% (4/9) had been treated with both agents since their COPD 
diagnosis, compared with 20.6% (7/34) of those taking LABA/ICS+LAMA. 
The following page contains the recording form and instructions with which the data in this substudy were 
collected. 
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SAND abstract number 248: Influenza risk factors and vaccination 
in general practice patients – 2016 
Organisation collaborating for this study: AstraZeneca Pty Ltd (Australia). 
Issues: Proportion of general practice patients with influenza (flu) infection risk factors; and for those 
at-risk, types of risk factors, awareness of eligibility for free flu vaccination. For all respondents: 
vaccination status for 2016 and for 2015; reasons for not vaccinating in 2015. Proportion diagnosed 
with influenza in prior 12 months. 
Sample: 2,826 patients from 95 GPs; data collection period: 23/02/2016 – 28/03/2016.  
Method: Detailed in the paper entitled SAND Method 2015–16 on this website: 
<sydney.edu.au/medicine/fmrc/publications/sand-abstracts>.  
Summary of results  
The age and sex distributions of patients did not differ from that of all BEACH encounters 2015–16. Of 
the 2,826 respondents: 51.0% (95% CI: 46.4–55.6) (n = 1,441) had at least one risk factor for 
influenza (31.0% had one, 13.0% two, and 7.0% had three or more risk factors). The most common 
risk factors were: older age (35.5% were aged 65+ years), chronic respiratory condition (10.4%), 
diabetes (10.3%), chronic heart disease (8.9%), chronic neurological condition (2.9%), and Indigenous 
patients aged between 6 months and 5 years, or aged 15 years or more (1.9%). 
For patients aged 15–64 years (n = 1,558), 27.7% (95% CI: 23.7–31.6) had at least one risk factor: 
9.2% had a chronic respiratory condition, 7.3% diabetes, 2.8% chronic heart disease, and 2.8% had 
impaired immunity. For patients aged 65+ years (n = 976), 50.4% had at least one risk factor (in 
addition to risk associated with age): 21.0% had chronic heart disease, 17.9% had diabetes, and 
13.3% had a chronic respiratory condition.  
Risk factor status increased significantly with patient age, risk(s) being present in 9.0% of patients 
aged 0–14 years, increasing to 100.0% of patients aged 65+. There was no significant difference 
between risk factor status of males (52.6%) and females (49.8%).  
Of 1,408 respondents with one or more risk factor(s), 92.0% were aware of the availability of free flu 
vaccinations through the National Immunisation Program. Awareness was significantly higher in older 
patients (95.8% of patients aged 65+ being aware) than among those less than 65 years (83.9%). 
Of 2,703 respondents, 56.5% were either already vaccinated, or planned to be vaccinated, for the 
2016 flu season. The proportion of respondents with influenza vaccination or planned vaccination rose 
significantly through each age group from the 25–44 age group upwards. Of 2,693, 50.4% had been 
vaccinated for the 2015 flu season. Of patients with at least one risk factor, 77.4% were vaccinated, 
and for those with no risk factors 20.2% were vaccinated. 
Of 1,240 patients who were not vaccinated for the 2015 flu season, 1,149 gave 1,201 reasons for non-
vaccination. Of these, 59.8% of patients reported they considered themselves at low risk and 14.1% 
stated ‘patient objections’ as the reason for not vaccinating. For 12.4%, the GP considered the patient 
‘not at risk’. There were 286 patients who had at least one influenza risk factor but were not 
vaccinated. Of these patients, 268 provided reasons for not vaccinating, the most common were that 
they considered themselves low risk (49.6%) or they objected to an influenza vaccination (26.9%). 
Of 2,679 respondents, 61 (2.3%, 95% CI: 1.4–3.1) had been diagnosed with influenza in the prior 12 
months. The 2015 flu vaccination status was known for 2,568 respondents: ‘yes’ for 1,341; and ‘no’ for 
1,227. Of those vaccinated, 35 (2.6%) had been diagnosed with influenza in the prior 12 months, and 
this did not significantly differ from the 26 (2.1%) of those not vaccinated.  
The following page contains the recording form and instructions with which the data in this substudy were 
collected.
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 Abbreviations 
ABS Australian Bureau of Statistics 
ACE angiotensin-converting enzyme  
ACRRM Australian College of Rural and Remote Medicine 
ADE adverse drug event 
AHS allied health service 
AHW Aboriginal health worker 
AIHW Australian Institute of Health and Welfare 
ASGC Australian Standard Geographical Classification 
ATC Anatomical Therapeutic Chemical (classification) 
ATRA angiotensin II receptor antagonist 
BEACH Bettering the Evaluation and Care of Health 
BMI body mass index 
BP blood pressure 
CAPS Coding Atlas for Pharmaceutical Substances 
CHF congestive heart failure 
CI confidence interval (in this report 95% CI is used) 
CT computerised tomography 
DoH Australian Government Department of Health 
DVA Australian Government Department of Veterans’ Affairs 
eGFR estimated glomerular filtration rate 
ENT ear, nose and throat 
HCV hepatitis C virus 
FACRRM Fellow of the Australian College of Rural and Remote Medicine 
FMRC Family Medicine Research Centre 
FRACGP Fellow of the Royal Australian College of General Practitioners 
FMRC Family Medicine Research Centre 
FTE full-time equivalent 
GDP gross domestic product 
GP general practitioner 
HbA1c haemoglobin, type A1c 
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ICPC-2 International Classification of Primary Care – Version 2 
ICPC-2 PLUS a terminology classified according to ICPC-2 
ICS inhaled corticosteroid 
INR international normalised ratio 
LABA long-acting beta agonist 
LCL lower confidence limit 
MBS Medicare Benefits Schedule 
M,C&S microscopy, culture and sensitivity 
NDSHS National Drug Strategy Household Survey 
NEC not elsewhere classified 
NESB non-English-speaking background 
NHMRC National Health and Medical Research Council 
NOS not otherwise specified 
OECD Organisation for Economic Co-operation and Development 
OTC over-the-counter (medications advised for over-the-counter purchase) 
Pap Papanicolaou test 
PBS Pharmaceutical Benefits Scheme 
PIP practice incentive payments 
PN practice nurse 
PPP purchasing power parity 
RACF residential aged care facility 
RACGP Royal Australian College of General Practitioners 
RFE reason for encounter 
SABA short-acting beta agonist 
SAND Supplementary Analysis of Nominated Data 
SAS Statistical Analysis System 
SIP service incentive payments 
UCL upper confidence limit 
URTI upper respiratory tract infection 
USD United States Dollars 
WHO World Health Organization 
Wonca World Organization of Family Doctors 
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 Symbols 
2 chi-square 
— not applicable 
< less than 
> more than 
n number 
Ŧ rate is less than 0.05 per 100 encounters 
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 Glossary 
A1 Medicare items: See MBS/DVA items: A1 Medicare items. 
Aboriginal: The patient identifies himself or herself as an Aboriginal person. 
Activity level: The number of general practice A1 Medicare items claimed during the previous 3 
months by a participating GP. 
Allied health services: Clinical and other specialised health services provided in the management of 
patients by allied and other health professionals including physiotherapists, occupational therapists, 
dietitians, dentists and pharmacists. 
Chapters (ICPC-2): The main divisions within ICPC-2. There are 17 chapters primarily representing 
the body systems. 
Chronic problem: See Diagnosis/problem: Chronic problem. 
Commonwealth concession card: An entitlement card provided by the Australian Government, which 
entitles the holder to reduced-cost medicines under the Pharmaceutical Benefits Scheme and some 
other concessions from state and local government authorities. 
Complaint: A symptom or disorder expressed by the patient when seeking care. 
Component (ICPC-2): In ICPC-2 there are seven components that act as a second axis across all 
chapters. 
Co-located health service: a health service (for example, physiotherapist, psychologist etc.) located in 
the practice building or within 50 metres of the practice building, available on a daily or regular basis. 
Co-operative after-hours arrangements: the normal after-hours arrangements for patient care 
provision is undertaken in co-operation with another practice(s). 
Consultation: See Encounter. 
Diagnosis/problem: A statement of the provider’s understanding of a health problem presented by a 
patient, family or community. GPs are instructed to record at the most specific level possible from the 
information available at the time. It may be limited to the level of symptoms. 
• New problem: The first presentation of a problem, including the first presentation of a recurrence 
of a previously resolved problem, but excluding the presentation of a problem first assessed by 
another provider. 
• Old problem: A previously assessed problem that requires ongoing care, including follow-up for a 
problem or an initial presentation of a problem previously assessed by another provider. 
• Chronic problem: A medical condition characterised by a combination of the following 
characteristics: duration that has lasted, or is expected to last, 6 months or more, a pattern of 
recurrence or deterioration, a poor prognosis, and consequences or sequelae that impact on an 
individual’s quality of life. (Source: O’Halloran J, Miller GC, Britt H 2004. Defining chronic 
conditions for primary care with ICPC-2. Fam Pract 21(4):381–6).  
• Work-related problem: Irrespective of the source of payment for the encounter, it is likely in the 
GP’s view that the problem has resulted from work-related activity or workplace exposure, or that 
a pre-existing condition has been significantly exacerbated by work activity or workplace 
exposure. 
Encounter (enc): Any professional interchange between a patient and a GP. 
Indirect: Encounter where there is no face-to-face meeting between the patient and the GP but a 
service is provided (for example, prescription, referral). 
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Direct: Encounter where there is a face-to-face meeting of the patient and the GP. Direct encounters 
can be further divided into: 
– MBS/DVA-claimable: Encounters for which GPs have recorded at least one MBS item number 
as claimable, where the conditions of use of the item require that the patient be present at the 
encounter.  
– Workers compensation: Encounters paid by workers compensation insurance. 
– Other paid: Encounters paid from another source (for example, state). 
Full-time equivalent (FTE): A GP working 35–45 hours per week. 
General practitioner (GP): A medical practitioner who provides primary comprehensive and continuing 
care to patients and their families within the community (Source: Royal Australian College of General 
Practitioners). 
Generic medication: See Medication: Generic 
GP consultation service items: See MBS/DVA items: GP consultation service items.  
MBS/DVA items: MBS item numbers recorded as claimable for activities undertaken by GPs and staff 
under the supervision of GPs. In BEACH, an MBS item number may be funded by Medicare or by the 
Department of Veterans’ Affairs (DVA). 
• A1 Medicare items: Medicare item numbers 1, 2, 3, 4, 13, 19, 20, 23, 24, 25, 33, 35, 36, 37, 38, 
40, 43, 44, 47, 48, 50, 51, 601, 602. 
• GP consultation service items: Includes GP services provided under the MBS professional 
services category including MBS items classed as A1, A2, A5, A6, A7, A14, A17, A18, A19, A20, 
A22, A23, A27, A30 and selected items provided by GPs classified in A11 and A15. 
• MBS/DVA item categories: (Note: item numbers recorded in BEACH in earlier years which are no 
longer valid are mapped to the current MBS groups). 
– Surgery consultations: Identified by any of the following item numbers: short 3, 52, 5000, 5200; 
standard 23, 53, 5020, 5203; long 36, 54, 2143, 5040; prolonged 44, 57, 2195, 5060, 5208. 
– Residential aged care facility: Identified by any of the following item numbers: 20, 35, 43, 51, 
92, 93, 95, 96, 5010, 5028, 5049, 5067, 5260, 5263, 5265, 5267. 
– Home or institution visits (excluding residential aged care facilities): Identified by any of the 
following item numbers: 4, 19, 24, 33, 37, 40, 47, 50, 58, 59, 60, 65, 87, 89, 90, 91, 503, 507, 
5003, 5023, 5043, 5063, 5220, 5223, 5227, 5228. 
– GP mental health care: Identified by any of the following item numbers: 2700, 2701, 2702, 
2704, 2705, 2710, 2712, 2713, 2715, 2717, 2721, 2723, 2725. 
– Chronic disease management items: Identified by any of the following item numbers: 720, 721, 
722, 723, 724, 725, 726, 727, 729, 730, 731, 732. 
– Health assessments: Identified by any of the following item numbers: 700, 702, 703, 704, 705, 
706, 707, 708, 709, 710, 712, 713, 714, 715, 717, 718, 719. 
– Case conferences: Identified by any of the following item numbers: 139, 734, 735, 736, 738, 
739, 740, 742, 743, 744, 747, 750, 762, 765, 771, 773, 775, 778. 
– Attendances associated with Practice Incentives Program payments: Identified by any of the 
following item numbers: 2497, 2501, 2503, 2504, 2506, 2507, 2509, 2517, 2518, 2521, 2522, 
2525, 2526, 2546, 2547, 2552, 2553, 2558, 2559, 2574, 2575, 2577, 2598, 2600, 2603, 2606, 
2610, 2613, 2616, 2620, 2622, 2624, 2631, 2633, 2635, 2664, 2666, 2668, 2673, 2675, 2677, 
2704, 2705. 
– Practice nurse/Aboriginal health worker/allied health worker services: Identified by any of the 
following item numbers: 711, 10950, 10951, 10960, 10966, 10970, 10986, 10987, 10988, 
10989, 10993, 10994, 10995, 10996, 10997, 10998, 10999, 16400, 82210. 
– Acupuncture: Identified by any of the following item numbers: 173, 193, 195, 197, 199. 
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– Diagnostic procedures and investigations: Identified by item numbers: 11000–12533. 
– Therapeutic procedures: Identified by item numbers: 13206–23042 (excluding 16400). 
– Surgical operations: Identified by item numbers: 30001–52036. 
– Diagnostic imaging services: Identified by item numbers: 55037–63000. 
– Pathology services: Identified by item numbers: 65120–74991. 
Medication:  
• Generic: The generic name of a medication is its non-proprietary name, which describes the 
pharmaceutical substance(s) or active pharmaceutical ingredient(s). 
• GP-supplied: The medication is provided directly to the patient by the GP at the encounter. 
• Over-the-counter (OTC): Medication that the GP advises the patient to purchase OTC (a 
prescription is not required for the patient to obtain an OTC medication). 
• Prescribed: Medications that are prescribed by the GP (that is, does not include medications that 
were GP-supplied or advised for over-the-counter purchase). 
Medication status: 
• New: The medication prescribed/provided at the encounter/advised is being used for the 
management of the problem for the first time. 
• Continued: The medication prescribed/provided at the encounter/advised is a continuation or 
repeat of previous therapy for this problem. 
• Old: See Continued. 
Morbidity: Any departure, subjective or objective, from a state of physiological wellbeing. In this sense, 
sickness, illness and morbid conditions are synonymous. 
Non-English speaking background: The patient reported that the primary language spoken at home is 
not English. 
Patient status: The status of the patient to the practice. 
• New patient: The patient has not been seen before in the practice. 
• Patient seen previously: The patient has attended the practice before. 
Problem managed: See Diagnosis/problem. 
Provider: A person to whom a patient has access when contacting the healthcare system. 
Reasons for encounter (RFEs): The subjective reasons given by the patient for seeing or contacting 
the general practitioner. These can be expressed in terms of symptoms, diagnoses or the need for a 
service. 
Recognised GP: A medical practitioner who is: 
• vocationally recognised under Section 3F of the Health Insurance Act, or 
• a holder of the Fellowship of the Royal Australian College of General Practitioners who 
participates in, and meets the requirements for, quality assurance and continuing medical 
education as defined in the Royal Australian College of General Practitioners (RACGP) Quality 
Assurance and Continuing Medical Education Program, or 
• undertaking an approved placement in general practice as part of a training program for general 
practice leading to the award of the Fellowship of the Royal Australian College of General 
Practitioners, or undertaking an approved placement in general practice as part of some other 
training program recognised by the RACGP as being of equivalent standard. (Source: 
Commonwealth Department of Health and Aged Care (DHAC) 2001. Medicare Benefits Schedule 
book. Canberra: DHAC).  
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Referral: The process by which the responsibility for part, or all, of the care of a patient is temporarily 
transferred to another health care provider. Only new referrals to specialists and allied health services, 
and for hospital and residential aged care facility admissions arising at a recorded encounter are 
included. Continuation referrals are not included. Multiple referrals can be recorded at any one 
encounter. 
Repatriation Health Card: An entitlement card provided by the Department of Veterans’ Affairs that 
entitles the holder to access a range of repatriation health care benefits, including access to 
prescription and other medications under the Pharmaceutical Benefits Scheme. 
Rubric: The title of an individual code in ICPC-2. 
Significant: This term is used to refer to a statistically significant result. Statistical significance is 
measured at the 95% confidence level in this report.  
Torres Strait Islander: The patient identifies himself or herself as a Torres Strait Islander person. 
Work-related problem: See Diagnosis/problem. 
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 Appendices 
Appendix 1: Example of a 2015–16 recording form
176
  
177
  
Appendix 2: GP characteristics questionnaire, 
2015–16 
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Appendix 3: Patient information card, 2015–16 
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Appendix 4: Code groups from ICPC-2 and 
ICPC-2 PLUS  
Available at: <hdl.handle.net/2123/15514>. 
Table A4.1:  Code groups from ICPC-2 and ICPC-2 PLUS – reasons for encounter  
and problems managed 
Table A4.2: Code groups from ICPC-2 and ICPC-2 PLUS – chronic problems 
Table A4.3: Code groups from ICPC-2 and ICPC-2 PLUS – clinical treatments 
Table A4.4: Code groups from ICPC-2 and ICPC-2 PLUS – procedures 
Table A4.5: Code groups from ICPC-2 and ICPC-2 PLUS – clinical measurements 
Table A4.6: Code groups from ICPC-2 and ICPC-2 PLUS – referrals 
Table A4.7:  Code groups from ICPC-2 and ICPC-2 PLUS – pathology test orders  
(MBS groups) 
Table A4.8:  Code groups from ICPC-2 and ICPC-2 PLUS – imaging test orders  
(MBS groups) 
 
  
181
  
Appendix 5: Calculation methods for Table 14.1 
Attending population weight 
On the SAND recording form (see Appendix 1), there was a question asking the number of times the 
patient had seen a GP in the previous 12 months (including the current visit). An attending population 
weight was created by weighting each surveyed patient by their chance of being in our sample. The 
chance of being in our sample is based on how many times they had visited a GP in the previous year. 
A weight of X/(number of GP visits) was applied to each patient. 
Management ratios 
The management ratio was calculated by dividing the proportion of encounters at which the chronic 
condition was managed, by the prevalence of the condition among patients at general practice 
encounters. 
Number of GP visits in previous 12 months 
The average number of times patients aged 65+ with a certain chronic condition had seen a GP in the 
previous year was calculated using the attending population weight (described above). 
Number of times condition was managed in general practice 
The number of times a condition was managed in general practice was calculated by multiplying the 
management ratio by the average number of times patients with the selected chronic condition had 
visited a GP in the previous 12 months. 
Population prevalence 
Population prevalence was calculated by first applying the attending population weight to the data. A 
second weight was created so that when applied to the attending population weight, the proportion of 
surveyed patients in each age–sex group matched the proportion represented by that age–sex group 
in the Australian population.  
The numerator of whether a patient had a specific chronic condition (1 = patient has chronic condition, 
0 = patient does not have condition) was weighted by the proportion of people in that age–sex group 
that saw a GP at least once in the previous year. This adjusted the data for those who did not see a 
GP, who we assumed had not been diagnosed with that chronic condition. 
Proportion of patients with a selected condition, who had 2 or more other 
chronic conditions 
The proportion of people aged 65+ with a selected condition who had two or more other diagnosed 
chronic conditions was calculated using the attending population weight. This means that the results 
are representative of people in the population who have the selected diagnosed condition. 
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